| Line |
Label |
Object Class |
Period Type |
Balance |
Report ElementName |
| 1 |
1001 - Document - Document and Entity Information |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DocumentandEntityInformation |
| 2 |
Implied Table |
Table |
* |
* |
implied:Table |
| 3 |
Document and entity information [abstract] |
Abstract |
|
|
gsk:DocumentAndEntityInformationAbstract |
| 4 |
Document Type |
Concept (Submission Type) |
For Period |
|
dei:DocumentType |
| 5 |
Amendment Flag |
Concept (Yes/No) |
For Period |
|
dei:AmendmentFlag |
| 6 |
Document Period End Date |
Concept (Date) |
For Period |
|
dei:DocumentPeriodEndDate |
| 7 |
Document Fiscal Year Focus |
Concept (Year) |
For Period |
|
dei:DocumentFiscalYearFocus |
| 8 |
Document Fiscal Period Focus |
Concept (Fiscal Period) |
For Period |
|
dei:DocumentFiscalPeriodFocus |
| 9 |
Trading Symbol |
Concept (Text/String) |
For Period |
|
dei:TradingSymbol |
| 10 |
Entity Registrant Name |
Concept (Text/String) |
For Period |
|
dei:EntityRegistrantName |
| 11 |
Entity Central Index Key |
Concept (CIK Number) |
For Period |
|
dei:EntityCentralIndexKey |
| 12 |
Current Fiscal Year End Date |
Concept (Month/Day) |
For Period |
|
dei:CurrentFiscalYearEndDate |
| 13 |
Entity Well-known Seasoned Issuer |
Concept (Yes/No) |
For Period |
|
dei:EntityWellKnownSeasonedIssuer |
| 14 |
Entity Current Reporting Status |
Concept (Yes/No) |
For Period |
|
dei:EntityCurrentReportingStatus |
| 15 |
Entity Filer Category |
Concept (Filer Category) |
For Period |
|
dei:EntityFilerCategory |
| 16 |
Entity Emerging Growth Company |
Concept (Yes/No) |
For Period |
|
dei:EntityEmergingGrowthCompany |
| 17 |
Entity Shell Company |
Concept (Yes/No) |
For Period |
|
dei:EntityShellCompany |
| 18 |
Entity Common Stock, Shares Outstanding |
Concept (Shares) |
As Of |
|
dei:EntityCommonStockSharesOutstanding |
| 19 |
1003 - Statement - Consolidated income statement |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000 |
| 20 |
Implied Table |
Table |
* |
* |
implied:Table |
| 21 |
Profit or loss [abstract] |
Abstract |
|
|
ifrs-full:IncomeStatementAbstract |
| 22 |
Turnover |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:Revenue |
| 23 |
Cost of sales |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CostOfSales |
| 24 |
Gross profit |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GrossProfit |
| 25 |
Selling, general and administration |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:SellingGeneralAndAdministrativeExpense |
| 26 |
Research and development |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ResearchAndDevelopmentExpense |
| 27 |
Royalty income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueFromRoyalties |
| 28 |
Other operating income/(expense) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherOperatingIncomeExpense |
| 29 |
Operating profit |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossFromOperatingActivities |
| 30 |
Finance income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:FinanceIncome |
| 31 |
Finance expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:FinanceCosts |
| 32 |
Profit on disposal of interest in associates |
Concept (Monetary) |
For Period |
Credit |
gsk:GainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates |
| 33 |
Share of after tax profits of associates and joint ventures |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod |
| 34 |
Profit before taxation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossBeforeTax |
| 35 |
Taxation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 36 |
Profit after taxation for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 37 |
Profit attributable to non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossAttributableToNoncontrollingInterests |
| 38 |
Profit attributable to shareholders |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossAttributableToOwnersOfParent |
| 39 |
Profit after taxation for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 40 |
Basic earnings per share (pence) |
Concept (Share) |
For Period |
|
ifrs-full:BasicEarningsLossPerShare |
| 41 |
Diluted earnings per share (pence) |
Concept (Share) |
For Period |
|
ifrs-full:DilutedEarningsLossPerShare |
| 42 |
1004 - Statement - Consolidated statement of comprehensive income |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/StatementOfComprehensiveIncomeOCIComponentsPresentedBeforeTax-420000 |
| 43 |
Implied Table |
Table |
* |
* |
implied:Table |
| 44 |
Statement of comprehensive income [abstract] |
Abstract |
|
|
ifrs-full:StatementOfComprehensiveIncomeAbstract |
| 45 |
Profit after taxation for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 46 |
Items that may be subsequently reclassified to income statement: |
Abstract |
|
|
ifrs-full:ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract |
| 47 |
Exchange movements on overseas net assets and net investment hedges |
Concept (Monetary) |
For Period |
Credit |
gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges |
| 48 |
Reclassification of exchange on liquidation or disposal of overseas subsidiaries |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax |
| 49 |
Fair value movements on equity investments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeBeforeTax |
| 50 |
Deferred tax on fair value movements on equity investments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxRelatingToFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome |
| 51 |
Reclassification of fair value movements on equity investments |
Concept (Monetary) |
For Period |
Debit |
gsk:ReclassificationOfFairValueMovementsOnEquityInvestments |
| 52 |
Deferred tax reversed on reclassification of equity investments |
Concept (Monetary) |
For Period |
Debit |
gsk:DeferredTaxReversedOnReclassificationOfEquityInvestment |
| 53 |
Fair value movements on cash flow hedges |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax |
| 54 |
Deferred tax on fair value movements on cash flow hedges |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome |
| 55 |
Reclassification of cash flow hedges to income statement |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax |
| 56 |
Deferred tax reversed on reclassification of cash flow hedges |
Concept (Monetary) |
For Period |
Credit |
gsk:DeferredTaxReversedOnReclassificationOfCashFlowHedges |
| 57 |
Items that may be subsequently reclassified to income statement |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax |
| 58 |
Items that will not be reclassified to income statement: |
Abstract |
|
|
ifrs-full:ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract |
| 59 |
Exchange movements on overseas net assets of non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests |
| 60 |
Fair value movements on equity investments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments |
| 61 |
Deferred tax on fair value movements on equity investments |
Concept (Monetary) |
For Period |
Credit |
gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments |
| 62 |
Remeasurement gains/(losses) on defined benefit plans |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans |
| 63 |
Tax on remeasurement of defined benefit plans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome |
| 64 |
Items that will not be reclassified to income statement |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax |
| 65 |
Other comprehensive income for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncome |
| 66 |
Total comprehensive income/(expense) for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 67 |
Total comprehensive income for the year attributable to: |
Abstract |
|
|
ifrs-full:ComprehensiveIncomeAttributableToAbstract |
| 68 |
Shareholders |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent |
| 69 |
Non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests |
| 70 |
Total comprehensive income/(expense) for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 71 |
1005 - Statement - Consolidated balance sheet |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000 |
| 72 |
Implied Table |
Table |
* |
* |
implied:Table |
| 73 |
Statement of financial position [abstract] |
Abstract |
|
|
ifrs-full:StatementOfFinancialPositionAbstract |
| 74 |
Non-current assets |
Abstract |
|
|
ifrs-full:NoncurrentAssetsAbstract |
| 75 |
Property, plant and equipment |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 76 |
Goodwill |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Goodwill |
| 77 |
Other intangible assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 78 |
Investments in associates and joint ventures |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:InvestmentAccountedForUsingEquityMethod |
| 79 |
Other investments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod |
| 80 |
Deferred tax assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:DeferredTaxAssets |
| 81 |
Derivative financial instruments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentDerivativeFinancialAssets |
| 82 |
Other non-current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherNoncurrentAssets |
| 83 |
Total non-current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentAssets |
| 84 |
Current assets |
Abstract |
|
|
ifrs-full:CurrentAssetsAbstract |
| 85 |
Inventories |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Inventories |
| 86 |
Current tax recoverable |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentTaxAssets |
| 87 |
Trade and other receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:TradeAndOtherCurrentReceivables |
| 88 |
Derivative financial instruments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentDerivativeFinancialAssets |
| 89 |
Liquid investments |
Concept (Monetary) |
As Of |
Debit |
gsk:LiquidInvestmentsCurrent |
| 90 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 91 |
Assets held for sale |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners |
| 92 |
Current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentAssets |
| 93 |
Total assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Assets |
| 94 |
Current liabilities |
Abstract |
|
|
ifrs-full:CurrentLiabilitiesAbstract |
| 95 |
Short-term borrowings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ShorttermBorrowings |
| 96 |
Contingent consideration liabilities |
Concept (Monetary) |
As Of |
Credit |
gsk:ContingentConsiderationLiabilitiesCurrent |
| 97 |
Trade and other payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayables |
| 98 |
Derivative financial instruments |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentDerivativeFinancialLiabilities |
| 99 |
Current tax payable |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentTaxLiabilities |
| 100 |
Short-term provisions |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherShorttermProvisions |
| 101 |
Total current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentLiabilities |
| 102 |
Non-current liabilities |
Abstract |
|
|
ifrs-full:NoncurrentLiabilitiesAbstract |
| 103 |
Long-term borrowings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LongtermBorrowings |
| 104 |
Corporation tax payable |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentTaxLiabilitiesNoncurrent |
| 105 |
Deferred tax liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredTaxLiabilities |
| 106 |
Pensions and other post-employment benefits |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentProvisionsForEmployeeBenefits |
| 107 |
Other provisions |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherLongtermProvisions |
| 108 |
Derivative financial instruments |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentDerivativeFinancialLiabilities |
| 109 |
Contingent consideration liabilities |
Concept (Monetary) |
As Of |
Credit |
gsk:ContingentConsiderationLiabilitiesNoncurrent |
| 110 |
Other non-current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherNoncurrentLiabilities |
| 111 |
Total non-current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentLiabilities |
| 112 |
Total liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Liabilities |
| 113 |
Net assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NetAssetsLiabilities |
| 114 |
Equity |
Abstract |
|
|
ifrs-full:EquityAbstract |
| 115 |
Share capital |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:IssuedCapital |
| 116 |
Share premium account |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:SharePremium |
| 117 |
Retained earnings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:RetainedEarnings |
| 118 |
Other reserves |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherReserves |
| 119 |
Shareholders' equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityAttributableToOwnersOfParent |
| 120 |
Non-controlling interests |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncontrollingInterests |
| 121 |
Total equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 122 |
1006 - Statement - Consolidated statement of changes in equity |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/StatementOfChangesInEquity-610000 |
| 123 |
Statement of changes in equity [table] |
Table |
* |
* |
ifrs-full:StatementOfChangesInEquityTable |
| 124 |
Components of equity [axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 125 |
Equity [member] |
Member |
|
|
ifrs-full:EquityMember |
| 126 |
Share capital [member] |
Member |
|
|
ifrs-full:IssuedCapitalMember |
| 127 |
Share premium [member] |
Member |
|
|
ifrs-full:SharePremiumMember |
| 128 |
Retained earnings [member] |
Member |
|
|
ifrs-full:RetainedEarningsMember |
| 129 |
Other reserves [member] |
Member |
|
|
ifrs-full:OtherReservesMember |
| 130 |
Total [member] |
Member |
|
|
ifrs-full:EquityAttributableToOwnersOfParentMember |
| 131 |
Non- controlling interests [member] |
Member |
|
|
ifrs-full:NoncontrollingInterestsMember |
| 132 |
Retrospective application and retrospective restatement [axis] |
Axis |
|
|
ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis |
| 133 |
Currently stated [member] |
Member |
|
|
ifrs-full:RestatedMember |
| 134 |
Previously stated [member] |
Member |
|
|
ifrs-full:PreviouslyStatedMember |
| 135 |
IFRS 15 adjustments [member] |
Member |
|
|
ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member |
| 136 |
IFRS 9 adjustments [member] |
Member |
|
|
gsk:IncreaseDecreaseDueToApplicationOfIFRS9Member |
| 137 |
Statement of changes in equity [line items] |
LineItems |
|
|
ifrs-full:StatementOfChangesInEquityLineItems |
| 138 |
Equity at beginning of period |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 139 |
Profit after taxation for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 140 |
Other comprehensive income/(expense) for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncome |
| 141 |
Total comprehensive income for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 142 |
Distributions to non-controlling interests |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests |
| 143 |
Contribution from non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseThroughOtherContributionsByNoncontrollingInterestsEquity |
| 144 |
Derecognition of non-controlling interests in Consumer Healthcare Joint Venture |
Concept (Monetary) |
For Period |
Credit |
gsk:DerecognitionOfNoncontrollingInterests |
| 145 |
Dividends to shareholders |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DividendsPaidClassifiedAsFinancingActivities |
| 146 |
Dividends to shareholders |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DividendsPaid |
| 147 |
Recognition of liabilities with non-controlling interests |
Concept (Monetary) |
For Period |
Debit |
gsk:RecognitionOfLiabilitiesWithNoncontrollingInterests |
| 148 |
Realised profits on disposal of equity investments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments |
| 149 |
Derecognition of liabilities with non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
gsk:DerecognitionOfLiabilitiesWithNoncontrollingInterests |
| 150 |
Share of associates and joint ventures realised profits on disposal of equity investments |
Concept (Monetary) |
For Period |
Credit |
gsk:ShareOfAssociatesAndJointVenturesRealisedProfitsOnDisposalOfEquityInvestments |
| 151 |
Changes in non-controllinginterests |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseInNoncontrollingInterests |
| 152 |
Shares issued |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IssueOfEquity |
| 153 |
Shares acquired by ESOP Trusts |
Concept (Monetary) |
For Period |
Credit |
gsk:PaymentForSharesAcquiredByEmployeeStockOptionPlanTrusts |
| 154 |
Write-down of shares held by ESOP Trusts |
Concept (Monetary) |
For Period |
Credit |
gsk:WritedownOfSharesHeldByEmployeeStockOwnershipPlan |
| 155 |
Share-based incentive plans |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions |
| 156 |
Tax on share-based incentive plans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions |
| 157 |
Equity at end of period |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 158 |
Equity at end of period at Dec 31, 2017, as adjusted |
Concept (Monetary) |
As Of |
Credit |
gsk:AdjustedEquity |
| 159 |
1007 - Statement - Consolidated cash flow statement |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000 |
| 160 |
Implied Table |
Table |
* |
* |
implied:Table |
| 161 |
Statement of cash flows [abstract] |
Abstract |
|
|
ifrs-full:StatementOfCashFlowsAbstract |
| 162 |
Cash flow from operating activities |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract |
| 163 |
Profit after taxation for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 164 |
Adjustments reconciling profit after tax to operating cash flows |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForReconcileProfitLoss |
| 165 |
Cash generated from operations |
Concept (Monetary) |
For Period |
|
ifrs-full:CashFlowsFromUsedInOperations |
| 166 |
Taxation paid |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities |
| 167 |
Net cash inflow from operating activities |
Concept (Monetary) |
For Period |
|
ifrs-full:CashFlowsFromUsedInOperatingActivities |
| 168 |
Cash flow from investing activities |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract |
| 169 |
Purchase of property, plant and equipment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| 170 |
Proceeds from sale of property, plant and equipment |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| 171 |
Purchase of intangible assets |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities |
| 172 |
Proceeds from sale of intangible assets |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities |
| 173 |
Purchase of equity investments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities |
| 174 |
Proceeds from sale of equity investments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities |
| 175 |
Contingent consideration paid |
Concept (Monetary) |
For Period |
Credit |
gsk:ContingentConsiderationPaid |
| 176 |
Purchase of businesses, net of cash acquired |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities |
| 177 |
Disposal of businesses |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities |
| 178 |
Investments in associates and joint ventures |
Concept (Monetary) |
For Period |
Credit |
gsk:PurchaseOfInvestmentInAssociatesAndJointVentures |
| 179 |
Proceeds from disposal of interests in associates |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromSalesOfInterestsInAssociates |
| 180 |
Decrease in liquid investments |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseInLiquidInvestments |
| 181 |
Interest received |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:InterestReceivedClassifiedAsInvestingActivities |
| 182 |
Dividends from associates, joint ventures and equity investments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DividendsReceivedClassifiedAsInvestingActivities |
| 183 |
Cash inflow |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInInvestingActivities |
| 184 |
Cash flow from financing activities |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract |
| 185 |
Shares acquired by ESOP Trusts |
Concept (Monetary) |
For Period |
Credit |
gsk:PaymentForSharesAcquiredByEmployeeStockOptionPlanTrusts |
| 186 |
Issue of share capital |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromIssuingShares |
| 187 |
Purchase of non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
gsk:PurchaseOfNonControllingInterests |
| 188 |
Increase in long-term loans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromNoncurrentBorrowings |
| 189 |
Repayment of short-term Notes |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RepaymentsOfCurrentBorrowings |
| 190 |
Increase in/(repayment of) other short-term loans |
Concept (Monetary) |
For Period |
Debit |
gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings |
| 191 |
Net repayment of obligations under finance leases |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities |
| 192 |
Interest paid |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestPaidClassifiedAsFinancingActivities |
| 193 |
Dividends paid to shareholders |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities |
| 194 |
Distributions to non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities |
| 195 |
Contributions from non-controlling interests |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests |
| 196 |
Other financing cash flows |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities |
| 197 |
Net cash outflow from financing activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInFinancingActivities |
| 198 |
Increase/(decrease) in cash and bank overdrafts |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges |
| 199 |
Cash and bank overdrafts at beginning of year |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition |
| 200 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| 201 |
Increase/(decrease) in cash and bank overdrafts |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges |
| 202 |
Cash and bank overdrafts at end of year |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition |
| 203 |
Cash and bank overdrafts at end of year comprise: |
Abstract |
|
|
ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPositionAbstract |
| 204 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 205 |
Cash and cash equivalents reported in assets held for sale |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalentsClassifiedAsPartOfDisposalGroupHeldForSale |
| 206 |
Cash and cash equivalents after assets held for sale reported |
Concept (Monetary) |
As Of |
Debit |
gsk:CashAndCashEquivalentsAfterAdjustmentForAssetsHeldForSale |
| 207 |
Overdrafts |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:BankOverdraftsClassifiedAsCashEquivalents |
| 208 |
Cash and bank overdrafts at end of year |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition |
| 209 |
1008 - Disclosure - Presentation of the financial statements |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory |
| 210 |
Implied Table |
Table |
* |
* |
implied:Table |
| 211 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 212 |
Presentation of the financial statements |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory |
| 213 |
1009 - Disclosure - Accounting principles and policies |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory |
| 214 |
Implied Table |
Table |
* |
* |
implied:Table |
| 215 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 216 |
Accounting principles and policies |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory |
| 217 |
1010 - Disclosure - Key accounting judgements and estimates |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory |
| 218 |
Implied Table |
Table |
* |
* |
implied:Table |
| 219 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 220 |
Key accounting judgements and estimates |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory |
| 221 |
1011 - Disclosure - New accounting requirements |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations |
| 222 |
Implied Table |
Table |
* |
* |
implied:Table |
| 223 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 224 |
New accounting requirements |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations |
| 225 |
1012 - Disclosure - Exchange rates |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory |
| 226 |
Implied Table |
Table |
* |
* |
implied:Table |
| 227 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 228 |
Exchange rates |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory |
| 229 |
1013 - Disclosure - Turnover and segment information |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEntitysReportableSegmentsExplanatory |
| 230 |
Implied Table |
Table |
* |
* |
implied:Table |
| 231 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 232 |
Turnover and segment information |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory |
| 233 |
1014 - Disclosure - Other operating income/(expense) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherOperatingIncomeExpenseExplanatory |
| 234 |
Implied Table |
Table |
* |
* |
implied:Table |
| 235 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 236 |
Other operating income/(expense) |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory |
| 237 |
1015 - Disclosure - Operating profit |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfProfitLossFromOperatingActivitiesExplanatory |
| 238 |
Implied Table |
Table |
* |
* |
implied:Table |
| 239 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 240 |
Operating profit |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory |
| 241 |
1016 - Disclosure - Employee costs |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeCostsExplanatory |
| 242 |
Implied Table |
Table |
* |
* |
implied:Table |
| 243 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 244 |
Employee costs |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfEmployeeCostsExplanatory |
| 245 |
1017 - Disclosure - Major restructuring costs |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfMajorRestructuringCostsExplanatory |
| 246 |
Implied Table |
Table |
* |
* |
implied:Table |
| 247 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 248 |
Major restructuring costs |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfMajorRestructuringCostsExplanatory |
| 249 |
1018 - Disclosure - Finance income |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinanceIncomeExplanatory |
| 250 |
Implied Table |
Table |
* |
* |
implied:Table |
| 251 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 252 |
Finance income |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinanceIncomeExplanatory |
| 253 |
1019 - Disclosure - Finance expense |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinanceIncomeExpenseExplanatory |
| 254 |
Implied Table |
Table |
* |
* |
implied:Table |
| 255 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 256 |
Finance expense |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory |
| 257 |
1020 - Disclosure - Associates and joint ventures |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfAssociatesAndJointVenturesExplanatory |
| 258 |
Implied Table |
Table |
* |
* |
implied:Table |
| 259 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 260 |
Associates and joint ventures |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfAssociatesAndJointVenturesExplanatory |
| 261 |
1021 - Disclosure - Taxation |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatory |
| 262 |
Implied Table |
Table |
* |
* |
implied:Table |
| 263 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 264 |
Taxation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIncomeTaxExplanatory |
| 265 |
1022 - Disclosure - Earnings per share |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatory |
| 266 |
Implied Table |
Table |
* |
* |
implied:Table |
| 267 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 268 |
Earnings per share |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfEarningsPerShareExplanatory |
| 269 |
1023 - Disclosure - Dividends |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfDividendsExplanatory |
| 270 |
Implied Table |
Table |
* |
* |
implied:Table |
| 271 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 272 |
Dividends |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDividendsExplanatory |
| 273 |
1024 - Disclosure - Property, plant and equipment |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatory |
| 274 |
Implied Table |
Table |
* |
* |
implied:Table |
| 275 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 276 |
Property, plant and equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory |
| 277 |
1025 - Disclosure - Goodwill |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfGoodwillExplanatory |
| 278 |
Implied Table |
Table |
* |
* |
implied:Table |
| 279 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 280 |
Goodwill |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfGoodwillExplanatory |
| 281 |
1026 - Disclosure - Other intangible assets |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatory |
| 282 |
Implied Table |
Table |
* |
* |
implied:Table |
| 283 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 284 |
Other intangible assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIntangibleAssetsExplanatory |
| 285 |
1027 - Disclosure - Investments in associates and joint ventures |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory |
| 286 |
Implied Table |
Table |
* |
* |
implied:Table |
| 287 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 288 |
Investments in associates and joint ventures |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory |
| 289 |
1028 - Disclosure - Other investments |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory |
| 290 |
Implied Table |
Table |
* |
* |
implied:Table |
| 291 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 292 |
Other investments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory |
| 293 |
1029 - Disclosure - Other non-current assets |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherNoncurrentAssetsExplanatory |
| 294 |
Implied Table |
Table |
* |
* |
implied:Table |
| 295 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 296 |
Other non-current assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory |
| 297 |
1030 - Disclosure - Inventories |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfInventoriesExplanatory |
| 298 |
Implied Table |
Table |
* |
* |
implied:Table |
| 299 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 300 |
Inventories |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfInventoriesExplanatory |
| 301 |
1031 - Disclosure - Trade and other receivables |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradesAndOtherReceivableExplanatory |
| 302 |
Implied Table |
Table |
* |
* |
implied:Table |
| 303 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 304 |
Trade and other receivables |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfTradesAndOtherReceivableExplanatory |
| 305 |
1032 - Disclosure - Cash and cash equivalents |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCashAndCashEquivalentsExplanatory |
| 306 |
Implied Table |
Table |
* |
* |
implied:Table |
| 307 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 308 |
Cash and cash equivalents |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory |
| 309 |
1033 - Disclosure - Assets held for sale |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory |
| 310 |
Implied Table |
Table |
* |
* |
implied:Table |
| 311 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 312 |
Assets held for sale |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory |
| 313 |
1034 - Disclosure - Trade and other payables |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEntireTradeAndOtherPayablesExplanatory |
| 314 |
Implied Table |
Table |
* |
* |
implied:Table |
| 315 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 316 |
Trade and other payables |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfEntireTradeAndOtherPayablesExplanatory |
| 317 |
1035 - Disclosure - Pensions and other post-employment benefits |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory |
| 318 |
Implied Table |
Table |
* |
* |
implied:Table |
| 319 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 320 |
Pensions and other post-employment benefits |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfEmployeeBenefitsExplanatory |
| 321 |
1036 - Disclosure - Other provisions |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory |
| 322 |
Implied Table |
Table |
* |
* |
implied:Table |
| 323 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 324 |
Other provisions |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory |
| 325 |
1037 - Disclosure - Other non-current liabilities |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherNoncurrentLiabilitiesExplanatory |
| 326 |
Implied Table |
Table |
* |
* |
implied:Table |
| 327 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 328 |
Other non-current liabilities |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory |
| 329 |
1038 - Disclosure - Net debt |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfBorrowingsExplanatory |
| 330 |
Implied Table |
Table |
* |
* |
implied:Table |
| 331 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 332 |
Net debt |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfBorrowingsExplanatory |
| 333 |
1039 - Disclosure - Contingent liabilities |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfContingentLiabilitiesExplanatory |
| 334 |
Implied Table |
Table |
* |
* |
implied:Table |
| 335 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 336 |
Contingent liabilities |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfContingentLiabilitiesExplanatory |
| 337 |
1040 - Disclosure - Share capital and share premium account |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfShareCapitalAndSharePremiumExplanatory |
| 338 |
Implied Table |
Table |
* |
* |
implied:Table |
| 339 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 340 |
Share capital and share premium account |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfShareCapitalAndSharePremiumExplanatory |
| 341 |
1041 - Disclosure - Movements in equity |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfMovementsInEquityExplanatory |
| 342 |
Implied Table |
Table |
* |
* |
implied:Table |
| 343 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 344 |
Movements in equity |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfMovementsInEquityExplanatory |
| 345 |
1042 - Disclosure - Related party transactions |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatory |
| 346 |
Implied Table |
Table |
* |
* |
implied:Table |
| 347 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 348 |
Related party transactions |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfRelatedPartyExplanatory |
| 349 |
1043 - Disclosure - Adjustments reconciling profit after tax to operating cash flows |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory |
| 350 |
Implied Table |
Table |
* |
* |
implied:Table |
| 351 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 352 |
Adjustments reconciling profit after tax to operating cash flows |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory |
| 353 |
1044 - Disclosure - Reconciliation of net cash flow to movement in net debt |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfDebtSecuritiesExplanatory |
| 354 |
Implied Table |
Table |
* |
* |
implied:Table |
| 355 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 356 |
Reconciliation of net cash flow to movement in net debt |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDebtSecuritiesExplanatory |
| 357 |
1045 - Disclosure - Acquisitions and disposals |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfBusinessCombinationsExplanatory |
| 358 |
Implied Table |
Table |
* |
* |
implied:Table |
| 359 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 360 |
Acquisitions and disposals |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfBusinessCombinationsExplanatory |
| 361 |
1046 - Disclosure - Contingent consideration liabilities |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfContingentConsiderationLiabilitiesExplanatory |
| 362 |
Implied Table |
Table |
* |
* |
implied:Table |
| 363 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 364 |
Contingent consideration liabilities |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfContingentConsiderationLiabilitiesExplanatory |
| 365 |
1047 - Disclosure - Non-controlling interests |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfNoncontrollingInterestsExplanatory |
| 366 |
Implied Table |
Table |
* |
* |
implied:Table |
| 367 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 368 |
Non-controlling interests |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory |
| 369 |
1048 - Disclosure - Commitments |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsExplanatory |
| 370 |
Implied Table |
Table |
* |
* |
implied:Table |
| 371 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 372 |
Commitments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfCommitmentsExplanatory |
| 373 |
1049 - Disclosure - Financial instruments and related disclosures |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatory |
| 374 |
Implied Table |
Table |
* |
* |
implied:Table |
| 375 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 376 |
Financial instruments and related disclosures |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinancialInstrumentsExplanatory |
| 377 |
1050 - Disclosure - Employee share schemes |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory |
| 378 |
Implied Table |
Table |
* |
* |
implied:Table |
| 379 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 380 |
Employee share schemes |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory |
| 381 |
1051 - Disclosure - Principal Group companies |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfPrincipalGroupCompaniesExplanatory |
| 382 |
Implied Table |
Table |
* |
* |
implied:Table |
| 383 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 384 |
Principal Group companies |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfPrincipalGroupCompaniesExplanatory |
| 385 |
1052 - Disclosure - Legal proceedings |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfLegalProceedingsExplanatory |
| 386 |
Implied Table |
Table |
* |
* |
implied:Table |
| 387 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 388 |
Legal proceedings |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfLegalProceedingsExplanatory |
| 389 |
1053 - Disclosure - Post balance sheet events |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory |
| 390 |
Implied Table |
Table |
* |
* |
implied:Table |
| 391 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 392 |
Post balance sheet events |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory |
| 393 |
1054 - Disclosure - Presentation of the financial statements (Policies) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatoryPolicies |
| 394 |
Statement [table] |
Table |
* |
* |
gsk:StatementTable |
| 395 |
Retrospective application and retrospective restatement [axis] |
Axis |
|
|
ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis |
| 396 |
Currently stated [member] |
Member |
|
|
ifrs-full:RestatedMember |
| 397 |
Previously stated [member] |
Member |
|
|
ifrs-full:PreviouslyStatedMember |
| 398 |
Statement [LineItems] |
LineItems |
|
|
gsk:StatementLineItems |
| 399 |
Implementation of IFRS 9 and IFRS 15 |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations |
| 400 |
Consolidation |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatory |
| 401 |
Business combinations |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory |
| 402 |
Foreign currency translation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory |
| 403 |
Revenue |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue |
| 404 |
Expenditure |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForExpensesExplanatory |
| 405 |
Research and development |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory |
| 406 |
Environmental expenditure |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForEnvironmentRelatedExpenseExplanatory |
| 407 |
Legal and other disputes |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DescriptionOfAccountingPolicyForLegalAndOtherDisputesExplanatory |
| 408 |
Pensions and other post-employment benefits |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory |
| 409 |
Employee share plans |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory |
| 410 |
Property, plant and equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory |
| 411 |
Leases |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory |
| 412 |
Goodwill |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory |
| 413 |
Other intangible assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory |
| 414 |
Impairment of non-current assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory |
| 415 |
Investments in associates, joint ventures and joint operations |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory |
| 416 |
Inventories |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories |
| 417 |
Financial assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory |
| 418 |
Other investments |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DescriptionOfAccountingPolicyForOtherInvestmentExplanatory |
| 419 |
Trade receivables |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory |
| 420 |
Cash and cash equivalents |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory |
| 421 |
Borrowings |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory |
| 422 |
Derivative financial instruments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory |
| 423 |
Hedge accounting |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForHedgingExplanatory |
| 424 |
Taxation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory |
| 425 |
Discounting |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DescriptionOfAccountingPolicyForDiscountingExplanatory |
| 426 |
Available-for-sale investments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory |
| 427 |
Derivative financial instruments and hedging |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory |
| 428 |
1055 - Disclosure - Presentation of the financial statements (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatoryTables |
| 429 |
Implied Table |
Table |
* |
* |
implied:Table |
| 430 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 431 |
Summary of Amount of Adjustment for Each Financial Statement Line Item Affected by Application of IFRS 9 and IFRS 15 |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIFRS9AndIFRS15Explanatory |
| 432 |
1056 - Disclosure - Accounting principles and policies (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryTables |
| 433 |
Implied Table |
Table |
* |
* |
implied:Table |
| 434 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 435 |
Summary of Expected Useful Lives of Property Plant and Equipment |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatory |
| 436 |
1057 - Disclosure - Exchange rates (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTables |
| 437 |
Implied Table |
Table |
* |
* |
implied:Table |
| 438 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 439 |
Summary of Currencies Translations and Relevant Exchange Rates |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDetailedInformationAboutEffectOfChangesInForeignExchangeRatesExplanatory |
| 440 |
1058 - Disclosure - Turnover and segment information (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEntitysReportableSegmentsExplanatoryTables |
| 441 |
Statement [table] |
Table |
* |
* |
gsk:StatementTable |
| 442 |
Segments [axis] |
Axis |
|
|
ifrs-full:SegmentsAxis |
| 443 |
Segments [member] |
Member |
|
|
ifrs-full:SegmentsMember |
| 444 |
Pharmaceuticals [member] |
Member |
|
|
gsk:PharmaceuticalsMember |
| 445 |
Vaccines [member] |
Member |
|
|
gsk:VaccinesMember |
| 446 |
Consumer Healthcare [member] |
Member |
|
|
gsk:ConsumerHealthcareMember |
| 447 |
Statement [LineItems] |
LineItems |
|
|
gsk:StatementLineItems |
| 448 |
Turnover by Segment |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfTurnoverBySegmentExplanatory |
| 449 |
Turnover by Product & Service |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfProductsAndServicesExplanatory |
| 450 |
Segment Profit and Operating Profit |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfOperatingSegmentsExplanatory |
| 451 |
Summary of Geographical Information |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfGeographicalAreasExplanatory |
| 452 |
1059 - Disclosure - Other operating income/(expense) (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherOperatingIncomeExpenseExplanatoryTables |
| 453 |
Implied Table |
Table |
* |
* |
implied:Table |
| 454 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 455 |
Summary Information about Other Operating Income Expense |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDetailedInformationAboutOtherOperatingIncomeExpenseExplanatory |
| 456 |
1060 - Disclosure - Operating profit (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfProfitLossFromOperatingActivitiesExplanatoryTables |
| 457 |
Statement [table] |
Table |
* |
* |
gsk:StatementTable |
| 458 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 459 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 460 |
Pension schemes [member] |
Member |
|
|
ifrs-full:PensionDefinedBenefitPlansMember |
| 461 |
Statement [LineItems] |
LineItems |
|
|
gsk:StatementLineItems |
| 462 |
Summary of Information About Profit Loss |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDetailedInformationAboutProfitLossExplanatory |
| 463 |
Summary of Auditors Remuneration |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfAuditorsRemunerationExplanatory |
| 464 |
1061 - Disclosure - Employee costs (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeCostsExplanatoryTables |
| 465 |
Implied Table |
Table |
* |
* |
implied:Table |
| 466 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 467 |
Summary of Employee Costs |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDetailedInformationAboutEmployeeCostsExplanatory |
| 468 |
Summary of Cost of Share-based Incentive Plans |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory |
| 469 |
Disclosure of Average Monthly Number of Persons Employed by the Group (Including Directors) |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfNumberOfEmployeesExplanatory |
| 470 |
Summary of Compensation of the Directors and Senior Management |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfCompensationOfDirectorsAndSeniorManagementExplanatory |
| 471 |
1062 - Disclosure - Major restructuring costs (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfMajorRestructuringCostsExplanatoryTables |
| 472 |
Implied Table |
Table |
* |
* |
implied:Table |
| 473 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 474 |
Summary of Analysis of Costs Charged to Operating Profit |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfMajorRestructuringCostsChargedToOperatingProfitExplanatory |
| 475 |
Summary of Major Restructuring Charges |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfRestructuringCostsExplanatory |
| 476 |
1063 - Disclosure - Finance income (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinanceIncomeExplanatoryTables |
| 477 |
Implied Table |
Table |
* |
* |
implied:Table |
| 478 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 479 |
Summary of Finance Income |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfInterestIncomeExplanatory |
| 480 |
1064 - Disclosure - Finance expense (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinanceIncomeExpenseExplanatoryTables |
| 481 |
Implied Table |
Table |
* |
* |
implied:Table |
| 482 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 483 |
Summary of Finance Cost |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinanceCostExplanatory |
| 484 |
1065 - Disclosure - Associates and joint ventures (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfAssociatesAndJointVenturesExplanatoryTables |
| 485 |
Implied Table |
Table |
* |
* |
implied:Table |
| 486 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 487 |
Summary of After Tax Profits and Losses of Associates and Joint Ventures |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfShareOfAfterTaxProfitsAndLossesOfAssociatesAndJointVenturesExplanatory |
| 488 |
Summary of Group Held for Significant Associate |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfGroupHeldSignificantAssociateExplanatory |
| 489 |
Summary of Aggregated Financial Information |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfAggregatedFinancialInformationOfAssociatesAndJointVenturesExplanatory |
| 490 |
1066 - Disclosure - Taxation (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatoryTables |
| 491 |
Implied Table |
Table |
* |
* |
implied:Table |
| 492 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 493 |
Summary of Taxation Charge Based on Profits |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfIncomeTaxExpenseBenefitsExplanatory |
| 494 |
Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfReconciliationOfActualTaxChargeAndProfitChargedAtUKTaxRateExplanatory |
| 495 |
Summary of Tax on Items Charged to Equity and Statement of Comprehensive Income |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfCurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeExplanatory |
| 496 |
Summary of Movement in Deferred Tax Assets and Liabilities |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesExplanatory |
| 497 |
Summary of Net Temporary Differences Include Accrued Expenses |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDeferredTaxesExplanatory |
| 498 |
Summary of Temporary Difference Unused Tax Losses and Unused Tax Credits |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory |
| 499 |
1067 - Disclosure - Earnings per share (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEarningsPerShareExplanatoryTables |
| 500 |
Implied Table |
Table |
* |
* |
implied:Table |
| 501 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 502 |
Summary of Basic and Diluted Earnings Per Share |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:EarningsPerShareExplanatory |
| 503 |
Schedule of Numbers of Shares Earnings Per Share |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfWeightedAverageNumbersOfSharesEarningsPerShareExplanatory |
| 504 |
1068 - Disclosure - Dividends (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfDividendsExplanatoryTables |
| 505 |
Implied Table |
Table |
* |
* |
implied:Table |
| 506 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 507 |
Summary of Interim Financial Reporting |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfInterimFinancialReportingExplanatory |
| 508 |
Summary of Dividends to Shareholders |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDividendsPaidExplanatory |
| 509 |
1069 - Disclosure - Property, plant and equipment (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTables |
| 510 |
Implied Table |
Table |
* |
* |
implied:Table |
| 511 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 512 |
Summary of Property, Plant and Equipment |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory |
| 513 |
1070 - Disclosure - Goodwill (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfGoodwillExplanatoryTables |
| 514 |
Implied Table |
Table |
* |
* |
implied:Table |
| 515 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 516 |
Summary of Changes in Goodwill |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory |
| 517 |
Summary of Goodwill Allocated to Segments |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfAllocationOfGoodwillToSegmentsExplanatory |
| 518 |
Schedule of Discounted Cash Flow Models Used in Impairment Tests |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesExplanatory |
| 519 |
1071 - Disclosure - Other intangible assets (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTables |
| 520 |
Implied Table |
Table |
* |
* |
implied:Table |
| 521 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 522 |
Summary of Other Intangible Assets |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory |
| 523 |
Schedule of Amortisation and Impairment Losses, Net of Reversals |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory |
| 524 |
Summary of Book Values of Largest Individual Items |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfLicencesIncludedInIntangibleAssetsExplanatory |
| 525 |
Summary of Book Values of Major Brands |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfBrandNamesRelatedToAcquisitionsExplanatory |
| 526 |
1072 - Disclosure - Investments in associates and joint ventures (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatoryTables |
| 527 |
Implied Table |
Table |
* |
* |
implied:Table |
| 528 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 529 |
Schedule of Investments in Associates and Joint Ventures |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDetailedInformationOfInvestmentsInAssociatesAndJointVenturesExplanatory |
| 530 |
Summary of Balance Sheet Information |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfInvestmentsAssociatesJointVenturesExplanatory |
| 531 |
1073 - Disclosure - Other investments (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables |
| 532 |
Implied Table |
Table |
* |
* |
implied:Table |
| 533 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 534 |
Schedule of Other Investments |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfScheduleOfOtherInvestmentExplanatory |
| 535 |
Schedule of Carrying Value of Other Investments |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfCarryingValueOfOtherInvestmentImpairedExplanatory |
| 536 |
1074 - Disclosure - Other non-current assets (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherNoncurrentAssetsExplanatoryTables |
| 537 |
Implied Table |
Table |
* |
* |
implied:Table |
| 538 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 539 |
Summary of Other Non-Current Assets |
Concept (Text Block (HTML)) |
For Period |
|
gsk:SummaryOfReceivablesInOtherNonCurrentAssetsExplanatory |
| 540 |
1075 - Disclosure - Inventories (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfInventoriesExplanatoryTables |
| 541 |
Implied Table |
Table |
* |
* |
implied:Table |
| 542 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 543 |
Summary of Inventories |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDetailedInformationOfInventoriesExplanatory |
| 544 |
1076 - Disclosure - Trade and other receivables (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradesAndOtherReceivableExplanatoryTables |
| 545 |
Implied Table |
Table |
* |
* |
implied:Table |
| 546 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 547 |
Summary of Trade and Other Receivables |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory |
| 548 |
Summary of Loss Allowance |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfExpectedCreditLossAllowanceExplanatory |
| 549 |
1077 - Disclosure - Cash and cash equivalents (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCashAndCashEquivalentsExplanatoryTables |
| 550 |
Implied Table |
Table |
* |
* |
implied:Table |
| 551 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 552 |
Summary of Cash and Cash Equivalents |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory |
| 553 |
1078 - Disclosure - Assets held for sale (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatoryTables |
| 554 |
Implied Table |
Table |
* |
* |
implied:Table |
| 555 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 556 |
Summary of Assets Held for Sale |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfAssetsHeldForSaleExplanatory |
| 557 |
1079 - Disclosure - Trade and other payables (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEntireTradeAndOtherPayablesExplanatoryTables |
| 558 |
Implied Table |
Table |
* |
* |
implied:Table |
| 559 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 560 |
Summary of Trade and Other Payables |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory |
| 561 |
Summary of Increase/(Decrease) in Financial Liability and Loss/(Gain) in Income Statement |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfIncomeStatementAndBalanceSheetSensitivityOfPutOptionToReasonablyPossibleChangesInKeyAssumptionExplanatory |
| 562 |
1080 - Disclosure - Pensions and other post-employment benefits (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables |
| 563 |
Statement [table] |
Table |
* |
* |
gsk:StatementTable |
| 564 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 565 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 566 |
Defined benefit pension and post-retirement healthcare scheme. [member] |
Member |
|
|
gsk:DefinedBenefitPensionAndPostretirementHealthcareSchemeMember |
| 567 |
Defined Benefit Pension Obligation [member] |
Member |
|
|
gsk:DefinedBenefitPensionObligationMember |
| 568 |
Post-retirement benefits [member] |
Member |
|
|
gsk:PostretirementBenefitsMember |
| 569 |
Statement [LineItems] |
LineItems |
|
|
gsk:StatementLineItems |
| 570 |
Summary of Analysis of Defined Benefit Pension Obligation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory |
| 571 |
Summary of Average Life Expectancy Assumed |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfAverageLifeExpectancyAssumptionsExplanatory |
| 572 |
Summary of Financial Assumptions in Assessing Defined Benefit Liabilities |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDefinedBenefitPlanActuarialAssumptionsExplanatory |
| 573 |
Summary of Amounts Recorded in Income Statement and Statement of Comprehensive Income Related to Defined Benefit Pension and Post-retirement Healthcare Schemes |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementChargesExplanatory |
| 574 |
Summary of Balance Sheet Presentation of Group Defined Benefit Pension Schemes and Other Post-retirement Benefits |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfBalanceSheetPresentationOfDefinedBenefitPensionAndPostRetirementExplanatory |
| 575 |
Summary of Fair Values of Assets and Liabilities of UK and US Defined Benefit Pension Schemes Together with Aggregated Data for Other Defined Benefit Pension Schemes in Group |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory |
| 576 |
Summary of Movements in Fair Values of Assets |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfMovementsInFairValuesOfAssetsExplanatory |
| 577 |
Summary of Movements in Defined Benefit Obligations |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfMovementInDefinedBenefitLiabilityExplanatory |
| 578 |
Summary of Net Defined Benefit Liability |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory |
| 579 |
Summary of Defined Benefit Pension Obligation Analysed by Membership Category |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDefinedBenefitPensionObligationAnalysedByMembershipCategoryExplanatory |
| 580 |
Summary of Post-Retirement Benefit Obligation Analysed By Membership Category |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfPostRetirementBenefitObligationAnalysedByMembershipCategoryExplanatory |
| 581 |
Summary of Weighted Average Duration of Defined Benefit Obligation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationExplanatory |
| 582 |
Summary of Changes In Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory |
| 583 |
1081 - Disclosure - Other provisions (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatoryTables |
| 584 |
Implied Table |
Table |
* |
* |
implied:Table |
| 585 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 586 |
Summary of Other Provisions |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfOtherProvisionsExplanatory |
| 587 |
1082 - Disclosure - Other non-current liabilities (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfOtherNoncurrentLiabilitiesExplanatoryTables |
| 588 |
Implied Table |
Table |
* |
* |
implied:Table |
| 589 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 590 |
Summary of Other Noncurrent Liabilities |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfOtherNonCurrentLiabilitiesDetailsExplanatory |
| 591 |
1083 - Disclosure - Net debt (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfBorrowingsExplanatoryTables |
| 592 |
Implied Table |
Table |
* |
* |
implied:Table |
| 593 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 594 |
Schedule of Current Assets, Short and Long Term Borrowings |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory |
| 595 |
Schedule of Finance Lease Obligations |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfFinanceLeaseObligationsExplanatory |
| 596 |
1084 - Disclosure - Share capital and share premium account (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfShareCapitalAndSharePremiumExplanatoryTables |
| 597 |
Implied Table |
Table |
* |
* |
implied:Table |
| 598 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 599 |
Summary of Share Capital and Share Premium |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumExplanatory |
| 600 |
Summary of Share Capital |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfClassesOfShareCapitalTableExplanatory |
| 601 |
1085 - Disclosure - Movements in equity (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfMovementsInEquityExplanatoryTables |
| 602 |
Implied Table |
Table |
* |
* |
implied:Table |
| 603 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 604 |
Summary of Cumulative Translation Exchange in Equity |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemExplanatory |
| 605 |
Summary of Analysis of Other Reserves |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory |
| 606 |
1086 - Disclosure - Adjustments reconciling profit after tax to operating cash flows (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatoryTables |
| 607 |
Implied Table |
Table |
* |
* |
implied:Table |
| 608 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 609 |
Summary of Cash Generated from Operations |
Concept (Text Block (HTML)) |
For Period |
|
gsk:ScheduleOfAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsExplanatory |
| 610 |
1087 - Disclosure - Reconciliation of net cash flow to movement in net debt (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfDebtSecuritiesExplanatoryTables |
| 611 |
Implied Table |
Table |
* |
* |
implied:Table |
| 612 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 613 |
Summary of Net Debt |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfReconciliationOfNetCashFlowToMovementInNetDebtExplanatory |
| 614 |
Summary of Analysis of Changes in Net Debt |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfAnalysisOfChangesInNetDebtExplanatory |
| 615 |
1088 - Disclosure - Acquisitions and disposals (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfBusinessCombinationsExplanatoryTables |
| 616 |
Implied Table |
Table |
* |
* |
implied:Table |
| 617 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 618 |
Summary of Cash Flows from Business Combinations |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfCashFlowsFromBusinessCombinationsExplanatory |
| 619 |
Summary of Profit on Disposal of Businesses |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfProfitOnDisposalOfBusinessesExplanatory |
| 620 |
Summary of Investment in Associates and Joint Ventures |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfInterestsInAssociatesAndJointVenturesExplanatory |
| 621 |
1089 - Disclosure - Contingent consideration liabilities (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfContingentConsiderationLiabilitiesExplanatoryTables |
| 622 |
Implied Table |
Table |
* |
* |
implied:Table |
| 623 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 624 |
Summary of Fair Value of Contingent Consideration Liabilities |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfFairValueOfContingentConsiderationLiabilitiesExplanatory |
| 625 |
Summary of Possible Changes in key Inputs to Valuation of Contingent Consideration Liabilities |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationExplanatory |
| 626 |
1090 - Disclosure - Non-controlling interests (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfNoncontrollingInterestsExplanatoryTables |
| 627 |
Statement [table] |
Table |
* |
* |
gsk:StatementTable |
| 628 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 629 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 630 |
ViiV healthcare [member] |
Member |
|
|
gsk:ViiVHealthCareMember |
| 631 |
Consumer health care joint venture [member] |
Member |
|
|
gsk:ConsumerHealthCareJointVentureMember |
| 632 |
Statement [LineItems] |
LineItems |
|
|
gsk:StatementLineItems |
| 633 |
Summarised Financial Information of Joint Venture |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfFinancialInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory |
| 634 |
Schedule of Amount Attributable to Joint Venture Included in GSK's Consolidated Statement of Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Balance Sheet |
Concept (Text Block (HTML)) |
For Period |
|
gsk:ScheduleOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatory |
| 635 |
1091 - Disclosure - Commitments (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCommitmentsExplanatoryTables |
| 636 |
Implied Table |
Table |
* |
* |
implied:Table |
| 637 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 638 |
Schedule of Contractual Obligations and Commitments |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfContractualObligationsAndCommitmentsExplanatory |
| 639 |
Summary of Commitments Under Non-Cancellable Operating Leases |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfOperatingLeasesExplanatory |
| 640 |
1092 - Disclosure - Financial instruments and related disclosures (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTables |
| 641 |
Statement [table] |
Table |
* |
* |
gsk:StatementTable |
| 642 |
Hedging instruments [axis] |
Axis |
|
|
ifrs-full:HedgingInstrumentsAxis |
| 643 |
Hedging instruments [member] |
Member |
|
|
ifrs-full:HedgingInstrumentsMember |
| 644 |
Interest rate swap contract [member] |
Member |
|
|
ifrs-full:InterestRateSwapContractMember |
| 645 |
Foreign Exchange Forward Contracts and Swaps [member] |
Member |
|
|
gsk:ForeignExchangeForwardContractsAndSwapsMember |
| 646 |
Levels of fair value hierarchy [axis] |
Axis |
|
|
ifrs-full:LevelsOfFairValueHierarchyAxis |
| 647 |
All levels of fair value hierarchy [member] |
Member |
|
|
ifrs-full:AllLevelsOfFairValueHierarchyMember |
| 648 |
Level 3 [member] |
Member |
|
|
ifrs-full:Level3OfFairValueHierarchyMember |
| 649 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 650 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 651 |
Interest rate risk [member] |
Member |
|
|
ifrs-full:InterestRateRiskMember |
| 652 |
Currency risk [member] |
Member |
|
|
ifrs-full:CurrencyRiskMember |
| 653 |
Statement [LineItems] |
LineItems |
|
|
gsk:StatementLineItems |
| 654 |
Summary of External Credit Exposure |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfExternalCreditExposuresExplanatory |
| 655 |
Summary of Financial Assets and Liabilities |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory |
| 656 |
Summary of Fair Value of Financial Instruments |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory |
| 657 |
Summary of Financial and Non Financial Assets |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfFinancialAssetsAndNonFinancialAssetsExplanatory |
| 658 |
Summary of Ageing of Financial Assets Which are Past Due and for Which No Provision for Bad or Doubtful Debts Has Been Made |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfFinancialAssetsThatArePastDueAndHaveNotBeenImpairedExplanatory |
| 659 |
Reconciliation of Financial Instruments Within Trade and Other Payables, Other Provisions, Other Non-current Liabilities and Contingent Consideration Liabilities |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory |
| 660 |
Summary of Fair Values of Derivatives Held |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory |
| 661 |
Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsExplanatory |
| 662 |
Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDetailedInformationAboutEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLossExplanatory |
| 663 |
Summary of Offsetting of Financial Assets and Liabilities |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory |
| 664 |
Summary of Debt Interest Rate Repricing |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfDebtInterestRateRepricingExplanatory |
| 665 |
Sensitivity Analysis for Each Type of Market Risk |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk |
| 666 |
Summary of Anticipated Contractual Cash Flows Including Interest Payable for the Non-Derivative Financial Liabilities on Undiscounted Basis |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities |
| 667 |
Summary of Anticipated Contractual Cash Flows for Derivative Instruments, Excluding Embedded Derivatives and Equity Options, Using Undiscounted Cash Flows |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfMaturityAnalysisForDerivativeFinancialInstrumentsExplanatory |
| 668 |
1093 - Disclosure - Employee share schemes (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables |
| 669 |
Implied Table |
Table |
* |
* |
implied:Table |
| 670 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 671 |
Schedule of Number of Shares and ADS Issuable |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfEmployeeShareValuePlanExplanatory |
| 672 |
Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfShareOptionsAssumptionsRelatedToSavingsRelatedSchemesExplanatory |
| 673 |
Summary of Option Outstanding |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfShareOptionsAndSavingsRelatedOptionsOutstandingExplanatory |
| 674 |
Summary of Shares Held for Share Award Schemes |
Concept (Text Block (HTML)) |
For Period |
|
gsk:DisclosureOfSharesHeldForShareAwardSchemesAndSharesOptionSchemesExplanatory |
| 675 |
1094 - Disclosure - Principal Group companies (Tables) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfPrincipalGroupCompaniesExplanatoryTables |
| 676 |
Implied Table |
Table |
* |
* |
implied:Table |
| 677 |
Text block [abstract] |
Abstract |
|
|
gsk:TextBlockAbstract |
| 678 |
Schedule of Principal Subsidiaries and Their Countries of Incorporation |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory |
| 679 |
1095 - Disclosure - Presentation of the Financial Statements - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePresentationOfTheFinancialStatementsAdditionalInformation |
| 680 |
Implied Table |
Table |
* |
* |
implied:Table |
| 681 |
Presentation Of The Financial Statements [abstract] |
Abstract |
|
|
gsk:PresentationOfTheFinancialStatementsAbstract |
| 682 |
Additional ECL allowance for trade receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount |
| 683 |
Other transition adjustments arising from change in impairment basis |
Concept (Monetary) |
For Period |
Debit |
gsk:OtherTransitionAdjustmentsArisingFromChangeInImpairmentBasis |
| 684 |
Deferred tax impact, retained earnings |
Concept (Monetary) |
As Of |
Credit |
gsk:DeferredTaxImpactOnRetainedEarnings |
| 685 |
Cumulative adjustment to decrease retained earnings |
Concept (Monetary) |
For Period |
Credit |
gsk:CumulativeAdjustmentToIncreaseDecreaseInRetainedEarnings |
| 686 |
Transfer between retained earnings and fair value reserve |
Concept (Monetary) |
For Period |
Credit |
gsk:TransferBetweenRetainedEarningsAndFairValueReserve |
| 687 |
1096 - Disclosure - Presentation of the Financial Statements - Summary of Amount of Adjustment for Each Financial Statement Line Item Affected by Application of IFRS 9 and IFRS 15 (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePresentationOfTheFinancialStatementsSummaryOfAmountOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationOfIFRS9AndIFRS15 |
| 688 |
Disclosure of adjustment for each financial statement line item affected by application IFRS 9 and IFRS 15 [table] |
Table |
* |
* |
gsk:DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIFRS9AndIFRS15Table |
| 689 |
Retrospective application and retrospective restatement [axis] |
Axis |
|
|
ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis |
| 690 |
Currently stated [member] |
Member |
|
|
ifrs-full:RestatedMember |
| 691 |
Previously stated [member] |
Member |
|
|
ifrs-full:PreviouslyStatedMember |
| 692 |
IFRS 9 adjustments [member] |
Member |
|
|
gsk:IncreaseDecreaseDueToApplicationOfIFRS9Member |
| 693 |
IFRS 15 adjustments [member] |
Member |
|
|
ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member |
| 694 |
Disclosure of adjustment for each financial statement line item affected by application IFRS 9 and IFRS 15 [line items] |
LineItems |
|
|
gsk:DisclosureOfAdjustmentForEachFinancialStatementLineItemAffectedByApplicationIFRS9AndIFRS15LineItems |
| 695 |
Trade and other receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:TradeAndOtherCurrentReceivables |
| 696 |
Liquid investments |
Concept (Monetary) |
As Of |
Debit |
gsk:LiquidInvestmentsCurrent |
| 697 |
Other payables - returns and rebates |
Concept (Monetary) |
As Of |
Credit |
gsk:OtherPayablesReturnsAndRebates |
| 698 |
Other payables - deferred income |
Concept (Monetary) |
As Of |
Credit |
gsk:OtherPayablesDeferredIncome |
| 699 |
Deferred tax assets |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredTaxLiabilityAsset |
| 700 |
Total effect on net assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NetAssetsLiabilities |
| 701 |
Fair value reserve |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherReserves |
| 702 |
Retained earnings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:RetainedEarnings |
| 703 |
Total effect on equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 704 |
1097 - Disclosure - Accounting Principles and Policies - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAccountingPrinciplesAndPoliciesAdditionalInformation |
| 705 |
Disclosure of accounting principles and policies [table] |
Table |
* |
* |
gsk:DisclosureOfAccountingPrinciplesAndPoliciesTable |
| 706 |
Classes of intangible assets other than goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis |
| 707 |
Intangible assets [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 708 |
Licences and franchises [member] |
Member |
|
|
ifrs-full:LicencesAndFranchisesMember |
| 709 |
Amortised brands [member] |
Member |
|
|
gsk:AmortisedBrandsMember |
| 710 |
ERP software systems [member] |
Member |
|
|
gsk:ERPSoftwareSystemsMember |
| 711 |
Other computer software [member] |
Member |
|
|
gsk:OtherComputerSoftwareMember |
| 712 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 713 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 714 |
Top of range [member] |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 715 |
Bottom of range [member] |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 716 |
Disclosure of accounting principles and policies [line items] |
LineItems |
|
|
gsk:DisclosureOfAccountingPrinciplesAndPoliciesLineItems |
| 717 |
Provisions related to legal and other disputes |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Provisions |
| 718 |
Estimated useful lives |
Concept (Text/String) |
For Period |
|
ifrs-full:UsefulLivesOrAmortisationRatesIntangibleAssetsOtherThanGoodwill |
| 719 |
1098 - Disclosure - Accounting Principles and Policies - Summary of Expected Useful Lives of Property Plant and Equipment (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAccountingPrinciplesAndPoliciesSummaryOfExpectedUsefulLivesOfPropertyPlantAndEquipment |
| 720 |
Disclosure of detailed information about property, plant and equipment [table] |
Table |
* |
* |
ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable |
| 721 |
Classes of property, plant and equipment [axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 722 |
Property, plant and equipment [member] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 723 |
Freehold buildings [member] |
Member |
|
|
gsk:FreeholdBuildingsMember |
| 724 |
Leasehold land and buildings [member] |
Member |
|
|
gsk:LeaseholdLandAndBuildingsMember |
| 725 |
Plant and machinery [member] |
Member |
|
|
gsk:PlantAndMachineryMember |
| 726 |
Equipment and vehicles [member] |
Member |
|
|
gsk:EquipmentAndVehiclesMember |
| 727 |
Disclosure of detailed information about property, plant and equipment [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems |
| 728 |
Useful lives of property plant and equipment |
Concept (Text/String) |
For Period |
|
ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment |
| 729 |
1099 - Disclosure - Key Accounting Judgements and Estimates - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureKeyAccountingJudgementsAndEstimatesAdditionalInformation |
| 730 |
Disclosure of changes in accounting estimates [table] |
Table |
* |
* |
ifrs-full:DisclosureOfChangesInAccountingEstimatesTable |
| 731 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 732 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 733 |
Business combinations [member] |
Member |
|
|
ifrs-full:BusinessCombinationsMember |
| 734 |
Novartis [member] |
Member |
|
|
gsk:NovartisMember |
| 735 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 736 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 737 |
Shionogi ViiV healthcare joint venture [member] |
Member |
|
|
gsk:ShionogiViiVHealthcareJointVentureMember |
| 738 |
Joint ventures [axis] |
Axis |
|
|
ifrs-full:JointVenturesAxis |
| 739 |
Entity's total for joint ventures [member] |
Member |
|
|
ifrs-full:EntitysTotalForJointVenturesMember |
| 740 |
Shionogi ViiV healthcare joint venture [member] |
Member |
|
|
gsk:ShionogiViiVHealthcareJointVentureMember |
| 741 |
Assets and liabilities [axis] |
Axis |
|
|
ifrs-full:AssetsAndLiabilitiesAxis |
| 742 |
Assets and liabilities [member] |
Member |
|
|
ifrs-full:AssetsAndLiabilitiesMember |
| 743 |
Trade and other payable [member] |
Member |
|
|
gsk:TradeAndOtherPayableMember |
| 744 |
Continuing involvement in derecognised financial assets by type of instrument [axis] |
Axis |
|
|
ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis |
| 745 |
Types of instrument [member] |
Member |
|
|
ifrs-full:TypesOfInstrumentMember |
| 746 |
Written put options [member] |
Member |
|
|
ifrs-full:WrittenPutOptionsMember |
| 747 |
Disclosure of changes in accounting estimates [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfChangesInAccountingEstimatesLineItems |
| 748 |
Turnover |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:Revenue |
| 749 |
Tax charge for the year |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 750 |
Tax payable, current |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentTaxLiabilities |
| 751 |
Tax recoverable, current |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentTaxAssets |
| 752 |
Tax payable, non-current |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentTaxLiabilitiesNoncurrent |
| 753 |
Uncertain tax position charge |
Concept (Monetary) |
For Period |
Debit |
gsk:UncertainTaxPositionsRecognised |
| 754 |
Legal costs |
Concept (Monetary) |
For Period |
Debit |
gsk:LegalCosts |
| 755 |
Provision for legal and other disputes |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LegalProceedingsProvision |
| 756 |
Contingent consideration and put option liabilities |
Concept (Monetary) |
For Period |
Credit |
gsk:GainLossOnContingentConsiderationAndPutOptionLiabilities |
| 757 |
Contingent consideration liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination |
| 758 |
Acquisition cost |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred |
| 759 |
Acquisition related net charge |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination |
| 760 |
Put option recognised |
Concept (Monetary) |
For Period |
Credit |
gsk:PutOptionRecognised |
| 761 |
Surplus on defined benefit schemes |
Concept (Monetary) |
As Of |
Debit |
gsk:DefinedBenefitPlanSurplusNet |
| 762 |
Percentage of decrease in discount rate |
Concept (Percent) |
For Period |
|
gsk:PercentageOfDecreaseInDiscountRate |
| 763 |
Net pension deficit |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseInPlanDeficit |
| 764 |
Increased annual pension cost |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseInAnnualPensionCost |
| 765 |
1100 - Disclosure - New Accounting Requirements - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureNewAccountingRequirementsAdditionalInformation |
| 766 |
Description Of New Accounting Requirements [table] |
Table |
* |
* |
gsk:DescriptionOfNewAccountingRequirementsTable |
| 767 |
Non-adjusting events after reporting period [axis] |
Axis |
|
|
ifrs-full:NonadjustingEventsAfterReportingPeriodAxis |
| 768 |
Non-adjusting events after reporting period [member] |
Member |
|
|
ifrs-full:NonadjustingEventsMember |
| 769 |
Events After Reporting Period [member] |
Member |
|
|
gsk:EventsAfterReportingPeriodMember |
| 770 |
Retrospective application and retrospective restatement [axis] |
Axis |
|
|
ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis |
| 771 |
Currently stated [member] |
Member |
|
|
ifrs-full:RestatedMember |
| 772 |
IFRS 16 leases [member] |
Member |
|
|
gsk:IFRS16LeasesMember |
| 773 |
Description Of New Accounting Requirements [line items] |
LineItems |
|
|
gsk:DescriptionOfNewAccountingRequirementsLineItems |
| 774 |
IFRS 16, description |
Concept (Text/String) |
For Period |
|
ifrs-full:StatementThatLesseeUsesPracticalExpedientsWhenApplyingIFRS16RetrospectivelyToLeasesClassifiedAsOperatingLeasesApplyingIAS17 |
| 775 |
Right of use of assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:RightofuseAssets |
| 776 |
Lease liability |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:FinanceLeaseLiabilities |
| 777 |
Reduction in net assets |
Concept (Monetary) |
For Period |
Debit |
gsk:IncreaseDecreaseInAssets |
| 778 |
Reduction in total equity |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseInEquity |
| 779 |
1101 - Disclosure - Exchange Rates - Summary of Currencies Translations and Relevant Exchange Rates (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureExchangeRatesSummaryOfCurrenciesTranslationsAndRelevantExchangeRates |
| 780 |
Disclosure Of Foreign Exchange Rates [table] |
Table |
* |
* |
gsk:DisclosureOfForeignExchangeRatesTable |
| 781 |
Currency [Axis] |
Axis |
|
|
srt:CurrencyAxis |
| 782 |
All Currencies [Domain] |
Member |
|
|
currency:AllCurrenciesDomain |
| 783 |
USD [member] |
Member |
|
|
currency:USD |
| 784 |
Euro [member] |
Member |
|
|
currency:EUR |
| 785 |
Yen [member] |
Member |
|
|
currency:JPY |
| 786 |
Disclosure of foreign exchange rates [line items] |
LineItems |
|
|
gsk:DisclosureOfForeignExchangeRatesLineItems |
| 787 |
Average rates |
Concept (Decimal) |
For Period |
|
ifrs-full:AverageForeignExchangeRate |
| 788 |
Period end rates |
Concept (Decimal) |
As Of |
|
ifrs-full:ClosingForeignExchangeRate |
| 789 |
1102 - Disclosure - Turnover and Segment Information - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTurnoverAndSegmentInformationAdditionalInformation |
| 790 |
Disclosure of operating segments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfOperatingSegmentsTable |
| 791 |
Major customers [axis] |
Axis |
|
|
ifrs-full:MajorCustomersAxis |
| 792 |
Customers [member] |
Member |
|
|
ifrs-full:MajorCustomersMember |
| 793 |
Wholesalers 1 [member] |
Member |
|
|
gsk:Wholesalers1Member |
| 794 |
Wholesalers 2 [member] |
Member |
|
|
gsk:Wholesalers2Member |
| 795 |
Wholesalers 3 [member] |
Member |
|
|
gsk:Wholesalers3Member |
| 796 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 797 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 798 |
US [member] |
Member |
|
|
country:US |
| 799 |
Segments [axis] |
Axis |
|
|
ifrs-full:SegmentsAxis |
| 800 |
Segments [member] |
Member |
|
|
ifrs-full:SegmentsMember |
| 801 |
Shionogi-ViiV Healthcare [member] |
Member |
|
|
gsk:ShionogiViivHealthcareMember |
| 802 |
Consumer Healthcare [member] |
Member |
|
|
gsk:ConsumerHealthcareMember |
| 803 |
Pharmaceuticals and Vaccines [member] |
Member |
|
|
gsk:PharmaceuticalsAndVaccinesMember |
| 804 |
Disclosure of operating segments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfOperatingSegmentsLineItems |
| 805 |
Number of reportable operating segments |
Concept (Integer) |
For Period |
|
gsk:NumberOfReportableOperatingSegments |
| 806 |
Description of factors used to identify entity's reportable segments |
Concept (Text/String) |
For Period |
|
ifrs-full:FactorsUsedToIdentifyEntitysReportableSegments |
| 807 |
Revenue recognised in year from performance obligations satisfied in previous periods |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods |
| 808 |
Turnover from changes to estimates of RAR accruals |
Concept (Monetary) |
For Period |
Credit |
gsk:RevenueFromChangesToEstimatesOfRARAccruals |
| 809 |
Royalty income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueFromRoyalties |
| 810 |
Number of wholesalers |
Concept (Integer) |
For Period |
|
gsk:NumberOfWholesalers |
| 811 |
Turnover |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:Revenue |
| 812 |
Contingent consideration liability |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination |
| 813 |
Pfizer put option |
Concept (Monetary) |
As Of |
Credit |
gsk:PutOption |
| 814 |
Put option liability |
Concept (Monetary) |
As Of |
Credit |
gsk:PutOptionsLiability |
| 815 |
1103 - Disclosure - Turnover and Segment Information - Turnover by Segment (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTurnoverAndSegmentInformationTurnoverBySegment |
| 816 |
Disclosure of operating segments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfOperatingSegmentsTable |
| 817 |
Segments [axis] |
Axis |
|
|
ifrs-full:SegmentsAxis |
| 818 |
Segments [member] |
Member |
|
|
ifrs-full:SegmentsMember |
| 819 |
Pharmaceuticals [member] |
Member |
|
|
gsk:PharmaceuticalsMember |
| 820 |
Vaccines [member] |
Member |
|
|
gsk:VaccinesMember |
| 821 |
Consumer Healthcare [member] |
Member |
|
|
gsk:ConsumerHealthcareMember |
| 822 |
Segment consolidation items [axis] |
Axis |
|
|
ifrs-full:SegmentConsolidationItemsAxis |
| 823 |
Entity's total for segment consolidation items [member] |
Member |
|
|
ifrs-full:EntitysTotalForSegmentConsolidationItemsMember |
| 824 |
Operating Segments [member] |
Member |
|
|
ifrs-full:OperatingSegmentsMember |
| 825 |
Disclosure of operating segments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfOperatingSegmentsLineItems |
| 826 |
Turnover |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:Revenue |
| 827 |
1104 - Disclosure - Turnover and Segment Information - Turnover by Product & Service (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTurnoverAndSegmentInformationTurnoverByProductService |
| 828 |
Disclosure of products and services [table] |
Table |
* |
* |
ifrs-full:DisclosureOfProductsAndServicesTable |
| 829 |
Segments [axis] |
Axis |
|
|
ifrs-full:SegmentsAxis |
| 830 |
Segments [member] |
Member |
|
|
ifrs-full:SegmentsMember |
| 831 |
Consumer Healthcare [member] |
Member |
|
|
gsk:ConsumerHealthcareMember |
| 832 |
Pharmaceuticals [member] |
Member |
|
|
gsk:PharmaceuticalsMember |
| 833 |
Vaccines [member] |
Member |
|
|
gsk:VaccinesMember |
| 834 |
Products and services [axis] |
Axis |
|
|
ifrs-full:ProductsAndServicesAxis |
| 835 |
Products and services [member] |
Member |
|
|
ifrs-full:ProductsAndServicesMember |
| 836 |
Wellness [member] |
Member |
|
|
gsk:WellnessMember |
| 837 |
Oral Care [member] |
Member |
|
|
gsk:OralCareMember |
| 838 |
Nutrition [member] |
Member |
|
|
gsk:NutritionMember |
| 839 |
Skin Health [member] |
Member |
|
|
gsk:SkinHealthMember |
| 840 |
Respiratory [member] |
Member |
|
|
gsk:RespiratoryMember |
| 841 |
HIV [member] |
Member |
|
|
gsk:HIVMember |
| 842 |
Immuno inflammation [member] |
Member |
|
|
gsk:ImmunoInflammationMember |
| 843 |
Established Pharmaceuticals [member] |
Member |
|
|
gsk:EstablishedPharmaceuticalsMember |
| 844 |
Meningitis [member] |
Member |
|
|
gsk:MeningitisMember |
| 845 |
Influenza [member] |
Member |
|
|
gsk:InfluenzaMember |
| 846 |
Shingles [member] |
Member |
|
|
gsk:ShinglesMember |
| 847 |
Established vaccines [member] |
Member |
|
|
gsk:EstablishedVaccinesMember |
| 848 |
Disclosure of products and services [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfProductsAndServicesLineItems |
| 849 |
Turnover |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:Revenue |
| 850 |
1105 - Disclosure - Turnover and Segment Information - Segment Profit and Operating Profit (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTurnoverAndSegmentInformationSegmentProfitAndOperatingProfit |
| 851 |
Disclosure of operating segments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfOperatingSegmentsTable |
| 852 |
Segments [axis] |
Axis |
|
|
ifrs-full:SegmentsAxis |
| 853 |
Segments [member] |
Member |
|
|
ifrs-full:SegmentsMember |
| 854 |
Pharmaceuticals [member] |
Member |
|
|
gsk:PharmaceuticalsMember |
| 855 |
Pharmaceuticals Research and Development [member] |
Member |
|
|
gsk:PharmaceuticalsResearchAndDevelopmentMember |
| 856 |
Pharmaceuticals Including Research and Development [member] |
Member |
|
|
gsk:PharmaceuticalsIncludingResearchAndDevelopmentMember |
| 857 |
Vaccines [member] |
Member |
|
|
gsk:VaccinesMember |
| 858 |
Consumer Healthcare [member] |
Member |
|
|
gsk:ConsumerHealthcareMember |
| 859 |
Segment consolidation items [axis] |
Axis |
|
|
ifrs-full:SegmentConsolidationItemsAxis |
| 860 |
Entity's total for segment consolidation items [member] |
Member |
|
|
ifrs-full:EntitysTotalForSegmentConsolidationItemsMember |
| 861 |
Operating Segments [member] |
Member |
|
|
ifrs-full:OperatingSegmentsMember |
| 862 |
Corporate and Other Unallocated [member] |
Member |
|
|
ifrs-full:UnallocatedAmountsMember |
| 863 |
Other Reconciling Items between Segment Profit and Operating Profit [member] |
Member |
|
|
ifrs-full:MaterialReconcilingItemsMember |
| 864 |
Disclosure of operating segments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfOperatingSegmentsLineItems |
| 865 |
Segment profit |
Abstract |
|
|
ifrs-full:ProfitLossAbstract |
| 866 |
Operating profit |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossFromOperatingActivities |
| 867 |
Finance income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:FinanceIncome |
| 868 |
Finance costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:FinanceCosts |
| 869 |
Profit on disposal of interest in associates |
Concept (Monetary) |
For Period |
Credit |
gsk:GainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates |
| 870 |
Share of after tax profits of associates and joint ventures |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod |
| 871 |
Profit before taxation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossBeforeTax |
| 872 |
Taxation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 873 |
Profit after taxation for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 874 |
Depreciation and amortisation by segment |
Abstract |
|
|
ifrs-full:DepreciationAndAmortisationExpenseAbstract |
| 875 |
Total depreciation and amortisation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DepreciationAndAmortisationExpense |
| 876 |
PP&E, intangible asset and goodwill impairment by segment |
Abstract |
|
|
ifrs-full:ChangesInIntangibleAssetsAndGoodwillAbstract |
| 877 |
Total impairment |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ImpairmentLossRecognisedInProfitOrLoss |
| 878 |
PP&E and intangible asset impairment reversals by segment |
Abstract |
|
|
gsk:ImpairmentReversalsBySegmentAbstract |
| 879 |
Total impairment reversals |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLoss |
| 880 |
Net operating assets |
Concept (Monetary) |
As Of |
Debit |
gsk:NetOperatingAssets |
| 881 |
Net debt |
Concept (Monetary) |
As Of |
Credit |
gsk:DebtNet |
| 882 |
Investments in associates and joint ventures |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates |
| 883 |
Derivative financial instruments |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DerivativeFinancialLiabilities |
| 884 |
Current and deferred taxation |
Concept (Monetary) |
As Of |
Debit |
gsk:CurrentAndDeferredTaxation |
| 885 |
Assets held for sale (excluding cash and cash equivalents) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale |
| 886 |
Net assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NetAssetsLiabilities |
| 887 |
1106 - Disclosure - Turnover and Segment Information - Summary of Geographical Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTurnoverAndSegmentInformationSummaryOfGeographicalInformation |
| 888 |
Disclosure of geographical areas [table] |
Table |
* |
* |
ifrs-full:DisclosureOfGeographicalAreasTable |
| 889 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 890 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 891 |
Customer [member] |
Member |
|
|
gsk:CustomerMember |
| 892 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 893 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 894 |
UK [member] |
Member |
|
|
country:GB |
| 895 |
US [member] |
Member |
|
|
country:US |
| 896 |
Rest of World. [member] |
Member |
|
|
gsk:RestOfWorldMember |
| 897 |
Disclosure of geographical areas [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfGeographicalAreasLineItems |
| 898 |
Turnover |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:Revenue |
| 899 |
Non-current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts |
| 900 |
1107 - Disclosure - Other Operating Income/(Expense) - Information about Other Operating Income Expense (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherOperatingIncomeExpenseInformationAboutOtherOperatingIncomeExpense |
| 901 |
Implied Table |
Table |
* |
* |
implied:Table |
| 902 |
Disclosure of other operating income expense [abstract] |
Abstract |
|
|
gsk:DisclosureOfOtherOperatingIncomeExpenseAbstract |
| 903 |
Fair value remeasurements of equity investments under IFRS 9 |
Concept (Monetary) |
For Period |
|
ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments |
| 904 |
Disposal of businesses and assets |
Concept (Monetary) |
For Period |
Credit |
gsk:DisposalOfBusinessesAndAssets |
| 905 |
Fair value remeasurements on contingent consideration recognised in business combinations |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination |
| 906 |
Remeasurement of ViiV Healthcare put option liabilities and preferential dividends |
Concept (Monetary) |
For Period |
Credit |
gsk:RemeasurementOfPutOptionLiabilitiesAndPreferentialDividends |
| 907 |
Remeasurement of Consumer Healthcare put option liability |
Concept (Monetary) |
For Period |
Credit |
gsk:RemeasurementOfPutOptionLiability |
| 908 |
Fair value adjustments on derivative financial instruments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives |
| 909 |
Other (expense)/income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherIncome |
| 910 |
Impairment of available-for-sale equity investments under IAS 39 |
Concept (Monetary) |
For Period |
Debit |
gsk:ImpairmentOfAvailableForSaleEquityInvestments |
| 911 |
Disposal of available-for-sale equity investments under IAS 39 |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsOnDisposalsOfInvestments |
| 912 |
Other operating income expense |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherOperatingIncomeExpense |
| 913 |
1108 - Disclosure - Other Operating Income/(Expense) - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherOperatingIncomeExpenseAdditionalInformation |
| 914 |
Disclosure Of Other Operating Income Expense [table] |
Table |
* |
* |
gsk:DisclosureOfOtherOperatingIncomeExpenseTable |
| 915 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 916 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 917 |
Shionogi ViiV healthcare joint venture [member] |
Member |
|
|
gsk:ShionogiViiVHealthcareJointVentureMember |
| 918 |
Tapinarof [member] |
Member |
|
|
gsk:TapinarofMember |
| 919 |
Consumer Tail Brands [member] |
Member |
|
|
gsk:ConsumerTailBrandsMember |
| 920 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 921 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 922 |
Vaccines business acquisition [member] |
Member |
|
|
gsk:VaccinesBusinessAcquisitionMember |
| 923 |
Disclosure of other operating income expense [line items] |
LineItems |
|
|
gsk:DisclosureOfOtherOperatingIncomeExpenseLineItems |
| 924 |
Disposal of businesses and assets |
Concept (Monetary) |
For Period |
Credit |
gsk:DisposalOfBusinessesAndAssets |
| 925 |
Fair value remeasurements on contingent consideration |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination |
| 926 |
1109 - Disclosure - Operating Profit - Summary of Information About Profit Loss (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOperatingProfitSummaryOfInformationAboutProfitLoss |
| 927 |
Implied Table |
Table |
* |
* |
implied:Table |
| 928 |
Profit or loss [abstract] |
Abstract |
|
|
ifrs-full:IncomeStatementAbstract |
| 929 |
Employee costs (Note 9) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:EmployeeBenefitsExpense |
| 930 |
Advertising |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdvertisingExpense |
| 931 |
Distribution costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DistributionCosts |
| 932 |
Depreciation of property, plant and equipment |
Concept (Monetary) |
For Period |
|
ifrs-full:DepreciationPropertyPlantAndEquipment |
| 933 |
Impairment of property, plant and equipment, net of reversals |
Concept (Monetary) |
For Period |
|
ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment |
| 934 |
Amortisation of intangible assets |
Concept (Monetary) |
For Period |
|
ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill |
| 935 |
Impairment of intangible assets, net of reversals |
Concept (Monetary) |
For Period |
|
ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill |
| 936 |
Net foreign exchange losses |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss |
| 937 |
Inventories: |
Abstract |
|
|
ifrs-full:ClassesOfInventoriesAbstract |
| 938 |
Cost of inventories included in cost of sales |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod |
| 939 |
Write-down of inventories |
Concept (Monetary) |
For Period |
|
ifrs-full:InventoryWritedown2011 |
| 940 |
Reversal of prior year write-down of inventories |
Concept (Monetary) |
For Period |
|
ifrs-full:ReversalOfInventoryWritedown |
| 941 |
Operating lease rentals: |
Abstract |
|
|
ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpenseAbstract |
| 942 |
Minimum lease payments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:MinimumOperatingLeasePayments |
| 943 |
Contingent rents |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ContingentRentsRecognisedAsExpenseClassifiedAsOperatingLease |
| 944 |
Sub-lease payments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:SubleasePaymentsRecognisedAsExpense |
| 945 |
Fees payable to the company's auditor and its associates in relation to the Group |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AuditorsRemuneration |
| 946 |
1110 - Disclosure - Operating Profit - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOperatingProfitAdditionalInformation |
| 947 |
Disclosure of operating profit [table] |
Table |
* |
* |
gsk:DisclosureOfOperatingProfitTable |
| 948 |
Subsidiaries [axis] |
Axis |
|
|
ifrs-full:SignificantInvestmentsInSubsidiariesAxis |
| 949 |
Entity's total for subsidiaries [member] |
Member |
|
|
ifrs-full:EntitysTotalForSubsidiariesMember |
| 950 |
Liquidation Or Disposal Of Overseas Subsidiary [member] |
Member |
|
|
gsk:LiquidationOrDisposalOfOverseasSubsidiaryMember |
| 951 |
Disclosure of Operating Profit [line items] |
LineItems |
|
|
gsk:DisclosureOfOperatingProfitLineItems |
| 952 |
Net foreign exchange losses |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss |
| 953 |
Major restructuring costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseOfRestructuringActivities |
| 954 |
1111 - Disclosure - Operating Profit - Summary of Auditors Remuneration (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOperatingProfitSummaryOfAuditorsRemuneration |
| 955 |
Disclosure Of Auditors Remuneration [table] |
Table |
* |
* |
gsk:DisclosureOfAuditorsRemunerationTable |
| 956 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 957 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 958 |
GLAXOSMITHKLINE PLC [member] |
Member |
|
|
ifrs-full:ParentMember |
| 959 |
Subsidiaries [member] |
Member |
|
|
ifrs-full:SubsidiariesMember |
| 960 |
Attestation under s.404 of Sarbanes-Oxley Act 2002 [member] |
Member |
|
|
gsk:AttestationUnderS404OfSarbanesOxleyAct2002Member |
| 961 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 962 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 963 |
Pension schemes [member] |
Member |
|
|
ifrs-full:PensionDefinedBenefitPlansMember |
| 964 |
Disclosure Of Auditors Remuneration [line items] |
LineItems |
|
|
gsk:DisclosureOfAuditorsRemunerationLineItems |
| 965 |
Auditor's remuneration [abstract] |
Abstract |
|
|
ifrs-full:AuditorsRemunerationAbstract |
| 966 |
Audit |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AuditorsRemunerationForAuditServices |
| 967 |
Taxation compliance |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AuditorsRemunerationForTaxServices |
| 968 |
Taxation advice |
Concept (Monetary) |
For Period |
Debit |
gsk:AuditorsRemunerationForTaxAdviceServices |
| 969 |
Other assurance services |
Concept (Monetary) |
For Period |
Debit |
gsk:AuditorsRemunerationForOtherAssuranceServices |
| 970 |
All other services |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AuditorsRemunerationForOtherServices |
| 971 |
Auditors remuneration |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AuditorsRemuneration |
| 972 |
1112 - Disclosure - Employee Costs - Summary of Employee Costs (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEmployeeCostsSummaryOfEmployeeCosts |
| 973 |
Implied Table |
Table |
* |
* |
implied:Table |
| 974 |
Short-term employee benefits expense [abstract] |
Abstract |
|
|
ifrs-full:ShorttermEmployeeBenefitsExpenseAbstract |
| 975 |
Wages and salaries |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:WagesAndSalaries |
| 976 |
Social security costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:SocialSecurityContributions |
| 977 |
Pension and other post-employment costs, including augmentations (Note 28) |
Concept (Monetary) |
For Period |
Debit |
gsk:PostEmploymentBenefitExpense |
| 978 |
Cost of share-based incentive plans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees |
| 979 |
Severance and other costs from integration and restructuring activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TerminationBenefitsExpense |
| 980 |
Employee benefits expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:EmployeeBenefitsExpense |
| 981 |
1113 - Disclosure - Employee Costs - Summary of Cost of Share-based Incentive Plans (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEmployeeCostsSummaryOfCostOfSharebasedIncentivePlans |
| 982 |
Expense From Sharebased Payment Transactions With Employees [table] |
Table |
* |
* |
gsk:ExpenseFromSharebasedPaymentTransactionsWithEmployeesTable |
| 983 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 984 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 985 |
Share Value Plan [member] |
Member |
|
|
gsk:ShareValuePlanMember |
| 986 |
Performance Share Plan [member] |
Member |
|
|
gsk:PerformanceSharePlansMember |
| 987 |
Share option plans [member] |
Member |
|
|
gsk:ShareOptionPlanMember |
| 988 |
Cash settled and other plans [member] |
Member |
|
|
gsk:CashSettledAndOtherPlansMember |
| 989 |
Expense from share based payment transactions with employees [line items] |
LineItems |
|
|
gsk:ExpenseFromShareBasedPaymentTransactionsWithEmployeesLineItems |
| 990 |
Cost of share-based incentive plans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees |
| 991 |
1114 - Disclosure - Employee Costs - Disclosure of Average Monthly Number of Persons Employed by the Group (Including Directors) (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEmployeeCostsDisclosureOfAverageMonthlyNumberOfPersonsEmployedByTheGroupIncludingDirectors |
| 992 |
Disclosure of Employee Costs and Numbers [table] |
Table |
* |
* |
gsk:DisclosureOfEmployeeCostsAndNumbersTable |
| 993 |
Segments [axis] |
Axis |
|
|
ifrs-full:SegmentsAxis |
| 994 |
Segments [member] |
Member |
|
|
ifrs-full:SegmentsMember |
| 995 |
Manufacturing [member] |
Member |
|
|
gsk:ManufacturingMember |
| 996 |
Selling, general and administration [member] |
Member |
|
|
gsk:SellingGeneralAndAdministrationMember |
| 997 |
Research and development [member] |
Member |
|
|
gsk:ResearchAndDevelopmentMember |
| 998 |
Disclosure of employee costs and numbers [line items] |
LineItems |
|
|
gsk:DisclosureOfEmployeeCostsAndNumbersLineItems |
| 999 |
Average number of employees |
Concept (Decimal) |
For Period |
|
ifrs-full:AverageNumberOfEmployees |
| 1000 |
1115 - Disclosure - Employee Costs - Summary of Compensation of the Directors and Senior Management (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEmployeeCostsSummaryOfCompensationOfTheDirectorsAndSeniorManagement |
| 1001 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1002 |
Employees Benefit [abstract] |
Abstract |
|
|
gsk:EmployeesBenefitAbstract |
| 1003 |
Wages and salaries |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits |
| 1004 |
Social security costs |
Concept (Monetary) |
For Period |
Debit |
gsk:KeyManagementPersonnelCompensationSocialSecurityCosts |
| 1005 |
Pension and other post-employment costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits |
| 1006 |
Cost of share-based incentive plans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment |
| 1007 |
Key management personnel compensation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensation |
| 1008 |
1116 - Disclosure - Major Restructuring Costs - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureMajorRestructuringCostsAdditionalInformation |
| 1009 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1010 |
Major Restructuring Costs [abstract] |
Abstract |
|
|
gsk:MajorRestructuringCostsAbstract |
| 1011 |
Total restructuring costs |
Concept (Monetary) |
For Period |
Debit |
gsk:RestructuringCosts1 |
| 1012 |
1117 - Disclosure - Major Restructuring Costs - Summary of Analysis of Costs Charged to Operating Profit (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureMajorRestructuringCostsSummaryOfAnalysisOfCostsChargedToOperatingProfit |
| 1013 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1014 |
Major Restructuring Costs [abstract] |
Abstract |
|
|
gsk:MajorRestructuringCostsAbstract |
| 1015 |
Increase in provision for Major restructuring programmes |
Concept (Monetary) |
For Period |
Debit |
gsk:IncreaseDecreaseInProvisionForMajorRestructuringProgrammes |
| 1016 |
Amount of provision reversed unused |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ReversalOfProvisionsForCostOfRestructuring |
| 1017 |
Impairment losses recognised |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ImpairmentLoss |
| 1018 |
Other non-cash charges |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OtherMaterialNoncashItems |
| 1019 |
Other cash costs |
Concept (Monetary) |
For Period |
Debit |
gsk:OtherCostsCashSettlement |
| 1020 |
Cost charged to operating profit |
Concept (Monetary) |
For Period |
Debit |
gsk:CostChargedToOperatingProfit |
| 1021 |
1118 - Disclosure - Major Restructuring Costs - Summary of Major Restructuring Charges (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureMajorRestructuringCostsSummaryOfMajorRestructuringCharges |
| 1022 |
Disclosure of restructuring costs [table] |
Table |
* |
* |
gsk:DisclosureOfRestructuringCostsTable |
| 1023 |
Restructuring Costs [axis] |
Axis |
|
|
gsk:RestructuringCostsAxis |
| 1024 |
Restructuring Costs [domain] |
Member |
|
|
gsk:RestructuringCostsDomain |
| 1025 |
Cost of major restructuring [member] |
Member |
|
|
gsk:CostOfMajorRestructuringMember |
| 1026 |
Disclosure of restructuring costs [line items] |
LineItems |
|
|
gsk:DisclosureOfRestructuringCostsLineItems |
| 1027 |
Cost of sales |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CostOfSales |
| 1028 |
Selling, general and administration |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:SellingGeneralAndAdministrativeExpense |
| 1029 |
Research and development |
Concept (Monetary) |
For Period |
Debit |
gsk:ResearchAndDevelopmentExpenses |
| 1030 |
Other operating income/(expense) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherOperatingIncomeExpense |
| 1031 |
Cost charged to operating profit |
Concept (Monetary) |
For Period |
Debit |
gsk:CostChargedToOperatingProfit |
| 1032 |
1119 - Disclosure - Finance Income - Summary of Finance Income (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinanceIncomeSummaryOfFinanceIncome |
| 1033 |
Disclosure Of Financial Income and Expense [table] |
Table |
* |
* |
gsk:DisclosureOfFinancialIncomeAndExpenseTable |
| 1034 |
Retrospective application and retrospective restatement [axis] |
Axis |
|
|
ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis |
| 1035 |
Currently stated [member] |
Member |
|
|
ifrs-full:RestatedMember |
| 1036 |
IFRS9 [member] |
Member |
|
|
gsk:IFRS9Member |
| 1037 |
IAS 39 [member] |
Member |
|
|
gsk:IAS39Member |
| 1038 |
Disclosure Of Financial Income and Expense [line items] |
LineItems |
|
|
gsk:DisclosureOfFinancialIncomeAndExpenseLineItems |
| 1039 |
Financial assets measured at amortised cost |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost |
| 1040 |
Financial assets measured at fair value through profit or loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss |
| 1041 |
Net gains arising from hedge ineffectiveness on net investment hedges |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations |
| 1042 |
Cash and cash equivalents |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestIncomeOnCashAndCashEquivalents |
| 1043 |
Available-for-sale investments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestIncomeOnAvailableforsaleFinancialAssets |
| 1044 |
Loans and receivables |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestIncomeOnLoansAndReceivables |
| 1045 |
Fair value adjustments on derivatives at fair value through profit or loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives |
| 1046 |
Finance income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:FinanceIncome |
| 1047 |
1120 - Disclosure - Finance Expense - Summary of Finance Cost (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinanceExpenseSummaryOfFinanceCost |
| 1048 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1049 |
Disclosure of finance expense [abstract] |
Abstract |
|
|
gsk:DisclosureOfFinanceExpenseAbstract |
| 1050 |
Finance expense arising on: |
Abstract |
|
|
ifrs-full:InterestCostsAbstract |
| 1051 |
Financial liabilities at amortised cost |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss |
| 1052 |
Derivatives at fair value through profit or loss |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:InterestExpenseOnFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLoss |
| 1053 |
Net losses arising from: Financial instruments mandatorily measured at fair value through profit or loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue |
| 1054 |
Reclassification of hedges from other comprehensive income |
Concept (Monetary) |
For Period |
Debit |
gsk:ReclassificationAdjustmentsOnHedgesFromOtherComprehensiveIncome |
| 1055 |
Unwinding of discounts on provisions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions |
| 1056 |
Other finance expense |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherFinanceIncomeCost |
| 1057 |
Finance Costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:FinanceCosts |
| 1058 |
1121 - Disclosure - Finance Expense - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinanceExpenseAdditionalInformation |
| 1059 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1060 |
Disclosure of finance expense [abstract] |
Abstract |
|
|
gsk:DisclosureOfFinanceExpenseAbstract |
| 1061 |
Description of financial instrument |
Concept (Text/String) |
For Period |
|
ifrs-full:DescriptionOfFinancialInstrumentsDesignatedAsHedgingInstrument |
| 1062 |
Interest paid relating to income taxes |
Concept (Monetary) |
For Period |
Debit |
gsk:InterestExpensePaid |
| 1063 |
Interest received relating to income taxes |
Concept (Monetary) |
For Period |
Credit |
gsk:InterestIncomeEarned |
| 1064 |
1122 - Disclosure - Associates and Joint Ventures - Summary of After Tax Profits and Losses of Associates and Joint Ventures (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAssociatesAndJointVenturesSummaryOfAfterTaxProfitsAndLossesOfAssociatesAndJointVentures |
| 1065 |
Disclosure Of Financial Information Of Associates And Joint Ventures [table] |
Table |
* |
* |
gsk:DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable |
| 1066 |
Associates [axis] |
Axis |
|
|
ifrs-full:SignificantInvestmentsInAssociatesAxis |
| 1067 |
Entity's total for associates [member] |
Member |
|
|
ifrs-full:EntitysTotalForAssociatesMember |
| 1068 |
Associates [member] |
Member |
|
|
ifrs-full:AssociatesMember |
| 1069 |
Joint ventures [axis] |
Axis |
|
|
ifrs-full:JointVenturesAxis |
| 1070 |
Entity's total for joint ventures [member] |
Member |
|
|
ifrs-full:EntitysTotalForJointVenturesMember |
| 1071 |
Joint ventures [member] |
Member |
|
|
ifrs-full:JointVenturesMember |
| 1072 |
Disclosure of financial information of associates and joint ventures [line items] |
LineItems |
|
|
gsk:DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems |
| 1073 |
Share of after tax profits and losses of associates and joint ventures |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod |
| 1074 |
Share of after tax profits and losses of associates and joint ventures |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod |
| 1075 |
1123 - Disclosure - Associates and joint ventures - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAssociatesAndJointVenturesAdditionalInformation |
| 1076 |
Disclosure Of Joint Ventures And Associates [table] |
Table |
* |
* |
gsk:DisclosureOfJointVenturesAndAssociatesTable |
| 1077 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 1078 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 1079 |
Innoviva Inc [member] |
Member |
|
|
gsk:InnovivaIncMember |
| 1080 |
Disclosure of joint ventures and associates [line items] |
LineItems |
|
|
gsk:DisclosureOfJointVenturesAndAssociatesLineItems |
| 1081 |
Profit after taxation for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod |
| 1082 |
Other comprehensive income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncome |
| 1083 |
Sales to associates and joint ventures |
Concept (Monetary) |
For Period |
Debit |
gsk:SalesToAssociatesAndJointVentures |
| 1084 |
1124 - Disclosure - Associates and Joint Ventures - Summary of Group Held for Significant Associate (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAssociatesAndJointVenturesSummaryOfGroupHeldForSignificantAssociate |
| 1085 |
Disclosure Of Financial Information Of Associates And Joint Ventures [table] |
Table |
* |
* |
gsk:DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable |
| 1086 |
Associates [axis] |
Axis |
|
|
ifrs-full:SignificantInvestmentsInAssociatesAxis |
| 1087 |
Entity's total for associates [member] |
Member |
|
|
ifrs-full:EntitysTotalForAssociatesMember |
| 1088 |
Innoviva Inc [member] |
Member |
|
|
gsk:InnovivaIncMember |
| 1089 |
Disclosure of financial information of associates and joint ventures [line items] |
LineItems |
|
|
gsk:DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems |
| 1090 |
Turnover |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:Revenue |
| 1091 |
Profit after taxation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 1092 |
Other comprehensive income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncome |
| 1093 |
Total comprehensive income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 1094 |
1125 - Disclosure - Associates and Joint Ventures - Summary of Aggregated Financial Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAssociatesAndJointVenturesSummaryOfAggregatedFinancialInformation |
| 1095 |
Disclosure Of Financial Information Of Associates And Joint Ventures [table] |
Table |
* |
* |
gsk:DisclosureOfFinancialInformationOfAssociatesAndJointVenturesTable |
| 1096 |
Associates [axis] |
Axis |
|
|
ifrs-full:SignificantInvestmentsInAssociatesAxis |
| 1097 |
Entity's total for associates [member] |
Member |
|
|
ifrs-full:EntitysTotalForAssociatesMember |
| 1098 |
Other associates [member] |
Member |
|
|
gsk:OtherAssociatesMember |
| 1099 |
Disclosure of financial information of associates and joint ventures [line items] |
LineItems |
|
|
gsk:DisclosureOfFinancialInformationOfAssociatesAndJointVenturesLineItems |
| 1100 |
Share of turnover |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:Revenue |
| 1101 |
Share of after tax (losses)/profits |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 1102 |
Share of other comprehensive income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncome |
| 1103 |
Share of total comprehensive (expense)/income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 1104 |
1126 - Disclosure - Taxation - Summary of Taxation Charge Based on Profits (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTaxationSummaryOfTaxationChargeBasedOnProfits |
| 1105 |
Income Tax Expense Benefits [table] |
Table |
* |
* |
gsk:IncomeTaxExpenseBenefitsTable |
| 1106 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 1107 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 1108 |
UK [member] |
Member |
|
|
country:GB |
| 1109 |
Rest of World [member] |
Member |
|
|
ifrs-full:ForeignCountriesMember |
| 1110 |
Income tax expense benefits [line items] |
LineItems |
|
|
gsk:IncomeTaxExpenseBenefitsLineItems |
| 1111 |
Current tax expense (income) and adjustments for current tax of prior periods [abstract] |
Abstract |
|
|
ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract |
| 1112 |
Current tax expense (income) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CurrentTaxExpenseIncome |
| 1113 |
Credit in respect of prior periods |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod |
| 1114 |
Total current taxation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods |
| 1115 |
Total deferred taxation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DeferredTaxExpenseIncome |
| 1116 |
Total tax |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 1117 |
1127 - Disclosure - Taxation - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTaxationAdditionalInformation |
| 1118 |
Income Tax Expense Benefits [table] |
Table |
* |
* |
gsk:IncomeTaxExpenseBenefitsTable |
| 1119 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 1120 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 1121 |
UK [member] |
Member |
|
|
country:GB |
| 1122 |
US [member] |
Member |
|
|
country:US |
| 1123 |
Subsidiaries [axis] |
Axis |
|
|
ifrs-full:SignificantInvestmentsInSubsidiariesAxis |
| 1124 |
Entity's total for subsidiaries [member] |
Member |
|
|
ifrs-full:EntitysTotalForSubsidiariesMember |
| 1125 |
Overseas [Member] |
Member |
|
|
gsk:OverseasMember |
| 1126 |
Income tax expense benefits [line items] |
LineItems |
|
|
gsk:IncomeTaxExpenseBenefitsLineItems |
| 1127 |
Payments of corporation tax |
Concept (Monetary) |
For Period |
Credit |
gsk:PaymentsOfCorporationTax |
| 1128 |
Average effective tax rate |
Concept (Percent) |
For Period |
|
ifrs-full:AverageEffectiveTaxRate |
| 1129 |
Reassessment of prior year estimate of US Tax Reform |
Concept (Monetary) |
For Period |
Debit |
gsk:TaxImpactOfUSTaxReform |
| 1130 |
Provisions For Uncertain Tax Position |
Concept (Monetary) |
For Period |
Credit |
gsk:ProvisionsForUncertainTaxPosition |
| 1131 |
Provision for deferred tax liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredTaxLiabilities |
| 1132 |
Unremitted profits |
Concept (Monetary) |
As Of |
Credit |
gsk:UnremittedEarnings |
| 1133 |
Unremitted profits for which deferred tax not provided |
Concept (Monetary) |
For Period |
Debit |
gsk:UnremittedProfitsForWhichDeferredTaxNotProvided |
| 1134 |
Deferred tax expense (income) recognised in profit or loss |
Concept (Monetary) |
For Period |
|
ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss |
| 1135 |
Research and development incentives recognised in operating profit |
Concept (Monetary) |
For Period |
Credit |
gsk:ResearchAndDevelopmentIncentivesRecognisedInOperatingProfit |
| 1136 |
Deferred tax assets recognized on trading losses |
Concept (Monetary) |
For Period |
Debit |
gsk:DeferredTaxAssetsRecognizedOnTradingLosses |
| 1137 |
Foreign tax credits for which deferred tax has not been provided |
Concept (Monetary) |
For Period |
Debit |
gsk:UnrecognisedDeferredTaxAssetOnForeignTaxCredits |
| 1138 |
1128 - Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxCharge |
| 1139 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1140 |
Disclosure - Taxation - Summary of Reconciliation of Tax Charge Calculated at the UK Statutory Rate on the Group Profit Before Tax with the Actual Tax Charge [Abstract] |
Abstract |
|
|
gsk:DisclosureTaxationSummaryOfReconciliationOfTaxChargeCalculatedAtTheUKStatutoryRateOnTheGroupProfitBeforeTaxWithTheActualTaxChargeAbstract |
| 1141 |
Profit before tax |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossBeforeTax |
| 1142 |
UK statutory rate of taxation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxExpenseIncomeAtApplicableTaxRate |
| 1143 |
Differences in overseas taxation rates |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxEffectOfForeignTaxRates |
| 1144 |
Benefit of intellectual property incentives |
Concept (Monetary) |
For Period |
Credit |
gsk:TaxEffectOfBenefitOfIntellectualPropertyIncentives |
| 1145 |
R&D credits |
Concept (Monetary) |
For Period |
Credit |
gsk:TaxEffectOfResearchAndDevelopmentCredits |
| 1146 |
FV remeasurement of non-taxable put options |
Concept (Monetary) |
For Period |
Debit |
gsk:TaxEffectOfFairValueRemeasurementOfNonTaxablePutOption |
| 1147 |
Tax losses where no benefit is recognised |
Concept (Monetary) |
As Of |
|
ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised |
| 1148 |
Permanent differences on disposals and acquisitions |
Concept (Monetary) |
For Period |
Credit |
gsk:TaxEffectOfPermanentDifferencesOnDisposalsAndAcquisitions |
| 1149 |
Other permanent differences |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome |
| 1150 |
Re-assessments of prior year estimates |
Concept (Monetary) |
For Period |
Credit |
gsk:TaxEffectOfReassessmentsOfPriorYearEstimates |
| 1151 |
US and Swiss Tax Reform |
Concept (Monetary) |
For Period |
Debit |
gsk:TaxEffectOfUSAndSwissTaxReform |
| 1152 |
Tax charge/tax rate |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 1153 |
UK statutory rate of taxation |
Concept (Percent) |
For Period |
|
ifrs-full:ApplicableTaxRate |
| 1154 |
Differences in overseas taxation rates |
Concept (Percent) |
For Period |
|
ifrs-full:TaxRateEffectOfForeignTaxRates |
| 1155 |
Benefit of intellectual property incentives |
Concept (Percent) |
For Period |
|
gsk:TaxRateEffectOfBenefitOfIntellectualPropertyIncentives |
| 1156 |
R&D credits |
Concept (Percent) |
For Period |
|
gsk:TaxRateEffectOfResearchAndDevelopmentCredits |
| 1157 |
FV remeasurement of non-taxable put options |
Concept (Percent) |
For Period |
|
gsk:TaxRateEffectOfFairValueRemeasurementOfNonTaxablePutOption |
| 1158 |
Tax losses where no benefit is recognised |
Concept (Percent) |
For Period |
|
ifrs-full:TaxRateEffectOfTaxLosses |
| 1159 |
Permanent differences on disposals and acquisitions |
Concept (Percent) |
For Period |
|
gsk:TaxRateEffectOfPermanentDifferencesOnDisposalsAndAcquisitions |
| 1160 |
Other permanent differences |
Concept (Percent) |
For Period |
|
ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome |
| 1161 |
Re-assessments of prior year estimates |
Concept (Percent) |
For Period |
|
gsk:TaxRateEffectOfReassessmentsOfPriorYearEstimates |
| 1162 |
US and Swiss Tax Reform |
Concept (Percent) |
For Period |
|
gsk:TaxRateEffectOfUsAndSwissTaxReform |
| 1163 |
Tax charge/tax rate |
Concept (Percent) |
For Period |
|
ifrs-full:AverageEffectiveTaxRate |
| 1164 |
1129 - Disclosure - Taxation - Summary of Tax on Items Charged to Equity and Statement of Comprehensive Income (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTaxationSummaryOfTaxOnItemsChargedToEquityAndStatementOfComprehensiveIncome |
| 1165 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1166 |
Current Tax Relating To Items Charged Or Credited Directly To Equity And Comprehensive Income [abstract] |
Abstract |
|
|
gsk:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract |
| 1167 |
Deferred taxation |
Abstract |
|
|
gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncomeAbstract |
| 1168 |
Share-based payments |
Concept (Monetary) |
For Period |
Debit |
gsk:DeferredTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome |
| 1169 |
Defined benefit plans |
Concept (Monetary) |
For Period |
Debit |
gsk:DeferredTaxRelatingToDefinedBenefitPlansChargedOrCreditedDirectlyToComprehensiveIncome |
| 1170 |
Fair value movements on cash flow hedges |
Concept (Monetary) |
For Period |
Debit |
gsk:DeferredTaxRelatingToFairValueMovementsOnCashFlowHedgesChargedOrCreditedDirectlyToComprehensiveIncome |
| 1171 |
Fair value movements on equity investments |
Concept (Monetary) |
For Period |
Debit |
gsk:DeferredTaxRelatingToFairValueMovementsOnEquityInvestmentsChargedOrCreditedDirectlyToComprehensiveIncome |
| 1172 |
Total equity and comprehensive income |
Concept (Monetary) |
For Period |
|
ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity |
| 1173 |
Total (charge)/credit to equity and statement of comprehensive income |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity |
| 1174 |
Share-based payments |
Concept (Monetary) |
For Period |
Debit |
gsk:CurrentTaxOnShareBasedPaymentsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome |
| 1175 |
Defined benefit plans |
Concept (Monetary) |
For Period |
Debit |
gsk:CurrentTaxOnDefinedBenefitPlansChargedOrCreditedDirectlyToEquityAndComprehensiveIncome |
| 1176 |
Total equity and comprehensive income |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity |
| 1177 |
1130 - Disclosure - Taxation - Summary of Movement in Deferred Tax Assets and Liabilities (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTaxationSummaryOfMovementInDeferredTaxAssetsAndLiabilities |
| 1178 |
Movement In Deferred Tax Assets And Liabilities [table] |
Table |
* |
* |
gsk:MovementInDeferredTaxAssetsAndLiabilitiesTable |
| 1179 |
Joint operations [axis] |
Axis |
|
|
ifrs-full:JointOperationsAxis |
| 1180 |
Entity's total for joint operations [member] |
Member |
|
|
ifrs-full:EntitysTotalForJointOperationsMember |
| 1181 |
Intra group profit [member] |
Member |
|
|
gsk:IntraGroupProfitMember |
| 1182 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 1183 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 1184 |
Pensions and other post-employment benefits [member] |
Member |
|
|
gsk:PensionsAndOtherPostemploymentBenefitsMember |
| 1185 |
Tax reforms period of application [axis] |
Axis |
|
|
gsk:TaxReformsPeriodOfApplicationAxis |
| 1186 |
Tax reforms period of application [domain] |
Member |
|
|
gsk:TaxReformsPeriodOfApplicationDomain |
| 1187 |
Origination and reversal of temporary differences [member] |
Member |
|
|
gsk:OriginationAndReversalOfTemporaryDifferencesMember |
| 1188 |
US tax reform [member] |
Member |
|
|
gsk:USTaxReformMember |
| 1189 |
Swiss tax reform [member] |
Member |
|
|
gsk:SwissTaxReformMember |
| 1190 |
Temporary difference, unused tax losses and unused tax credits [axis] |
Axis |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis |
| 1191 |
Temporary difference, unused tax losses and unused tax credits [member] |
Member |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember |
| 1192 |
Accelerated capital allowances [member] |
Member |
|
|
gsk:AcceleratedCapitalAllowancesMember |
| 1193 |
Tax losses [member] |
Member |
|
|
ifrs-full:UnusedTaxLossesMember |
| 1194 |
Other temporary differences [member] |
Member |
|
|
ifrs-full:OtherTemporaryDifferencesMember |
| 1195 |
Classes of assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfAssetsAxis |
| 1196 |
Assets [member] |
Member |
|
|
ifrs-full:ClassesOfAssetsMember |
| 1197 |
Intangible assets [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 1198 |
Assets and liabilities [axis] |
Axis |
|
|
ifrs-full:AssetsAndLiabilitiesAxis |
| 1199 |
Assets and liabilities [member] |
Member |
|
|
ifrs-full:AssetsAndLiabilitiesMember |
| 1200 |
Contingent Consideration [member] |
Member |
|
|
gsk:ContingentConsiderationMember |
| 1201 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 1202 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 1203 |
Share option and award schemes [member] |
Member |
|
|
gsk:ShareOptionAndAwardSchemesMember |
| 1204 |
Movement In Deferred Tax Assets And Liabilities [line items] |
LineItems |
|
|
gsk:MovementInDeferredTaxAssetsAndLiabilitiesLineItems |
| 1205 |
Changes in deferred tax liability (asset) [abstract] |
Abstract |
|
|
ifrs-full:ChangesInDeferredTaxLiabilityAssetAbstract |
| 1206 |
At 1 January 2017 |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredTaxLiabilityAsset |
| 1207 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset |
| 1208 |
Credit/(charge) to income statement |
Concept (Monetary) |
For Period |
|
ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss |
| 1209 |
(Charge)/credit to statement of comprehensive income and equity |
Concept (Monetary) |
For Period |
Debit |
gsk:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityAndComprehensiveIncome |
| 1210 |
Reclassification on disposal |
Concept (Monetary) |
For Period |
Debit |
gsk:DeferredTaxExpenseIncomeReclassOnDisposal |
| 1211 |
At 31 December 2017 |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredTaxLiabilityAsset |
| 1212 |
1131 - Disclosure - Taxation - Summary of Net Deferred Tax Asset (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTaxationSummaryOfNetDeferredTaxAsset |
| 1213 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1214 |
Major components of tax expense (income) [abstract] |
Abstract |
|
|
ifrs-full:MajorComponentsOfTaxExpenseIncomeAbstract |
| 1215 |
Deferred tax assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:DeferredTaxAssets |
| 1216 |
Deferred tax liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredTaxLiabilities |
| 1217 |
Total |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredTaxLiabilityAsset |
| 1218 |
1132 - Disclosure - Taxation - Summary of Temporary Difference Unused Tax Losses and Unused Tax Credits (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTaxationSummaryOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCredits |
| 1219 |
Disclosure of temporary difference, unused tax losses and unused tax credits [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable |
| 1220 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 1221 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 1222 |
Within 10 years [member] |
Member |
|
|
gsk:LaterThanOneYearAndNotLaterThanTenYearMember |
| 1223 |
Greater Than Ten Years [Member] |
Member |
|
|
ifrs-full:LaterThanTenYearsMember |
| 1224 |
Available indefinitely [member] |
Member |
|
|
gsk:AvailableIndefinitelyMember |
| 1225 |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems |
| 1226 |
Tax losses |
Concept (Monetary) |
For Period |
Credit |
gsk:TaxLosses |
| 1227 |
Unrecognised deferred tax asset |
Concept (Monetary) |
For Period |
Debit |
gsk:UnrecognisedDeferredTaxAssetOnTradingLosses |
| 1228 |
Tax losses |
Concept (Monetary) |
For Period |
Debit |
gsk:CapitalLosses |
| 1229 |
Capital losses |
Concept (Monetary) |
For Period |
Debit |
gsk:UnrecognisedDeferredTaxAssetOnCapitalLosses |
| 1230 |
1133 - Disclosure - Earnings per share - Summary of Basic and Diluted Earnings Per Share (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEarningsPerShareSummaryOfBasicAndDilutedEarningsPerShare |
| 1231 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1232 |
Earnings per share [abstract] |
Abstract |
|
|
ifrs-full:EarningsPerShareAbstract |
| 1233 |
Basic earnings per share |
Concept (Share) |
For Period |
|
ifrs-full:BasicEarningsLossPerShare |
| 1234 |
Diluted earnings per share |
Concept (Share) |
For Period |
|
ifrs-full:DilutedEarningsLossPerShare |
| 1235 |
1134 - Disclosure - Earnings per share - Schedule of Numbers of Shares Earnings Per Share (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEarningsPerShareScheduleOfNumbersOfSharesEarningsPerShare |
| 1236 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1237 |
Earnings per share [abstract] |
Abstract |
|
|
ifrs-full:EarningsPerShareAbstract |
| 1238 |
Weighted average number of shares in issue |
Abstract |
|
|
ifrs-full:WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract |
| 1239 |
Basic |
Concept (Shares) |
For Period |
|
ifrs-full:WeightedAverageShares |
| 1240 |
Dilution for share options and awards |
Concept (Shares) |
For Period |
|
ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares |
| 1241 |
Diluted |
Concept (Shares) |
For Period |
|
ifrs-full:AdjustedWeightedAverageShares |
| 1242 |
1135 - Disclosure - Dividends - Summary of Interim Financial Reporting (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureDividendsSummaryOfInterimFinancialReporting |
| 1243 |
Disclosure of Dividends [table] |
Table |
* |
* |
gsk:DisclosureOfDividendsTable |
| 1244 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 1245 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 1246 |
First interim [member] |
Member |
|
|
gsk:FirstInterimMember |
| 1247 |
Second interim [member] |
Member |
|
|
gsk:SecondInterimMember |
| 1248 |
Third interim [member] |
Member |
|
|
gsk:ThirdInterimMember |
| 1249 |
Fourth interim [member] |
Member |
|
|
gsk:FourthInterimMember |
| 1250 |
Disclosure of dividends [line items] |
LineItems |
|
|
gsk:DisclosureOfDividendsLineItems |
| 1251 |
Paid |
Concept (Date) |
For Period |
|
gsk:DividendsPaidDate |
| 1252 |
Dividend per share (pence) |
Concept (Share) |
For Period |
|
ifrs-full:DividendsPaidOrdinarySharesPerShare |
| 1253 |
Total dividend |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:DividendsPaidOrdinaryShares |
| 1254 |
1136 - Disclosure - Dividends - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureDividendsAdditionalInformation |
| 1255 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1256 |
Disclosure of Dividends [abstract] |
Abstract |
|
|
gsk:DisclosureOfDividendsAbstract |
| 1257 |
Description of compliance with IFRSs applied For interim financial report |
Concept (Text/String) |
For Period |
|
gsk:DescriptionOfRecognitionOfInterimDividends |
| 1258 |
1137 - Disclosure - Dividends - Summary of Dividends to Shareholders (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureDividendsSummaryOfDividendsToShareholders |
| 1259 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1260 |
Disclosure of Dividends [abstract] |
Abstract |
|
|
gsk:DisclosureOfDividendsAbstract |
| 1261 |
Dividends to shareholders |
Concept (Monetary) |
For Period |
Debit |
gsk:DividendsRecognisedInYear |
| 1262 |
1138 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipment |
| 1263 |
Disclosure of detailed information about property, plant and equipment [table] |
Table |
* |
* |
ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable |
| 1264 |
Classes of property, plant and equipment [axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 1265 |
Property, plant and equipment [member] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 1266 |
Land and buildings [member] |
Member |
|
|
ifrs-full:LandAndBuildingsMember |
| 1267 |
Plant, equipment and vehicles [member] |
Member |
|
|
gsk:PropertyPlantAndEquipmentAndVehiclesMember |
| 1268 |
Assets in construction [member] |
Member |
|
|
ifrs-full:ConstructionInProgressMember |
| 1269 |
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] |
Axis |
|
|
ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis |
| 1270 |
Carrying amount [member] |
Member |
|
|
ifrs-full:CarryingAmountMember |
| 1271 |
Cost [member] |
Member |
|
|
ifrs-full:GrossCarryingAmountMember |
| 1272 |
Depreciation and amortisation [member] |
Member |
|
|
ifrs-full:AccumulatedDepreciationAndAmortisationMember |
| 1273 |
Impairment [member] |
Member |
|
|
ifrs-full:AccumulatedImpairmentMember |
| 1274 |
Depreciation, amortisation, and impairment [member] |
Member |
|
|
ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember |
| 1275 |
Disclosure of detailed information about property, plant and equipment [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems |
| 1276 |
Property, plant and equipment at beginning of period |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 1277 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment |
| 1278 |
Other additions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment |
| 1279 |
Charge for the year |
Concept (Monetary) |
For Period |
|
ifrs-full:DepreciationPropertyPlantAndEquipment |
| 1280 |
Capitalised borrowing costs |
Concept (Monetary) |
For Period |
Debit |
gsk:PropertyPlantAndEquipmentBorrowingCostsCapitalised |
| 1281 |
Disposals and write-offs |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment |
| 1282 |
Reclassifications |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment |
| 1283 |
Impairment losses |
Concept (Monetary) |
For Period |
|
ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment |
| 1284 |
Reversal of impairments |
Concept (Monetary) |
For Period |
|
ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment |
| 1285 |
Transfer to assets held for sale |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment |
| 1286 |
Property, plant and equipment at end of period |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 1287 |
1139 - Disclosure - Property, Plant and Equipment - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformation |
| 1288 |
Disclosure of detailed information about property, plant and equipment [table] |
Table |
* |
* |
ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable |
| 1289 |
Classes of property, plant and equipment [axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 1290 |
Property, plant and equipment [member] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 1291 |
Land and buildings under operating leases [member] |
Member |
|
|
gsk:LandAndBuildingsUnderOperatingLeasesMember |
| 1292 |
Plant, equipment and vehicles under operating leases [member] |
Member |
|
|
gsk:PlantEquipmentAndVehiclesUnderOperatingLeasesMember |
| 1293 |
Measurement [axis] |
Axis |
|
|
ifrs-full:MeasurementAxis |
| 1294 |
Aggregated measurement [member] |
Member |
|
|
ifrs-full:AggregatedMeasurementMember |
| 1295 |
Cost of sales [member] |
Member |
|
|
gsk:CostOfSalesMember |
| 1296 |
Research and development [member] |
Member |
|
|
gsk:ResearchAndDevelopmentMember |
| 1297 |
Selling general and administrative expenses [member] |
Member |
|
|
gsk:SellingGeneralAndAdministrativeExpensesMember |
| 1298 |
Major restructuring programmes [member] |
Member |
|
|
gsk:MajorRestructuringProgrammesMember |
| 1299 |
Classes of intangible assets other than goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis |
| 1300 |
Intangible assets [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 1301 |
Computer software [member] |
Member |
|
|
ifrs-full:ComputerSoftwareMember |
| 1302 |
Disclosure of detailed information about property, plant and equipment [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems |
| 1303 |
Weighted average interest rate for capitalised borrowing costs |
Concept (Percent) |
For Period |
|
ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation |
| 1304 |
Property, plant and equipment |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 1305 |
Weighted average cost of capital post tax discount rate percentage |
Concept (Percent) |
As Of |
|
gsk:WeightedAverageCostOfCapitalAfterTaxDiscountRatePercentage |
| 1306 |
Weighted average cost of capital pre-tax discount rate percentage |
Concept (Percent) |
As Of |
|
gsk:WeightedAverageCostOfCapitalPreTaxDiscountRatePercentage |
| 1307 |
Impairment loss recognised in profit or loss, property, plant and equipment |
Concept (Monetary) |
For Period |
|
ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment |
| 1308 |
Impairments charged or reversed |
Concept (Monetary) |
For Period |
|
gsk:CarryingValueOfPropertyPlantEquipmentImpairedOrReversedInYear |
| 1309 |
Assets in construction reclassified to intangible assets |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment |
| 1310 |
1140 - Disclosure - Goodwill - Summary of Changes in Goodwill (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureGoodwillSummaryOfChangesInGoodwill |
| 1311 |
Disclosure of reconciliation of changes in goodwill [table] |
Table |
* |
* |
ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillTable |
| 1312 |
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] |
Axis |
|
|
ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis |
| 1313 |
Carrying amount [member] |
Member |
|
|
ifrs-full:CarryingAmountMember |
| 1314 |
Cost [member] |
Member |
|
|
ifrs-full:GrossCarryingAmountMember |
| 1315 |
Disclosure of reconciliation of changes in goodwill [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillLineItems |
| 1316 |
Goodwill Beginning balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Goodwill |
| 1317 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill |
| 1318 |
Transfer to assets held for sale |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DecreaseThroughClassifiedAsHeldForSaleGoodwill |
| 1319 |
Goodwill Ending Balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Goodwill |
| 1320 |
1141 - Disclosure - Goodwill - Summary of Goodwill Allocated to Segments (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureGoodwillSummaryOfGoodwillAllocatedToSegments |
| 1321 |
Disclosure of reconciliation of changes in goodwill [table] |
Table |
* |
* |
ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillTable |
| 1322 |
Segments [axis] |
Axis |
|
|
ifrs-full:SegmentsAxis |
| 1323 |
Segments [member] |
Member |
|
|
ifrs-full:SegmentsMember |
| 1324 |
Pharmaceuticals [member] |
Member |
|
|
gsk:PharmaceuticalsMember |
| 1325 |
Vaccines [member] |
Member |
|
|
gsk:VaccinesMember |
| 1326 |
Consumer Healthcare [member] |
Member |
|
|
gsk:ConsumerHealthcareMember |
| 1327 |
Disclosure of reconciliation of changes in goodwill [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillLineItems |
| 1328 |
Goodwill |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Goodwill |
| 1329 |
1142 - Disclosure - Goodwill - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureGoodwillAdditionalInformation |
| 1330 |
Disclosure of reconciliation of changes in goodwill [table] |
Table |
* |
* |
ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillTable |
| 1331 |
Products and services [axis] |
Axis |
|
|
ifrs-full:ProductsAndServicesAxis |
| 1332 |
Products and services [member] |
Member |
|
|
ifrs-full:ProductsAndServicesMember |
| 1333 |
Pharmaceuticals [member] |
Member |
|
|
gsk:PharmaceuticalsMember |
| 1334 |
Consumer Healthcare [member] |
Member |
|
|
gsk:ConsumerHealthcareMember |
| 1335 |
Disclosure of reconciliation of changes in goodwill [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillLineItems |
| 1336 |
Description of basis on which unit's recoverable amount has been determined |
Concept (Text/String) |
For Period |
|
ifrs-full:DescriptionOfBasisOnWhichUnitsRecoverableAmountHasBeenDetermined |
| 1337 |
Discount rate applied to cash flow projections |
Concept (Percent) |
As Of |
|
ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections |
| 1338 |
Carrying value of assets with indefinite lives |
Concept (Monetary) |
As Of |
Debit |
gsk:GoodwillWithIndefiniteUsefulLife |
| 1339 |
1143 - Disclosure - Goodwill - Schedule of Discounted Cash Flow Models Used in Impairment Tests (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureGoodwillScheduleOfDiscountedCashFlowModelsUsedInImpairmentTests |
| 1340 |
Disclosure of reconciliation of changes in goodwill [table] |
Table |
* |
* |
ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillTable |
| 1341 |
Products and services [axis] |
Axis |
|
|
ifrs-full:ProductsAndServicesAxis |
| 1342 |
Products and services [member] |
Member |
|
|
ifrs-full:ProductsAndServicesMember |
| 1343 |
Pharmaceuticals [member] |
Member |
|
|
gsk:PharmaceuticalsMember |
| 1344 |
Vaccines [member] |
Member |
|
|
gsk:VaccinesMember |
| 1345 |
Consumer Healthcare [member] |
Member |
|
|
gsk:ConsumerHealthcareMember |
| 1346 |
Disclosure of reconciliation of changes in goodwill [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillLineItems |
| 1347 |
Valuation basis |
Concept (Text/String) |
For Period |
|
ifrs-full:DescriptionOfValuationTechniquesUsedToMeasureFairValueLessCostsOfDisposal |
| 1348 |
Key assumptions |
Concept (Text/String) |
For Period |
|
ifrs-full:DescriptionOfKeyAssumptionsOnWhichManagementHasBasedCashFlowProjections |
| 1349 |
Determination of assumptions |
Concept (Text/String) |
For Period |
|
ifrs-full:DescriptionOfKeyAssumptionsOnWhichManagementHasBasedDeterminationOfFairValueLessCostsOfDisposal |
| 1350 |
Period of specific projected cash flows |
Concept (Text/String) |
For Period |
|
ifrs-full:ExplanationOfPeriodOverWhichManagementHasProjectedCashFlows |
| 1351 |
Terminal growth rate |
Concept (Percent) |
As Of |
|
ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections |
| 1352 |
Discount rate |
Concept (Percent) |
As Of |
|
ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections |
| 1353 |
1144 - Disclosure - Other Intangible Assets - Summary of Other Intangible Assets (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherIntangibleAssetsSummaryOfOtherIntangibleAssets |
| 1354 |
Disclosure of reconciliation of changes in intangible assets and goodwill [table] |
Table |
* |
* |
ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable |
| 1355 |
Classes of intangible assets other than goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis |
| 1356 |
Intangible assets [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 1357 |
Computer software [member] |
Member |
|
|
ifrs-full:ComputerSoftwareMember |
| 1358 |
Licences and franchises [member] |
Member |
|
|
ifrs-full:LicencesAndFranchisesMember |
| 1359 |
Amortised brands [member] |
Member |
|
|
gsk:AmortisedBrandsMember |
| 1360 |
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] |
Axis |
|
|
ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis |
| 1361 |
Carrying amount [member] |
Member |
|
|
ifrs-full:CarryingAmountMember |
| 1362 |
Cost [member] |
Member |
|
|
ifrs-full:GrossCarryingAmountMember |
| 1363 |
Depreciation and amortisation [member] |
Member |
|
|
ifrs-full:AccumulatedDepreciationAndAmortisationMember |
| 1364 |
Impairment [member] |
Member |
|
|
ifrs-full:AccumulatedImpairmentMember |
| 1365 |
Depreciation, amortisation, and impairment [member] |
Member |
|
|
ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember |
| 1366 |
Intangible assets with indefinite useful life [axis] |
Axis |
|
|
ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis |
| 1367 |
Intangible Assets with Indefinite Useful Life [Member] |
Member |
|
|
ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeMember |
| 1368 |
Brands with indefinite useful life [member] |
Member |
|
|
gsk:BrandsWithIndefiniteUsefulLifeMember |
| 1369 |
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems |
| 1370 |
Beginning Balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 1371 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill |
| 1372 |
Capitalised development costs |
Concept (Monetary) |
For Period |
Debit |
gsk:CapitalisedDevelopmentCosts |
| 1373 |
Charge for the year |
Concept (Monetary) |
For Period |
|
ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill |
| 1374 |
Impairment losses |
Concept (Monetary) |
For Period |
|
ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill |
| 1375 |
Capitalised borrowing costs |
Concept (Monetary) |
For Period |
|
ifrs-full:BorrowingCostsCapitalised |
| 1376 |
Reversal of impairments |
Concept (Monetary) |
For Period |
|
ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill |
| 1377 |
Other additions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill |
| 1378 |
Disposals and asset write-offs |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill |
| 1379 |
Disposals and asset write-offs |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill |
| 1380 |
Transfer to assets held for sale |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill |
| 1381 |
Reclassifications |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill |
| 1382 |
Ending Balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 1383 |
1145 - Disclosure - Other Intangible Assets - Additional information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherIntangibleAssetsAdditionalInformation |
| 1384 |
Disclosure of detailed information about intangible assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfIntangibleAssetsTable |
| 1385 |
Methods of generation [axis] |
Axis |
|
|
ifrs-full:MethodsOfGenerationAxis |
| 1386 |
Methods of generation [member] |
Member |
|
|
ifrs-full:MethodsOfGenerationMember |
| 1387 |
Internally generated [member] |
Member |
|
|
ifrs-full:InternallyGeneratedMember |
| 1388 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 1389 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 1390 |
Bottom of range [member] |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 1391 |
Top of range [member] |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 1392 |
Disclosure of detailed information about intangible assets [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfIntangibleAssetsLineItems |
| 1393 |
Weighted average interest rate for capitalised borrowing costs |
Concept (Percent) |
For Period |
|
ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation |
| 1394 |
Net book value of computer software |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:ComputerSoftware |
| 1395 |
Intangible assets, for which impairments have been charged or reversed |
Concept (Monetary) |
As Of |
Debit |
gsk:IntangibleAssetsForWhichImpairmentsHaveBeenChargedOrReversed |
| 1396 |
Discount rate equal to post-tax WACC |
Concept (Percent) |
As Of |
|
ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections |
| 1397 |
Terminal growth rate, estimates of future long-term average growth rate |
Concept (Percent) |
As Of |
|
ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections |
| 1398 |
1146 - Disclosure - Other Intangible Assets - Schedule of Amortisation and Impairment Losses, Net of Reversals (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfAmortisationAndImpairmentLossesNetOfReversals |
| 1399 |
Disclosure of reconciliation of changes in intangible assets and goodwill [table] |
Table |
* |
* |
ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable |
| 1400 |
Classes of intangible assets other than goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis |
| 1401 |
Intangible assets [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 1402 |
Cost of sales [member] |
Member |
|
|
gsk:CostOfSalesMember |
| 1403 |
Selling general and administrative expenses [member] |
Member |
|
|
gsk:SellingGeneralAndAdministrativeExpensesMember |
| 1404 |
Research and development [member] |
Member |
|
|
gsk:ResearchAndDevelopmentMember |
| 1405 |
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems |
| 1406 |
Amortisation of intangible assets |
Concept (Monetary) |
For Period |
|
ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill |
| 1407 |
Impairment of intangible assets, net of reversals |
Concept (Monetary) |
For Period |
|
ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill |
| 1408 |
1147 - Disclosure - Other Intangible Assets - Summary of Book Values of Largest Individual Items (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherIntangibleAssetsSummaryOfBookValuesOfLargestIndividualItems |
| 1409 |
Disclosure of reconciliation of changes in intangible assets and goodwill [table] |
Table |
* |
* |
ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable |
| 1410 |
Classes of intangible assets other than goodwill [axis] |
Axis |
|
|
ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis |
| 1411 |
Intangible assets [member] |
Member |
|
|
ifrs-full:IntangibleAssetsOtherThanGoodwillMember |
| 1412 |
Licences and franchises [member] |
Member |
|
|
ifrs-full:LicencesAndFranchisesMember |
| 1413 |
Intangible assets material to entity [axis] |
Axis |
|
|
ifrs-full:IntangibleAssetsMaterialToEntityAxis |
| 1414 |
Intangible assets material to entity [member] |
Member |
|
|
ifrs-full:IntangibleAssetsMaterialToEntityMember |
| 1415 |
Meningitis Portfolio [member] |
Member |
|
|
gsk:MeningitisPortfolioMember |
| 1416 |
Dolutegravir [member] |
Member |
|
|
gsk:DolutegravirMember |
| 1417 |
Benlysta [member] |
Member |
|
|
gsk:BenlystaMember |
| 1418 |
Fluarix FluLaval [member] |
Member |
|
|
gsk:FluarixFlulavalMember |
| 1419 |
HIV assets acquired from BMS [member] |
Member |
|
|
gsk:HIVAssetsAcquiredFromBMSMember |
| 1420 |
Selzentry [member] |
Member |
|
|
gsk:SelzentryMember |
| 1421 |
Okairos technology platform [member] |
Member |
|
|
gsk:OkairosTechnologyPlatformMember |
| 1422 |
Others products [member] |
Member |
|
|
gsk:OthersProductsMember |
| 1423 |
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems |
| 1424 |
Other intangible assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 1425 |
1148 - Disclosure - Other Intangible Assets - Summary of Book Values of Major Brands (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherIntangibleAssetsSummaryOfBookValuesOfMajorBrands |
| 1426 |
Disclosure of detailed information about intangible assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfIntangibleAssetsTable |
| 1427 |
Intangible assets with indefinite useful life [axis] |
Axis |
|
|
ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeAxis |
| 1428 |
Intangible Assets with Indefinite Useful Life [Member] |
Member |
|
|
ifrs-full:IntangibleAssetsWithIndefiniteUsefulLifeMember |
| 1429 |
Voltaren [member] |
Member |
|
|
gsk:VoltarenMember |
| 1430 |
Otrivin [member] |
Member |
|
|
gsk:OtrivinMember |
| 1431 |
Fenistil [member] |
Member |
|
|
gsk:FenistilMember |
| 1432 |
Theraflu [member] |
Member |
|
|
gsk:TherafluMember |
| 1433 |
Panadol [member] |
Member |
|
|
gsk:PanadolMember |
| 1434 |
Sensodyne [member] |
Member |
|
|
gsk:SensodyneMember |
| 1435 |
Lamisil [member] |
Member |
|
|
gsk:LamisilMember |
| 1436 |
Breathe Right [member] |
Member |
|
|
gsk:BreatheRightMember |
| 1437 |
Stiefel trade name [member] |
Member |
|
|
gsk:StiefelTradeNameMember |
| 1438 |
Excedrin [member] |
Member |
|
|
gsk:ExcedrinMember |
| 1439 |
Physiogel [member] |
Member |
|
|
gsk:PhysiogelMember |
| 1440 |
Polident [member] |
Member |
|
|
gsk:PolidentMember |
| 1441 |
Other Brands [member] |
Member |
|
|
gsk:OtherBrandsMember |
| 1442 |
Disclosure of detailed information about intangible assets [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfIntangibleAssetsLineItems |
| 1443 |
Indefinite life brands |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:BrandNames |
| 1444 |
1149 - Disclosure - Investments in Associates and Joint Ventures - Summary of Investments in Associates and Joint Ventures (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureInvestmentsInAssociatesAndJointVenturesSummaryOfInvestmentsInAssociatesAndJointVentures |
| 1445 |
Disclosure of Investments in Associates and Joint Ventures [table] |
Table |
* |
* |
gsk:DisclosureOfInvestmentsInAssociatesAndJointVenturesTable |
| 1446 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 1447 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 1448 |
Associates [member] |
Member |
|
|
ifrs-full:AssociatesMember |
| 1449 |
Joint ventures [axis] |
Axis |
|
|
ifrs-full:JointVenturesAxis |
| 1450 |
Entity's total for joint ventures [member] |
Member |
|
|
ifrs-full:EntitysTotalForJointVenturesMember |
| 1451 |
Joint ventures [member] |
Member |
|
|
ifrs-full:JointVenturesMember |
| 1452 |
Disclosure of Investments in Associates and Joint Ventures [line items] |
LineItems |
|
|
gsk:DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems |
| 1453 |
Beginning of investments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates |
| 1454 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets |
| 1455 |
Additions |
Concept (Monetary) |
For Period |
Debit |
gsk:AdditionsInInvestmentsInAssociatesAndJointVentures |
| 1456 |
Disposals |
Concept (Monetary) |
For Period |
Credit |
gsk:DisposalsInAssociatesAndJointVentures |
| 1457 |
Distributions received |
Concept (Monetary) |
For Period |
Credit |
gsk:DistributionsReceivedInInvestmentsInAssociatesAndJointVentures |
| 1458 |
Other movements |
Concept (Monetary) |
For Period |
Credit |
gsk:OtherMovementsInInvestmentsInSubsidiariesJointVenturesAndAssociates |
| 1459 |
Profit/(loss) after tax recognised in the consolidated income statement |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod |
| 1460 |
Ending of investments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates |
| 1461 |
1150 - Disclosure - Investments in Associates and Joint Ventures - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureInvestmentsInAssociatesAndJointVenturesAdditionalInformation |
| 1462 |
Disclosure of Investments in Associates and Joint Ventures [table] |
Table |
* |
* |
gsk:DisclosureOfInvestmentsInAssociatesAndJointVenturesTable |
| 1463 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 1464 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 1465 |
Innoviva Inc [member] |
Member |
|
|
gsk:InnovivaIncMember |
| 1466 |
Theravance Biopharma Inc [member] |
Member |
|
|
gsk:TheravanceBiopharmaIncMember |
| 1467 |
Disclosure of Investments in Associates and Joint Ventures [line items] |
LineItems |
|
|
gsk:DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems |
| 1468 |
Significant associate |
Concept (Integer) |
For Period |
|
gsk:NumberOfSignificantAssociate |
| 1469 |
Number of shares owned |
Concept (Shares) |
As Of |
|
ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates |
| 1470 |
Percentage of shares owned |
Concept (Percent) |
For Period |
|
ifrs-full:ProportionOfOwnershipInterestInAssociate |
| 1471 |
Percentage of interest in royalty |
Concept (Percent) |
For Period |
|
gsk:PercentageOfInterestInRoyalty |
| 1472 |
Percentage of common stock |
Concept (Percent) |
For Period |
|
gsk:PercentageOfCommonStock |
| 1473 |
Market value of investment |
Concept (Monetary) |
As Of |
Debit |
gsk:MarketValueOfInvestment |
| 1474 |
1151 - Disclosure - Investments in Associates and Joint Ventures - Summary of Balance Sheet Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureInvestmentsInAssociatesAndJointVenturesSummaryOfBalanceSheetInformation |
| 1475 |
Disclosure of Investments in Associates and Joint Ventures [table] |
Table |
* |
* |
gsk:DisclosureOfInvestmentsInAssociatesAndJointVenturesTable |
| 1476 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 1477 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 1478 |
Innoviva Inc [member] |
Member |
|
|
gsk:InnovivaIncMember |
| 1479 |
Disclosure of Investments in Associates and Joint Ventures [line items] |
LineItems |
|
|
gsk:DisclosureOfInvestmentsInAssociatesAndJointVenturesLineItems |
| 1480 |
Non-current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentAssets |
| 1481 |
Current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentAssets |
| 1482 |
Current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentLiabilities |
| 1483 |
Non-current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentLiabilities |
| 1484 |
Net assets/(liabilities) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NetAssetsLiabilities |
| 1485 |
Interest in associated undertaking |
Concept (Monetary) |
As Of |
Credit |
gsk:InterestInAssociatedUndertaking |
| 1486 |
Goodwill |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Goodwill |
| 1487 |
Fair value and other adjustments |
Concept (Monetary) |
For Period |
Debit |
gsk:FairValueAndOtherAdjustment |
| 1488 |
Carrying value at 31 December |
Concept (Monetary) |
As Of |
Debit |
gsk:CarryingValue |
| 1489 |
1152 - Disclosure - Other Investments - Schedule of Other Investments (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherInvestmentsScheduleOfOtherInvestments |
| 1490 |
Other investments [table] |
Table |
* |
* |
gsk:OtherInvestmentsTable |
| 1491 |
Categories of financial assets [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialAssetsAxis |
| 1492 |
Financial assets, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsCategoryMember |
| 1493 |
Investments designated as measured at FVTOCI [member] |
Member |
|
|
ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember |
| 1494 |
Investments measured a FVTPL [member] |
Member |
|
|
gsk:InvestmentsMeasuredAtFairValueThroughProfitOrLossMember |
| 1495 |
Other investments [line items] |
LineItems |
|
|
gsk:OtherInvestmentsLineItems |
| 1496 |
Beginning of other investments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod |
| 1497 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Debit |
gsk:AdjustmentsForForeignExchangeOtherInvestments |
| 1498 |
Additions |
Concept (Monetary) |
For Period |
Debit |
gsk:AdditionsToOtherInvestments |
| 1499 |
Net fair value movements through Other comprehensive income |
Concept (Monetary) |
For Period |
Debit |
gsk:NetFairValueMovementsInvestmentsThroughOtherComprehensiveIncome |
| 1500 |
Net fair value movements through profit or loss |
Concept (Monetary) |
For Period |
Debit |
gsk:NetFairValueMovementsThroughProfitOrLossOtherInvestments |
| 1501 |
Impairment losses |
Concept (Monetary) |
For Period |
Debit |
gsk:ImpairmentLossesRecognisedInOtherInvestments |
| 1502 |
Disposals and settlements |
Concept (Monetary) |
For Period |
Debit |
gsk:DisposalsAndSettlementsOtherInvestments |
| 1503 |
Transfers to Assets held for sale |
Concept (Monetary) |
For Period |
Debit |
gsk:TransfersToAssetsHeldForSaleOtherInvestments |
| 1504 |
Ending of other investments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod |
| 1505 |
1153 - Disclosure - Other Investments - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherInvestmentsAdditionalInformation |
| 1506 |
Other investments [table] |
Table |
* |
* |
gsk:OtherInvestmentsTable |
| 1507 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 1508 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 1509 |
Theravance Biopharma Inc [member] |
Member |
|
|
gsk:TheravanceBiopharmaIncMember |
| 1510 |
Tandem [member] |
Member |
|
|
gsk:TandemMember |
| 1511 |
Orchard [member] |
Member |
|
|
gsk:OrchardMember |
| 1512 |
23 and Me [member] |
Member |
|
|
gsk:TwentyThreeAndMeMember |
| 1513 |
Classes of financial assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialAssetsAxis |
| 1514 |
Financial assets, class [member] |
Member |
|
|
ifrs-full:FinancialAssetsMember |
| 1515 |
Equity investments measured at fair value through other comprehensive income (FVTOCI) [member] |
Member |
|
|
gsk:EquityInvestmentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember |
| 1516 |
Equity investments measured at fair value through profit or loss (FVTPL) [member] |
Member |
|
|
gsk:EquityInvestmentsMeasuredAtFairValueThroughProfitOrLossMember |
| 1517 |
Other investments [line items] |
LineItems |
|
|
gsk:OtherInvestmentsLineItems |
| 1518 |
Listed investments |
Concept (Monetary) |
For Period |
Debit |
gsk:ListedInvestments |
| 1519 |
Percentage of common stock held |
Concept (Percent) |
For Period |
|
gsk:PercentageHeldOfCommonStock |
| 1520 |
Investment fair value |
Concept (Monetary) |
As Of |
Debit |
gsk:InvestmentFairValue |
| 1521 |
Fair value of investment disposed during the year |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition |
| 1522 |
Cumulative gain loss on disposal of investments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome |
| 1523 |
1154 - Disclosure - Other Investments - Schedule of Carrying Value of Other Investments (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherInvestmentsScheduleOfCarryingValueOfOtherInvestments |
| 1524 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1525 |
Other investments 1 [abstract] |
Abstract |
|
|
gsk:OtherInvestments1Abstract |
| 1526 |
Carrying value at original cost |
Concept (Monetary) |
As Of |
Debit |
gsk:CarryingValueOfImpairedInvestments |
| 1527 |
Cumulative impairments recognised in the income statement |
Concept (Monetary) |
For Period |
Credit |
gsk:CumulativeImpairmentsRecognisedInIncomeStatement |
| 1528 |
Subsequent fair value increases |
Concept (Monetary) |
For Period |
Debit |
gsk:IncreaseDecreaseInSubsequentFairValue |
| 1529 |
Carrying value, ending balance |
Concept (Monetary) |
As Of |
Debit |
gsk:CarryingValueOfImpairedInvestments |
| 1530 |
1155 - Disclosure - Other Non-Current Assets - Summary of Other Non-Current Assets (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherNonCurrentAssetsSummaryOfOtherNonCurrentAssets |
| 1531 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1532 |
Miscellaneous non-current assets [abstract] |
Abstract |
|
|
ifrs-full:MiscellaneousNoncurrentAssetsAbstract |
| 1533 |
Amounts receivable under insurance contracts |
Concept (Monetary) |
As Of |
Debit |
gsk:ReceivablesRelatedToInsuranceContracts |
| 1534 |
Pension schemes in surplus |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan |
| 1535 |
Other receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherNoncurrentReceivables |
| 1536 |
Total |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherNoncurrentAssets |
| 1537 |
1156 - Disclosure - Other Non-Current Assets - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherNonCurrentAssetsAdditionalInformation |
| 1538 |
Disclosure Of Other Non-current Assets [table] |
Table |
* |
* |
gsk:DisclosureOfOtherNoncurrentAssetsTable |
| 1539 |
Classes of financial instruments [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialInstrumentsAxis |
| 1540 |
Financial Instruments, Class [Member] |
Member |
|
|
ifrs-full:ClassesOfFinancialInstrumentsMember |
| 1541 |
Other Non Current Receivables [member] |
Member |
|
|
gsk:OtherNonCurrentReceivablesMember |
| 1542 |
Categories of financial assets [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialAssetsAxis |
| 1543 |
Financial assets, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsCategoryMember |
| 1544 |
Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember |
| 1545 |
Remaining Balance [member] |
Member |
|
|
gsk:RemainingBalanceMember |
| 1546 |
Disclosure Of Other Non Current Assets [line items] |
LineItems |
|
|
gsk:DisclosureOfOtherNonCurrentAssetsLineItems |
| 1547 |
Other receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherNoncurrentReceivables |
| 1548 |
Financial assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssets |
| 1549 |
1157 - Disclosure - Inventories - Summary of Inventories (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureInventoriesSummaryOfInventories |
| 1550 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1551 |
Classes of current inventories [abstract] |
Abstract |
|
|
ifrs-full:ClassesOfInventoriesAbstract |
| 1552 |
Raw materials and consumables |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:RawMaterialsAndConsumablesUsed |
| 1553 |
Work in progress |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:WorkInProgress |
| 1554 |
Finished goods |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinishedGoods |
| 1555 |
Total |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Inventories |
| 1556 |
1158 - Disclosure - Trade and Other Receivables - Summary of Trade and Other Receivables (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivables |
| 1557 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1558 |
Trade and other receivables [abstract] |
Abstract |
|
|
ifrs-full:TradeAndOtherReceivablesAbstract |
| 1559 |
Trade receivables, net of loss allowance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:TradeReceivables |
| 1560 |
Accrued income |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:AccruedIncome |
| 1561 |
Other prepayments |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Prepayments |
| 1562 |
Interest receivable |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:InterestReceivable |
| 1563 |
Employee loans and advances |
Concept (Monetary) |
As Of |
Debit |
gsk:EmployeeLoansAndAdvances |
| 1564 |
Other receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherReceivables |
| 1565 |
Total trade and other receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:TradeAndOtherReceivables |
| 1566 |
1159 - Disclosure - Trade and Other Receivables - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTradeAndOtherReceivablesAdditionalInformation |
| 1567 |
Disclosure of Trade and Other Receivables [table] |
Table |
* |
* |
gsk:DisclosureOfTradeAndOtherReceivablesTable |
| 1568 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 1569 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 1570 |
Associates and joint ventures [member] |
Member |
|
|
gsk:AssociatesAndJointVenturesMember |
| 1571 |
Credit impairment of financial instruments [axis] |
Axis |
|
|
ifrs-full:CreditImpairmentOfFinancialInstrumentsAxis |
| 1572 |
Credit impairment of financial instruments [member] |
Member |
|
|
ifrs-full:CreditImpairmentOfFinancialInstrumentsMember |
| 1573 |
Financial instruments credit-impaired [member] |
Member |
|
|
ifrs-full:FinancialInstrumentsCreditimpairedMember |
| 1574 |
Classes of financial instruments [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialInstrumentsAxis |
| 1575 |
Financial Instruments, Class [Member] |
Member |
|
|
ifrs-full:ClassesOfFinancialInstrumentsMember |
| 1576 |
Trade and other receivables [member] |
Member |
|
|
ifrs-full:TradeReceivablesMember |
| 1577 |
Categories of financial assets [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialAssetsAxis |
| 1578 |
Financial assets, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsCategoryMember |
| 1579 |
Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember |
| 1580 |
Remaining Balance [member] |
Member |
|
|
gsk:RemainingBalanceMember |
| 1581 |
Disclosure of trade and other receivables [line items] |
LineItems |
|
|
gsk:DisclosureOfTradeAndOtherReceivablesLineItems |
| 1582 |
Trade receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:TradeReceivables |
| 1583 |
Other receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherReceivables |
| 1584 |
Trade receivables |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:TradeAndOtherReceivables |
| 1585 |
Expected credit loss allowance on trade receivables credit impaired |
Concept (Monetary) |
As Of |
Debit |
gsk:ExpectedCreditLossAllowanceOnTradeReceivablesCreditImpaired |
| 1586 |
Financial assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssets |
| 1587 |
Expected credit loss allowance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount |
| 1588 |
1160 - Disclosure - Trade and Other Receivables - Summary of Loss Allowance (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfLossAllowance |
| 1589 |
Disclosure of Trade and Other Receivables [table] |
Table |
* |
* |
gsk:DisclosureOfTradeAndOtherReceivablesTable |
| 1590 |
Retrospective application and retrospective restatement [axis] |
Axis |
|
|
ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis |
| 1591 |
Currently stated [member] |
Member |
|
|
ifrs-full:RestatedMember |
| 1592 |
Previously stated [member] |
Member |
|
|
ifrs-full:PreviouslyStatedMember |
| 1593 |
Disclosure of trade and other receivables [line items] |
LineItems |
|
|
gsk:DisclosureOfTradeAndOtherReceivablesLineItems |
| 1594 |
Implementation of IFRS 9 |
Concept (Monetary) |
For Period |
Debit |
gsk:AdjustmentForAdoptionOfIFRS9 |
| 1595 |
Beginning balance |
Concept (Monetary) |
As Of |
Debit |
gsk:ExpectedCreditLossAllowance |
| 1596 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Debit |
gsk:ExpectedCreditLossAllowanceExchangeAdjustments |
| 1597 |
Charge for the year |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseInExpectedCreditLossesAllowance |
| 1598 |
Subsequent recoveries of amounts provided for |
Concept (Monetary) |
For Period |
Debit |
gsk:SubsequentRecoveriesOfAmountsProvidedForExpectedCreditLossAllowance |
| 1599 |
Utilised |
Concept (Monetary) |
For Period |
Debit |
gsk:ExpectedCreditLossAllowanceUtilised |
| 1600 |
Ending balance |
Concept (Monetary) |
As Of |
Debit |
gsk:ExpectedCreditLossAllowance |
| 1601 |
1161 - Disclosure - Cash and cash equivalents - Summary of Cash and Cash Equivalents (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureCashAndCashEquivalentsSummaryOfCashAndCashEquivalents |
| 1602 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1603 |
Cash and cash equivalents [abstract] |
Abstract |
|
|
ifrs-full:CashAndCashEquivalentsAbstract |
| 1604 |
Cash at bank and in hand |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Cash |
| 1605 |
Short-term deposits |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents |
| 1606 |
Total cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 1607 |
1162 - Disclosure - Cash and cash equivalents - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformation |
| 1608 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1609 |
Cash and cash equivalents [abstract] |
Abstract |
|
|
ifrs-full:CashAndCashEquivalentsAbstract |
| 1610 |
Cash and cash equivalents reported in assets held for sale |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalentsClassifiedAsPartOfDisposalGroupHeldForSale |
| 1611 |
Cash and cash equivalents not available for general use |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup |
| 1612 |
1163 - Disclosure - Assets Held for Sale - Summary of Assets Held for Sale (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAssetsHeldForSaleSummaryOfAssetsHeldForSale |
| 1613 |
Assets Held For Sale [table] |
Table |
* |
* |
gsk:AssetsHeldForSaleTable |
| 1614 |
Assets and liabilities classified as held for sale [axis] |
Axis |
|
|
ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis |
| 1615 |
Assets and liabilities not classified as held for sale [member] |
Member |
|
|
ifrs-full:AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember |
| 1616 |
Assets held for sale [member] |
Member |
|
|
ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember |
| 1617 |
Assets Held For Sale [line items] |
LineItems |
|
|
gsk:AssetsHeldForSaleLineItems |
| 1618 |
Property, plant and equipment |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 1619 |
Goodwill |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Goodwill |
| 1620 |
Other intangibles |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherIntangibleAssets |
| 1621 |
Inventory |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Inventories |
| 1622 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 1623 |
Other |
Concept (Monetary) |
As Of |
Credit |
gsk:OtherLiabilitiesNet |
| 1624 |
Total assets held for sale |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale |
| 1625 |
1164 - Disclosure - Assets Held for Sale - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAssetsHeldForSaleAdditionalInformation |
| 1626 |
Disclosure of detailed information about intangible assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfIntangibleAssetsTable |
| 1627 |
Assets and liabilities classified as held for sale [axis] |
Axis |
|
|
ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis |
| 1628 |
Assets and liabilities not classified as held for sale [member] |
Member |
|
|
ifrs-full:AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember |
| 1629 |
Assets held for sale [member] |
Member |
|
|
ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleMember |
| 1630 |
Levels of fair value hierarchy [axis] |
Axis |
|
|
ifrs-full:LevelsOfFairValueHierarchyAxis |
| 1631 |
All levels of fair value hierarchy [member] |
Member |
|
|
ifrs-full:AllLevelsOfFairValueHierarchyMember |
| 1632 |
Level 3 [member] |
Member |
|
|
ifrs-full:Level3OfFairValueHierarchyMember |
| 1633 |
Disclosure of detailed information about intangible assets [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfIntangibleAssetsLineItems |
| 1634 |
Financial assets written down to fair value |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsAtFairValue |
| 1635 |
1165 - Disclosure - Trade and Other Payables - Summary of Trade and Other Payables (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTradeAndOtherPayablesSummaryOfTradeAndOtherPayables |
| 1636 |
Disclosure of trade and other payables [table] |
Table |
* |
* |
gsk:DisclosureOfTradeAndOtherPayablesTable |
| 1637 |
Segments [axis] |
Axis |
|
|
ifrs-full:SegmentsAxis |
| 1638 |
Segments [member] |
Member |
|
|
ifrs-full:SegmentsMember |
| 1639 |
Consumer Healthcare [member] |
Member |
|
|
gsk:ConsumerHealthcareMember |
| 1640 |
Shionogi-ViiV Healthcare [member] |
Member |
|
|
gsk:ShionogiViivHealthcareMember |
| 1641 |
Disclosure of trade and other payables [line items] |
LineItems |
|
|
gsk:DisclosureOfTradeAndOtherPayablesLineItems |
| 1642 |
Trade payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherPayablesToTradeSuppliers |
| 1643 |
Wages and salaries |
Concept (Monetary) |
As Of |
Credit |
gsk:WagesAndSalariesPayable |
| 1644 |
Social security |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax |
| 1645 |
Put option payable |
Concept (Monetary) |
As Of |
Credit |
gsk:PutOptionPayable |
| 1646 |
Other payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherCurrentPayables |
| 1647 |
Deferred income |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredIncome |
| 1648 |
Customer return and rebate accruals |
Concept (Monetary) |
As Of |
Credit |
gsk:CustomerReturnAndRebateAccruals |
| 1649 |
Other accruals |
Concept (Monetary) |
As Of |
Credit |
gsk:OtherAccruals |
| 1650 |
Total trade and other payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayables |
| 1651 |
1166 - Disclosure - Trade and Other Payables - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformation |
| 1652 |
Disclosure of trade and other payables [table] |
Table |
* |
* |
gsk:DisclosureOfTradeAndOtherPayablesTable |
| 1653 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 1654 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 1655 |
Associates and joint ventures [member] |
Member |
|
|
gsk:AssociatesAndJointVenturesMember |
| 1656 |
Assets and liabilities [axis] |
Axis |
|
|
ifrs-full:AssetsAndLiabilitiesAxis |
| 1657 |
Assets and liabilities [member] |
Member |
|
|
ifrs-full:AssetsAndLiabilitiesMember |
| 1658 |
Estimated rebates, discounts or allowances payable to customers [member] |
Member |
|
|
gsk:EstimatedRebatesDiscountsOrAllowancePayableToCustomerMember |
| 1659 |
Geographical [Axis] |
Axis |
|
|
srt:StatementGeographicalAxis |
| 1660 |
Geographical [Domain] |
Member |
|
|
srt:SegmentGeographicalDomain |
| 1661 |
India [member] |
Member |
|
|
country:IN |
| 1662 |
Segment consolidation items [axis] |
Axis |
|
|
ifrs-full:SegmentConsolidationItemsAxis |
| 1663 |
Entity's total for segment consolidation items [member] |
Member |
|
|
ifrs-full:EntitysTotalForSegmentConsolidationItemsMember |
| 1664 |
US Pharmaceuticals and vaccines [member] |
Member |
|
|
gsk:UsPharmaceuticalsAndVaccinesMember |
| 1665 |
Disclosure of trade and other payables [line items] |
LineItems |
|
|
gsk:DisclosureOfTradeAndOtherPayablesLineItems |
| 1666 |
Trade and other current payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayables |
| 1667 |
Revenue recognized in deferred income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueAndOperatingIncome |
| 1668 |
Revenue recognized related to proceeds from a site disposal |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations |
| 1669 |
Customer return and rebate accruals |
Concept (Monetary) |
As Of |
Credit |
gsk:CustomerReturnAndRebateAccruals |
| 1670 |
1167 - Disclosure - Trade and Other Payables - Summary of Increase/(Decrease) in Financial Liability and Loss/(Gain) in Income Statement (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureTradeAndOtherPayablesSummaryOfIncreaseDecreaseInFinancialLiabilityAndLossGainInIncomeStatement |
| 1671 |
Disclosure of information about activities subject to rate regulation [table] |
Table |
* |
* |
ifrs-full:DisclosureOfInformationAboutActivitiesSubjectToRateRegulationTable |
| 1672 |
Valuation techniques used in fair value measurement [axis] |
Axis |
|
|
ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis |
| 1673 |
Valuation techniques [member] |
Member |
|
|
ifrs-full:ValuationTechniquesMember |
| 1674 |
Pfizer put option [member] |
Member |
|
|
gsk:PfizerPutOptionMember |
| 1675 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 1676 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 1677 |
10% increase in sales forecasts or sales multiple applied [member] |
Member |
|
|
gsk:CurrencyRiskTenPercentageIncreaseInSalesForecastsOrSalesMultipleAppliedMember |
| 1678 |
10% decrease in sales forecasts or sales multiple applied [member] |
Member |
|
|
gsk:CurrencyRiskTenPercentageDecreaseInSalesForecastsOrSalesMultipleAppliedMember |
| 1679 |
10 cent appreciation of the US Dollar [member] |
Member |
|
|
gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember |
| 1680 |
10 cent depreciation of US Dollar [member] |
Member |
|
|
gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember |
| 1681 |
10 cent appreciation of the Euro [member] |
Member |
|
|
gsk:CurrencyRiskTenCentAppreciationOfEuroMember |
| 1682 |
10 cent depreciation of Euro [member] |
Member |
|
|
gsk:CurrencyRiskTenCentDepreciationOfEuroMember |
| 1683 |
Disclosure of information about activities subject to rate regulation [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfInformationAboutActivitiesSubjectToRateRegulationLineItems |
| 1684 |
Increase/(decrease) in financial liability |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseInFinancialLiability |
| 1685 |
Loss/(gain) in Income statement |
Concept (Monetary) |
For Period |
Debit |
gsk:LossGainInIncomeStatement |
| 1686 |
1168 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Pension and Other Post-employment Costs (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostemploymentBenefitsSummaryOfPensionAndOtherPostemploymentCosts |
| 1687 |
Disclosure of pension and other post employment plan [table] |
Table |
* |
* |
gsk:DisclosureOfPensionAndOtherPostEmploymentPlanTable |
| 1688 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 1689 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 1690 |
UK Defined Benefit Plans [member] |
Member |
|
|
gsk:UkDefinedBenefitPlansMember |
| 1691 |
US Defined Benefit Plans [member] |
Member |
|
|
gsk:UsDefinedBenefitPlansMember |
| 1692 |
Other overseas pension schemes [member] |
Member |
|
|
gsk:OtherOverseasPensionPlansMember |
| 1693 |
Unfunded post retirement healthcare schemes [member] |
Member |
|
|
gsk:UnfundedPostRetirementPensionPlansMember |
| 1694 |
Funded defined benefit pension plans [member] |
Member |
|
|
gsk:FundedDefinedBenefitPensionPlansMember |
| 1695 |
Unfunded defined benefit pension plan [member] |
Member |
|
|
gsk:UnfundedDefinedBenefitPensionPlanMember |
| 1696 |
Defined benefit pension and post-retirement healthcare scheme. [member] |
Member |
|
|
gsk:DefinedBenefitPensionAndPostretirementHealthcareSchemeMember |
| 1697 |
Defined benefit schemes [member] |
Member |
|
|
gsk:DefinedBenefitSchemesMember |
| 1698 |
Defined contribution pension scheme [member] |
Member |
|
|
gsk:DefinedContributionPensionSchemeMember |
| 1699 |
Disclosure of pension and other post employment plan [line items] |
LineItems |
|
|
gsk:DisclosureOfPensionAndOtherPostEmploymentPlanLineItems |
| 1700 |
Pension and other post-employment cost Analysed |
Concept (Monetary) |
For Period |
Debit |
gsk:DisclosureOfDefinedContributionPlans |
| 1701 |
Cost of sales |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CostOfSales |
| 1702 |
Selling, general and administration |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:SellingGeneralAndAdministrativeExpense |
| 1703 |
Research and development |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ResearchAndDevelopmentExpense |
| 1704 |
Defined benefit pension and post retirement cost |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans |
| 1705 |
Pension and other post-employment cost |
Concept (Monetary) |
For Period |
Debit |
gsk:PostemploymentBenefitExpensePlans |
| 1706 |
Pension and other post-employment cost Analysed |
Concept (Monetary) |
For Period |
Debit |
gsk:PostemploymentBenefitExpenseDefinedBenefitPlansAnalysed |
| 1707 |
1169 - Disclosure - Pensions and Other Post-employment Benefits - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostemploymentBenefitsAdditionalInformation |
| 1708 |
Disclosure of Pensions and Other Post-employment Benefits [table] |
Table |
* |
* |
gsk:DisclosureOfPensionsAndOtherPostemploymentBenefitsTable |
| 1709 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 1710 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 1711 |
UK [member] |
Member |
|
|
country:GB |
| 1712 |
US [member] |
Member |
|
|
country:US |
| 1713 |
Classes of assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfAssetsAxis |
| 1714 |
Assets [member] |
Member |
|
|
ifrs-full:ClassesOfAssetsMember |
| 1715 |
Other assets [member] |
Member |
|
|
ifrs-full:OtherAssetsMember |
| 1716 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 1717 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 1718 |
Unfunded [member] |
Member |
|
|
ifrs-full:WhollyUnfundedDefinedBenefitPlansMember |
| 1719 |
Pension schemes [member] |
Member |
|
|
ifrs-full:PensionDefinedBenefitPlansMember |
| 1720 |
Post-retirement benefits [member] |
Member |
|
|
gsk:PostretirementBenefitsMember |
| 1721 |
Non-adjusting events after reporting period [axis] |
Axis |
|
|
ifrs-full:NonadjustingEventsAfterReportingPeriodAxis |
| 1722 |
Non-adjusting events after reporting period [member] |
Member |
|
|
ifrs-full:NonadjustingEventsMember |
| 1723 |
2026 and thereafter [member] |
Member |
|
|
gsk:TwoThousandTwentySixAndThereafterMember |
| 1724 |
Disclosure of Pensions and Other Post-employment Benefits [line items] |
LineItems |
|
|
gsk:DisclosureOfPensionsAndOtherPostemploymentBenefitsLineItems |
| 1725 |
Long term rate of improvement per year |
Concept (Percent) |
For Period |
|
gsk:MortalityProjectionsModelLongtermImprovementParameterPerYearPercentage |
| 1726 |
Percentage allocated to return seeking assets |
Concept (Percent) |
For Period |
|
gsk:AllocationToReturnSeekingAssets |
| 1727 |
Percentage allocated to liability matching assets |
Concept (Percent) |
For Period |
|
gsk:AllocationToLiabilityMatchingAssets |
| 1728 |
GMP costs included in past service costs |
Concept (Monetary) |
For Period |
Debit |
gsk:GuaranteedMinimumPensionEqualisationCostsIncludedInPastServiceCosts |
| 1729 |
Augmentation costs included in past service costs |
Concept (Monetary) |
For Period |
Debit |
gsk:AugmentationCostsIncludedInPastServiceCosts |
| 1730 |
Augmentation costs arising from major restructuring programmes |
Concept (Monetary) |
For Period |
Debit |
gsk:AugmentationCostsFromRestructuringProgrammes |
| 1731 |
Loans on structured debt amount contributed to fair value of plan assets |
Concept (Monetary) |
As Of |
Credit |
gsk:LoansOnStructuredDebtAmountContributedToFairValueOfPlanAssets |
| 1732 |
Special contributions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset |
| 1733 |
Payment due, 2019 |
Concept (Monetary) |
For Period |
Credit |
gsk:ContributionsToEliminateThePensionDeficitPaymentsWithInOneYear |
| 1734 |
Employer contributions |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan |
| 1735 |
Assumption for future medical inflation |
Concept (Percent) |
As Of |
|
gsk:ActuarialAssumptionOfExpectedRatesOfMedicalInflation |
| 1736 |
US post retirement healthcare scheme obligation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans |
| 1737 |
1170 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Average Life Expectancy Assumed (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostemploymentBenefitsSummaryOfAverageLifeExpectancyAssumed |
| 1738 |
Disclosure of sensitivity analysis for actuarial assumptions [table] |
Table |
* |
* |
ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable |
| 1739 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 1740 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 1741 |
UK [member] |
Member |
|
|
country:GB |
| 1742 |
US [member] |
Member |
|
|
country:US |
| 1743 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 1744 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 1745 |
Current. [member] |
Member |
|
|
gsk:CurrentPeriodMember |
| 1746 |
Projected at 2038 [member] |
Member |
|
|
gsk:ProjectedPeriodMember |
| 1747 |
Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems |
| 1748 |
Male Years |
Concept (xbrli:durationItemType) |
For Period |
|
gsk:MalePensionersAverageLifeExpectancyAtSixty |
| 1749 |
Female Years |
Concept (xbrli:durationItemType) |
For Period |
|
gsk:FemalePensionersAverageLifeExpectancyAtSixty |
| 1750 |
1171 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Financial Assumptions in Assessing Defined Benefit Liabilities (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostemploymentBenefitsSummaryOfFinancialAssumptionsInAssessingDefinedBenefitLiabilities |
| 1751 |
Disclosure of defined benefit plan actuarial assumptions [table] |
Table |
* |
* |
gsk:DisclosureOfDefinedBenefitPlanActuarialAssumptionsTable |
| 1752 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 1753 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 1754 |
UK [member] |
Member |
|
|
country:GB |
| 1755 |
US [member] |
Member |
|
|
country:US |
| 1756 |
Rest of World. [member] |
Member |
|
|
gsk:RestOfWorldMember |
| 1757 |
Disclosure Of Defined Benefit Plan Actuarial Assumptions [line items] |
LineItems |
|
|
gsk:DisclosureOfDefinedBenefitPlanActuarialAssumptionsLineItems |
| 1758 |
Rate of increase of future earnings |
Concept (Percent) |
As Of |
|
ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases |
| 1759 |
Discount rate |
Concept (Percent) |
As Of |
|
ifrs-full:ActuarialAssumptionOfDiscountRates |
| 1760 |
Expected pension increases |
Concept (Percent) |
As Of |
|
ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases |
| 1761 |
Cash balance credit/conversion rate |
Concept (Percent) |
For Period |
|
gsk:ActuarialAssumptionOfCashBalanceCreditRate |
| 1762 |
Inflation rate |
Concept (Percent) |
As Of |
|
ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation |
| 1763 |
1172 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Amounts Recorded in Income Statement and Statement of Comprehensive Income Related to Defined Benefit Pension and Post-retirement Healthcare Schemes (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostemploymentBenefitsSummaryOfAmountsRecordedInIncomeStatementAndStatementOfComprehensiveIncomeRelatedToDefinedBenefitPensionAndPostretirementHealthcareSchemes |
| 1764 |
Disclosure Of Defined Benefit Pension And Post Retirement [table] |
Table |
* |
* |
gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementTable |
| 1765 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 1766 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 1767 |
UK [member] |
Member |
|
|
country:GB |
| 1768 |
US [member] |
Member |
|
|
country:US |
| 1769 |
Rest of World. [member] |
Member |
|
|
gsk:RestOfWorldMember |
| 1770 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 1771 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 1772 |
Pension schemes [member] |
Member |
|
|
ifrs-full:PensionDefinedBenefitPlansMember |
| 1773 |
Post-retirement benefits [member] |
Member |
|
|
gsk:PostretirementBenefitsMember |
| 1774 |
Net defined benefit liability (asset) [axis] |
Axis |
|
|
ifrs-full:NetDefinedBenefitLiabilityAssetAxis |
| 1775 |
Net defined benefit liability (asset) [member] |
Member |
|
|
ifrs-full:NetDefinedBenefitLiabilityAssetMember |
| 1776 |
Defined benefit pension and post-retirement healthcare scheme. [member] |
Member |
|
|
gsk:DefinedBenefitPensionAndPostretirementHealthcareSchemeMember |
| 1777 |
Disclosure Of Defined Benefit Pension And Post Retirement [line items] |
LineItems |
|
|
gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems |
| 1778 |
Current service cost |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset |
| 1779 |
Past service cost/(credit) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset |
| 1780 |
Net interest (income)/cost |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset |
| 1781 |
Gains from settlements |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset |
| 1782 |
Expenses |
Concept (Monetary) |
As Of |
Debit |
gsk:ExpensesNetDefinedBenefitLiabilityAsset |
| 1783 |
Net operating cost |
Concept (Monetary) |
For Period |
Debit |
gsk:NetOperatingChargeForPensionsAndOtherPostRetirementBenefits |
| 1784 |
Remeasurement gains/(losses) recorded in the statement of comprehensive income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans |
| 1785 |
1173 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Balance Sheet Presentation of Group Defined Benefit Pension Schemes and Other Post-retirement Benefits (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostemploymentBenefitsSummaryOfBalanceSheetPresentationOfGroupDefinedBenefitPensionSchemesAndOtherPostretirementBenefits |
| 1786 |
Disclosure Of Defined Benefit Pension And Post Retirement [table] |
Table |
* |
* |
gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementTable |
| 1787 |
Assets and liabilities [axis] |
Axis |
|
|
ifrs-full:AssetsAndLiabilitiesAxis |
| 1788 |
Assets and liabilities [member] |
Member |
|
|
ifrs-full:AssetsAndLiabilitiesMember |
| 1789 |
Other Noncurrent Assets [member] |
Member |
|
|
gsk:OtherNoncurrentAssetsMember |
| 1790 |
Assets classified as held for sale [member] |
Member |
|
|
gsk:AssetsClassifiedAsHeldForSaleMember |
| 1791 |
Pensions and other post-employment benefits [member] |
Member |
|
|
gsk:PensionsAndOtherPostemploymentBenefitsMember |
| 1792 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 1793 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 1794 |
Pension schemes [member] |
Member |
|
|
ifrs-full:PensionDefinedBenefitPlansMember |
| 1795 |
Post-retirement benefits [member] |
Member |
|
|
gsk:PostretirementBenefitsMember |
| 1796 |
Disclosure Of Defined Benefit Pension And Post Retirement [line items] |
LineItems |
|
|
gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems |
| 1797 |
Post-retirement benefits/Pension schemes in deficit and surplus |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentRecognisedAssetsDefinedBenefitPlan |
| 1798 |
Post-retirement benefits/Pension schemes in deficit and surplus |
Concept (Monetary) |
As Of |
Credit |
gsk:OtherLiabilitiesNetAssetHeldForSaleDefinedBenefitPlan |
| 1799 |
Post-retirement benefits/Pension schemes in deficit and surplus |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan |
| 1800 |
Benefit plans |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentProvisionsForEmployeeBenefits |
| 1801 |
1174 - Disclosure - Pensions and Other Post-employment Benefits - Fair Values of Assets and Liabilities of UK and US Defined Benefit Pension Schemes Together with Aggregated Data for Other Defined Benefit Pension Schemes in Group (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostemploymentBenefitsFairValuesOfAssetsAndLiabilitiesOfUKAndUSDefinedBenefitPensionSchemesTogetherWithAggregatedDataForOtherDefinedBenefitPensionSchemesInGroup |
| 1802 |
Disclosure Of Defined Benefit Pension And Post Retirement [table] |
Table |
* |
* |
gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementTable |
| 1803 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 1804 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 1805 |
UK [member] |
Member |
|
|
country:GB |
| 1806 |
US [member] |
Member |
|
|
country:US |
| 1807 |
Rest of World. [member] |
Member |
|
|
gsk:RestOfWorldMember |
| 1808 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 1809 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 1810 |
Group [member] |
Member |
|
|
gsk:GroupMember |
| 1811 |
Assets and liabilities [axis] |
Axis |
|
|
ifrs-full:AssetsAndLiabilitiesAxis |
| 1812 |
Assets and liabilities [member] |
Member |
|
|
ifrs-full:AssetsAndLiabilitiesMember |
| 1813 |
Other Noncurrent Assets [member] |
Member |
|
|
gsk:OtherNoncurrentAssetsMember |
| 1814 |
Pensions and other post-employment benefits [member] |
Member |
|
|
gsk:PensionsAndOtherPostemploymentBenefitsMember |
| 1815 |
Disclosure Of Defined Benefit Pension And Post Retirement [line items] |
LineItems |
|
|
gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems |
| 1816 |
Equities, listed |
Concept (Monetary) |
As Of |
Debit |
gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsListed |
| 1817 |
Equity, unlisted |
Concept (Monetary) |
As Of |
Debit |
gsk:EquityInstrumentsAmountContributedToFairValueOfPlanAssetsUnlisted |
| 1818 |
Multi-asset funds |
Concept (Monetary) |
As Of |
Debit |
gsk:MultiAssetFunds |
| 1819 |
Property, listed |
Concept (Monetary) |
As Of |
Debit |
gsk:PropertyAmountContributedToFairValueOfPlanAssetsListed |
| 1820 |
Property, unlisted |
Concept (Monetary) |
As Of |
Debit |
gsk:PropertyAmountContributedToFairValueOfPlanAssetsUnlisted |
| 1821 |
Corporate bonds, listed |
Concept (Monetary) |
As Of |
Debit |
gsk:CorporateBondsContributedToFairValueOfPlanAssetsListed |
| 1822 |
Corporate bonds, unlisted |
Concept (Monetary) |
As Of |
Debit |
gsk:CorporateBondsContributedToFairValueOfPlanAssetsUnlisted |
| 1823 |
Government bonds, listed |
Concept (Monetary) |
As Of |
Debit |
gsk:GovernmentBondsContributedToFairValueOfPlanAssetsListed |
| 1824 |
Insurance contracts |
Concept (Monetary) |
As Of |
Debit |
gsk:InsuranceContractsAmountContributedToFairValueOfPlanAssets |
| 1825 |
Other assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets |
| 1826 |
Fair value of assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PlanAssetsAtFairValue |
| 1827 |
Present value of scheme obligations |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DefinedBenefitObligationAtPresentValue |
| 1828 |
Net surplus/(obligation) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:SurplusDeficitInPlan |
| 1829 |
Actual return on plan assets |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset |
| 1830 |
1175 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Movements in Fair Values of Assets (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostemploymentBenefitsSummaryOfMovementsInFairValuesOfAssets |
| 1831 |
Disclosure Of Defined Benefit Pension And Post Retirement [table] |
Table |
* |
* |
gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementTable |
| 1832 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 1833 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 1834 |
Pension schemes [member] |
Member |
|
|
ifrs-full:PensionDefinedBenefitPlansMember |
| 1835 |
Post-retirement benefits [member] |
Member |
|
|
gsk:PostretirementBenefitsMember |
| 1836 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 1837 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 1838 |
UK [member] |
Member |
|
|
country:GB |
| 1839 |
US [member] |
Member |
|
|
country:US |
| 1840 |
Rest of World. [member] |
Member |
|
|
gsk:RestOfWorldMember |
| 1841 |
Net defined benefit liability (asset) [axis] |
Axis |
|
|
ifrs-full:NetDefinedBenefitLiabilityAssetAxis |
| 1842 |
Net defined benefit liability (asset) [member] |
Member |
|
|
ifrs-full:NetDefinedBenefitLiabilityAssetMember |
| 1843 |
Plan Assets [Member] |
Member |
|
|
ifrs-full:PlanAssetsMember |
| 1844 |
Disclosure Of Defined Benefit Pension And Post Retirement [line items] |
LineItems |
|
|
gsk:DisclosureOfDefinedBenefitPensionAndPostRetirementLineItems |
| 1845 |
Assets, beginning balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PlanAssetsAtFairValue |
| 1846 |
Obligations beginning balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DefinedBenefitObligationAtPresentValue |
| 1847 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset |
| 1848 |
Service cost |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset |
| 1849 |
Past service cost/(credit) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset |
| 1850 |
Interest cost |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset |
| 1851 |
Expenses |
Concept (Monetary) |
As Of |
Debit |
gsk:ExpensesNetDefinedBenefitLiabilityAsset |
| 1852 |
Settlements and curtailments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset |
| 1853 |
Remeasurement |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset |
| 1854 |
Employer contributions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset |
| 1855 |
Scheme participants' contributions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset |
| 1856 |
Benefits paid |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset |
| 1857 |
Assets, ending balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PlanAssetsAtFairValue |
| 1858 |
Obligations ending balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DefinedBenefitObligationAtPresentValue |
| 1859 |
1176 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Analysis of Defined Benefit Pension Obligation (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostemploymentBenefitsSummaryOfAnalysisOfDefinedBenefitPensionObligation |
| 1860 |
Disclosure of defined benefit plans [table] |
Table |
* |
* |
ifrs-full:DisclosureOfDefinedBenefitPlansTable |
| 1861 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 1862 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 1863 |
Funded [member] |
Member |
|
|
ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember |
| 1864 |
Unfunded [member] |
Member |
|
|
ifrs-full:WhollyUnfundedDefinedBenefitPlansMember |
| 1865 |
Disclosure of defined benefit plans [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfDefinedBenefitPlansLineItems |
| 1866 |
Defined benefit obligation |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DefinedBenefitObligationAtPresentValue |
| 1867 |
1177 - Disclosure - Pensions and Other Post-employment Benefits - Summary of Movement in Net Defined Benefit Liability (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostemploymentBenefitsSummaryOfMovementInNetDefinedBenefitLiability |
| 1868 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1869 |
Disclosure of defined benefit plans [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfDefinedBenefitPlansAbstract |
| 1870 |
Beginning of net defined benefit liability |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LiabilityAssetOfDefinedBenefitPlans |
| 1871 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset |
| 1872 |
Service cost |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset |
| 1873 |
Past service cost |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset |
| 1874 |
Interest cost |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset |
| 1875 |
Settlements and curtailments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset |
| 1876 |
Remeasurements: |
Abstract |
|
|
ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract |
| 1877 |
Return on plan assets, excluding amounts included in interest |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset |
| 1878 |
Gain/(loss) from change in demographic assumptions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset |
| 1879 |
Gain/(loss) from change in financial assumptions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset |
| 1880 |
Experience (losses)/gains |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset |
| 1881 |
Employer contributions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset |
| 1882 |
Expenses |
Concept (Monetary) |
For Period |
Debit |
gsk:AdjustmentsInExpensesNetDefinedBenefitLiabilityAsset |
| 1883 |
Ending of net defined benefit liability |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LiabilityAssetOfDefinedBenefitPlans |
| 1884 |
1178 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Remeasurements Within Post-Retirement Benefits (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostEmploymentBenefitsSummaryOfRemeasurementsWithinPostRetirementBenefits |
| 1885 |
Disclosure of net defined benefit liability (asset) [table] |
Table |
* |
* |
ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetTable |
| 1886 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 1887 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 1888 |
Post-retirement benefits [member] |
Member |
|
|
gsk:PostretirementBenefitsMember |
| 1889 |
Disclosure of net defined benefit liability (asset) [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetLineItems |
| 1890 |
Gain from change in demographic assumptions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset |
| 1891 |
Gain/(loss) from change in financial assumptions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset |
| 1892 |
Experience gains |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset |
| 1893 |
Total |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset |
| 1894 |
1179 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Defined Benefit Pension Obligation Analysed by Membership Category (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostEmploymentBenefitsSummaryOfDefinedBenefitPensionObligationAnalysedByMembershipCategory |
| 1895 |
Disclosure of defined benefit plans [table] |
Table |
* |
* |
ifrs-full:DisclosureOfDefinedBenefitPlansTable |
| 1896 |
Categories of financial liabilities [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialLiabilitiesAxis |
| 1897 |
Financial liabilities, category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesCategoryMember |
| 1898 |
Active [member] |
Member |
|
|
gsk:DefinedBenefitObligationActiveMember |
| 1899 |
Retired [member] |
Member |
|
|
gsk:DefinedBenefitObligationRetiredMember |
| 1900 |
Deferred [member] |
Member |
|
|
gsk:DefinedBenefitObligationDeferredMember |
| 1901 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 1902 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 1903 |
Pension schemes [member] |
Member |
|
|
ifrs-full:PensionDefinedBenefitPlansMember |
| 1904 |
Disclosure of defined benefit plans [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfDefinedBenefitPlansLineItems |
| 1905 |
Defined benefit pension obligation analysed by membership category |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DefinedBenefitObligationAtPresentValue |
| 1906 |
1180 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Post-Retirement Benefit Obligation Analysed by Membership Category (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostEmploymentBenefitsSummaryOfPostRetirementBenefitObligationAnalysedByMembershipCategory |
| 1907 |
Disclosure of defined benefit plans [table] |
Table |
* |
* |
ifrs-full:DisclosureOfDefinedBenefitPlansTable |
| 1908 |
Categories of financial liabilities [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialLiabilitiesAxis |
| 1909 |
Financial liabilities, category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesCategoryMember |
| 1910 |
Active [member] |
Member |
|
|
gsk:DefinedBenefitObligationActiveMember |
| 1911 |
Retired [member] |
Member |
|
|
gsk:DefinedBenefitObligationRetiredMember |
| 1912 |
Deferred [member] |
Member |
|
|
gsk:DefinedBenefitObligationDeferredMember |
| 1913 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 1914 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 1915 |
Post-retirement benefits [member] |
Member |
|
|
gsk:PostretirementBenefitsMember |
| 1916 |
Disclosure of defined benefit plans [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfDefinedBenefitPlansLineItems |
| 1917 |
Post-retirement benefit obligation analysed by membership category |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DefinedBenefitObligationAtPresentValue |
| 1918 |
1181 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Weighted Average Duration Defined Benefit Obligation (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostEmploymentBenefitsSummaryOfWeightedAverageDurationDefinedBenefitObligation |
| 1919 |
Disclosure of Information About Maturity Profile of Defined Benefit Obligation [table] |
Table |
* |
* |
gsk:DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationTable |
| 1920 |
Defined benefit plans [axis] |
Axis |
|
|
ifrs-full:DefinedBenefitPlansAxis |
| 1921 |
Defined benefit plans [member] |
Member |
|
|
ifrs-full:DefinedBenefitPlansMember |
| 1922 |
Pension schemes [member] |
Member |
|
|
ifrs-full:PensionDefinedBenefitPlansMember |
| 1923 |
Post retirement benefit [Member] |
Member |
|
|
gsk:PostRetirementBenefitMember |
| 1924 |
Disclosure of Information About Maturity Profile of Defined Benefit Obligation [line items] |
LineItems |
|
|
gsk:DisclosureOfInformationAboutMaturityProfileOfDefinedBenefitObligationLineItems |
| 1925 |
Weighted average duration of the defined benefit obligation |
Concept (Decimal) |
For Period |
|
ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation |
| 1926 |
1182 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Changes in Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs (Details) (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetails |
| 1927 |
Disclosure of sensitivity analysis for actuarial assumptions [table] |
Table |
* |
* |
ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable |
| 1928 |
Actuarial assumptions [axis] |
Axis |
|
|
ifrs-full:ActuarialAssumptionsAxis |
| 1929 |
Actuarial assumptions [member] |
Member |
|
|
ifrs-full:ActuarialAssumptionsMember |
| 1930 |
Actuarial assumption of discount rates [Member] |
Member |
|
|
ifrs-full:ActuarialAssumptionOfDiscountRatesMember |
| 1931 |
Actuarial assumption of life expectancy rates [Member] |
Member |
|
|
gsk:ActuarialAssumptionOfLifeExpectancyRatesMember |
| 1932 |
Actuarial assumption for future healthcare inflation [member] |
Member |
|
|
gsk:ActuarialAssumptionForFutureHealthcareInflationMember |
| 1933 |
Actuarial assumption of expected rates of inflation [Member] |
Member |
|
|
ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember |
| 1934 |
Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems |
| 1935 |
Increase in annual pension cost |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseInAnnualPensionCost |
| 1936 |
Increase/Decrease in annual post-retirement benefits cost |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseInAnnualPostretirementBenefitsCost |
| 1937 |
Increase in pension obligation |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreasePensionObligations |
| 1938 |
Increase in post-retirement benefits obligation |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseInPostretirementBenefitsObligation |
| 1939 |
1183 - Disclosure - Pensions and Other Post-Employment Benefits - Summary of Changes in Assumptions Used on Benefit Obligations, Defined Benefit Pension and Post Retirement Costs (Details) (Parenthetical) (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePensionsAndOtherPostEmploymentBenefitsSummaryOfChangesInAssumptionsUsedOnBenefitObligationsDefinedBenefitPensionAndPostRetirementCostsDetailsParenthetical |
| 1940 |
Disclosure of sensitivity analysis for actuarial assumptions [table] |
Table |
* |
* |
ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable |
| 1941 |
Actuarial assumptions [axis] |
Axis |
|
|
ifrs-full:ActuarialAssumptionsAxis |
| 1942 |
Actuarial assumptions [member] |
Member |
|
|
ifrs-full:ActuarialAssumptionsMember |
| 1943 |
Actuarial assumption of discount rates [Member] |
Member |
|
|
ifrs-full:ActuarialAssumptionOfDiscountRatesMember |
| 1944 |
Actuarial assumption of life expectancy rates [Member] |
Member |
|
|
gsk:ActuarialAssumptionOfLifeExpectancyRatesMember |
| 1945 |
Actuarial assumption for future healthcare inflation [member] |
Member |
|
|
gsk:ActuarialAssumptionForFutureHealthcareInflationMember |
| 1946 |
Actuarial assumption of expected rates of inflation [Member] |
Member |
|
|
ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember |
| 1947 |
Disclosure of Sensitivity Analysis for Actuarial Assumptions [Line Items] |
LineItems |
|
|
ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems |
| 1948 |
Decrease in discount rate |
Concept (Percent) |
As Of |
|
ifrs-full:ActuarialAssumptionOfDiscountRates |
| 1949 |
Increase in life expectancy |
Concept (xbrli:durationItemType) |
For Period |
|
gsk:ActuarialAssumptionOfLifeExpectancy |
| 1950 |
Increase in rate of future healthcare inflation |
Concept (Percent) |
As Of |
|
gsk:ActuarialAssumptionForRateOfFutureHealthcareInflation |
| 1951 |
Increase in inflation |
Concept (Percent) |
As Of |
|
ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation |
| 1952 |
1184 - Disclosure - Other Provisions - Summary of Other Provisions (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherProvisionsSummaryOfOtherProvisions |
| 1953 |
Disclosure of other provisions [table] |
Table |
* |
* |
ifrs-full:DisclosureOfOtherProvisionsTable |
| 1954 |
Classes of other provisions [axis] |
Axis |
|
|
ifrs-full:ClassesOfProvisionsAxis |
| 1955 |
Other provisions [member] |
Member |
|
|
ifrs-full:OtherProvisionsMember |
| 1956 |
Legal and other disputes [member] |
Member |
|
|
gsk:LegalAndOtherDisputesMember |
| 1957 |
Major Restructuring Programmes [Member] |
Member |
|
|
ifrs-full:RestructuringProvisionMember |
| 1958 |
Employee Related Provisions [Member] |
Member |
|
|
gsk:EmployeeRelatedProvisionsMember |
| 1959 |
Other Provision [Member] |
Member |
|
|
gsk:OtherProvisionMember |
| 1960 |
Disclosure of other provisions [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfOtherProvisionsLineItems |
| 1961 |
Other provisions, beginning balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherProvisions |
| 1962 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions |
| 1963 |
Charge for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:AdditionalProvisionsOtherProvisions |
| 1964 |
Reversed unused |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:UnusedProvisionReversedOtherProvisions |
| 1965 |
Unwinding of discount |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions |
| 1966 |
Utilised |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProvisionUsedOtherProvisions |
| 1967 |
Reclassifications and other movements |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions |
| 1968 |
Transfer to Pension obligations |
Concept (Monetary) |
For Period |
Debit |
gsk:TransferToPensionObligations |
| 1969 |
Other provisions, ending balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherProvisions |
| 1970 |
To be settled within one year |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherShorttermProvisions |
| 1971 |
To be settled after one year |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherLongtermProvisions |
| 1972 |
Other provisions |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherProvisions |
| 1973 |
1185 - Disclosure - Other provisions - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherProvisionsAdditionalInformation |
| 1974 |
Disclosure of other provisions [table] |
Table |
* |
* |
ifrs-full:DisclosureOfOtherProvisionsTable |
| 1975 |
Classes of other provisions [axis] |
Axis |
|
|
ifrs-full:ClassesOfProvisionsAxis |
| 1976 |
Other provisions [member] |
Member |
|
|
ifrs-full:OtherProvisionsMember |
| 1977 |
Legal and other disputes [member] |
Member |
|
|
gsk:LegalAndOtherDisputesMember |
| 1978 |
Title of individual 1 [axis] |
Axis |
|
|
gsk:TitleOfIndividual1Axis |
| 1979 |
Government Grants [domain] |
Member |
|
|
gsk:GovernmentGrantsDomain |
| 1980 |
Disabled employees [member] |
Member |
|
|
gsk:DisabledEmployeesMember |
| 1981 |
Disclosure of other provisions [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfOtherProvisionsLineItems |
| 1982 |
Charges on other provisions |
Concept (Monetary) |
For Period |
Credit |
gsk:AdditionalProvisionsNetOfReversalsAndRecoveriesOtherProvisions |
| 1983 |
Discount on the provisions |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions |
| 1984 |
Short term legal proceedings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ShorttermLegalProceedingsProvision |
| 1985 |
Legal proceedings and other disputes provision estimated |
Concept (Monetary) |
As Of |
Credit |
gsk:LegalProceedingsAndOtherDisputesProvisionEstimated |
| 1986 |
Pension augmentations arising from staff redundancies |
Concept (Monetary) |
As Of |
Debit |
gsk:PensionObligationProvisions |
| 1987 |
Period for amounts provided are expected to be utilised |
Concept (xbrli:durationItemType) |
For Period |
|
gsk:PeriodForTheAmountToBeUtilised |
| 1988 |
Provision for employee benefits |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ProvisionsForEmployeeBenefits |
| 1989 |
Provision for employee benefits |
Concept (Monetary) |
For Period |
Debit |
gsk:InsuranceProvisions |
| 1990 |
Onerous property lease provisions |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OnerousContractsProvision |
| 1991 |
1186 - Disclosure - Other Non-current Liabilities - Summary of Other Noncurrent Liabilities (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureOtherNoncurrentLiabilitiesSummaryOfOtherNoncurrentLiabilities |
| 1992 |
Implied Table |
Table |
* |
* |
implied:Table |
| 1993 |
Other non-current liabilities [abstract] |
Abstract |
|
|
gsk:OtherNoncurrentLiabilitiesAbstract |
| 1994 |
Accruals |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Accruals |
| 1995 |
Deferred Income |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:DeferredIncomeClassifiedAsNoncurrent |
| 1996 |
Other payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherNoncurrentPayables |
| 1997 |
Other noncurrent liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherNoncurrentLiabilities |
| 1998 |
1187 - Disclosure - Net Debt - Schedule of Current Assets, Short and Long Term Borrowings (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureNetDebtScheduleOfCurrentAssetsShortAndLongTermBorrowings |
| 1999 |
Disclosure of debt [Table] |
Table |
* |
* |
gsk:DisclosureOfDebtTable |
| 2000 |
Classes of financial instruments [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialInstrumentsAxis |
| 2001 |
Financial Instruments, Class [Member] |
Member |
|
|
ifrs-full:ClassesOfFinancialInstrumentsMember |
| 2002 |
Net debt [member] |
Member |
|
|
gsk:Debt1Member |
| 2003 |
Entity Listings, Exchange [Axis] |
Axis |
|
|
dei:EntityListingsExchangeAxis |
| 2004 |
Exchange [Domain] |
Member |
|
|
dei:ExchangeDomain |
| 2005 |
New York Stock Exchange [member] |
Member |
|
|
gsk:NewYorkStockExchangeMember |
| 2006 |
London Stock Exchange [member] |
Member |
|
|
gsk:LondonStockExchangeMember |
| 2007 |
Borrowings by name [axis] |
Axis |
|
|
ifrs-full:BorrowingsByNameAxis |
| 2008 |
Borrowings by name [member] |
Member |
|
|
ifrs-full:BorrowingsByNameMember |
| 2009 |
Short-term borrowings [member] |
Member |
|
|
ifrs-full:ShorttermBorrowingsMember |
| 2010 |
5.650% US$ US Medium Term Note 2018 [member] |
Member |
|
|
gsk:FivePointSixFivePercentUsMediumTermNoteTwoThousandEighteenMember |
| 2011 |
0.625% European Medium Term Notes 2019 [member] |
Member |
|
|
gsk:ZeroPointSixTwoFivePercentEuropeanMediumTermNotesTwoThousandNineteenMember |
| 2012 |
EURIBOR +0.20% European Medium Term Note 2020 [member] |
Member |
|
|
gsk:EURIBORPlusZeroPointTwoZeroPercentageEuropeanMediumTermNoteTwoThousandTwentyMember |
| 2013 |
0.000% European Medium Term Note 2020 [member] |
Member |
|
|
gsk:ZeroPercentEuropeanMediumTermNotesTwoThousandTwentyMember |
| 2014 |
3.125% US$ US Medium Term Note 2021 [member] |
Member |
|
|
gsk:ThreePointOneTwoFivePercentageUSMediumTermNoteTwoThousandTwentyOneMember |
| 2015 |
LIBOR +0.35% US$ US Medium Term Note 2021 [member] |
Member |
|
|
gsk:LIBORPlusZeroPointThreeFivePercentageUSMediumTermNoteTwoThousandTwentyOneMember |
| 2016 |
2.850% US$ US Medium Term Note 2022 [Member] |
Member |
|
|
gsk:TwoPointEightFivePercentUsMediumTermNoteTwoThousandTwentyTwoMember |
| 2017 |
2.800% US$ US Medium Term Note 2023 [member] |
Member |
|
|
gsk:TwoPointEightPercentageUSMediumTermNoteTwoThousandTwentyThreeMember |
| 2018 |
3.375% US$ US Medium Term Note 2023 [member] |
Member |
|
|
gsk:ThreePointThreeSevenFivePercentageUSMediumTermNoteTwoThousandTwentyThreeMember |
| 2019 |
1.375% European Medium Term Notes 2024 [Member] |
Member |
|
|
gsk:OnePointThreeSevenFivePercentEuropeanMediumTermNotesTwoThousandTwentyFourMember |
| 2020 |
4.000% European Medium Term Note 2025 [Member] |
Member |
|
|
gsk:FourPointZeroZeroPercentEuropeanMediumTermNoteTwoThousandTwentyFiveMember |
| 2021 |
3.625% US$ US Medium Term Note 2025 [member] |
Member |
|
|
gsk:ThreePointSixTwoFivePercentUsMediumTermNoteTwoThousandTwentyFiveMember |
| 2022 |
1.000% European Medium Term Note 2026 [Member] |
Member |
|
|
gsk:OnePercentEuropeanMediumTermNotesTwoThousandTwentySixMember |
| 2023 |
1.250% European Medium Term Note 2026 [member] |
Member |
|
|
gsk:OnePointTwoFivePercentageEuropeanMediumTermNoteTwoThousandTwentySixMember |
| 2024 |
3.375% European Medium Term Note 2027 [Member] |
Member |
|
|
gsk:ThreePointThreeSevenFivePercentEuropeanMediumTermNoteTwoThousandTwentySevenMember |
| 2025 |
3.875% US$ US Medium Term Note 2028 [member] |
Member |
|
|
gsk:ThreePointEightSevenFivePercentageUSMediumTermNoteTwoThousandTwentyEightMember |
| 2026 |
1.375% European Medium Term Notes Two Thousand twenty nine [Member] |
Member |
|
|
gsk:OnePointThreeSevenFivePercentEuropeanMediumTermNotesTwoThousandTwentyNineMember |
| 2027 |
1.750% European Medium Term Note 2030 [member] |
Member |
|
|
gsk:OnePointSevenFiveZeroPercentageEuropeanMediumTermNoteTwoThousandThirtyMember |
| 2028 |
5.250% European Medium Term Note 2033 [Member] |
Member |
|
|
gsk:FivePointTwoFivePercentEuropeanMediumTermNoteTwoThousandThirtyThreeMember |
| 2029 |
5.375% US Medium Term Note 2034 [Member] |
Member |
|
|
gsk:FivePointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyFourMember |
| 2030 |
6.375% US Medium Term Note 2038 [Member] |
Member |
|
|
gsk:SixPointThreeSevenFivePercentUsMediumTermNoteTwoThousandThirtyEightMember |
| 2031 |
6.375% European Medium Term Note 2039 [Member] |
Member |
|
|
gsk:SixPointThreeSevenFivePercentEuropeanMediumTermNoteTwoThousandThirtyNineMember |
| 2032 |
5.250% European Medium Term Note 2042 [Member] |
Member |
|
|
gsk:FivePointTwoFivePercentEuropeanTermNoteTwoThousandFortyTwoMember |
| 2033 |
4.200% US$ US Medium Term Note 2043 [Member] |
Member |
|
|
gsk:FourPointTwoPercentUsMediumTermNoteTwoThousandFortyThreeMember |
| 2034 |
4.250% European Medium Term Note 2045 [Member] |
Member |
|
|
gsk:FourPointTwoFivePercentEuropeanMediumTermNoteTwoThousandFortyFiveMember |
| 2035 |
Long Term Borrowings [Member] |
Member |
|
|
ifrs-full:LongtermBorrowingsMember |
| 2036 |
Other LongTerm Borrowings [member] |
Member |
|
|
gsk:OtherLongtermBorrowingsMember |
| 2037 |
Disclosure of debt [line items] |
LineItems |
|
|
gsk:DisclosureOfDebtLineItems |
| 2038 |
Current assets: |
Abstract |
|
|
ifrs-full:CurrentAssetsAbstract |
| 2039 |
Liquid investments |
Concept (Monetary) |
As Of |
Debit |
gsk:LiquidInvestmentsCurrent |
| 2040 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 2041 |
Cash and cash equivalents reported in assets held for sale |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalentsClassifiedAsPartOfDisposalGroupHeldForSale |
| 2042 |
Current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentAssets |
| 2043 |
Short-term borrowings: |
Abstract |
|
|
ifrs-full:BorrowingsAbstract |
| 2044 |
Commercial paper |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CommercialPapersIssued |
| 2045 |
Bank loans and overdrafts |
Concept (Monetary) |
As Of |
Credit |
gsk:BankLoansAndOverdrafts |
| 2046 |
Obligations under finance leases |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentFinanceLeaseLiabilities |
| 2047 |
Drawn bank facility |
Concept (Monetary) |
As Of |
Credit |
gsk:DrawnBankFacility |
| 2048 |
Short-term borrowings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ShorttermBorrowings |
| 2049 |
Long-term borrowings: |
Abstract |
|
|
gsk:LongTermBorrowingsAbstract |
| 2050 |
Obligations under finance leases |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentFinanceLeaseLiabilities |
| 2051 |
Long-term borrowings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LongtermBorrowings |
| 2052 |
Net debt |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Borrowings |
| 2053 |
1188 - Disclosure - Net Debt - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureNetDebtAdditionalInformation |
| 2054 |
Disclosure of debt [Table] |
Table |
* |
* |
gsk:DisclosureOfDebtTable |
| 2055 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 2056 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 2057 |
Later than 5 years [member] |
Member |
|
|
ifrs-full:LaterThanFiveYearsMember |
| 2058 |
Matured in May 2018 [member] |
Member |
|
|
gsk:MaturedInMayTwoThousandEighteenMember |
| 2059 |
Matures in December 2019 [member] |
Member |
|
|
gsk:MaturesInDecemberTwoThousandNineteenMember |
| 2060 |
Borrowings by name [axis] |
Axis |
|
|
ifrs-full:BorrowingsByNameAxis |
| 2061 |
Borrowings by name [member] |
Member |
|
|
ifrs-full:BorrowingsByNameMember |
| 2062 |
Commercial paper [member] |
Member |
|
|
gsk:CommercialPaper1Member |
| 2063 |
Letter of credit 1 [member] |
Member |
|
|
gsk:LetterOfCredit1Member |
| 2064 |
364 day committed facilities [member] |
Member |
|
|
gsk:ThreeSixtyFourDayCommittedFacilitiesMember |
| 2065 |
Five -year commitment facility [member] |
Member |
|
|
gsk:FiveYearCommitmentFacilityMember |
| 2066 |
Types of interest rates [axis] |
Axis |
|
|
ifrs-full:TypesOfInterestRatesAxis |
| 2067 |
Interest rate types [member] |
Member |
|
|
ifrs-full:InterestRateTypesMember |
| 2068 |
Floating interest rate [member] |
Member |
|
|
ifrs-full:FloatingInterestRateMember |
| 2069 |
Fixed interest rate [member] |
Member |
|
|
ifrs-full:FixedInterestRateMember |
| 2070 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 2071 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 2072 |
Bottom of range [member] |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 2073 |
Top of range [member] |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 2074 |
Classes of financial instruments [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialInstrumentsAxis |
| 2075 |
Financial Instruments, Class [Member] |
Member |
|
|
ifrs-full:ClassesOfFinancialInstrumentsMember |
| 2076 |
US commercial paper program [member] |
Member |
|
|
gsk:UsCommercialPaperProgramMember |
| 2077 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 2078 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 2079 |
Disproportionate Effect on Weighted Average Rate [member] |
Member |
|
|
gsk:DisproportionateEffectOnWeightedAverageRateMember |
| 2080 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 2081 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 2082 |
Argentina [member] |
Member |
|
|
country:AR |
| 2083 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 2084 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 2085 |
Novartis [member] |
Member |
|
|
gsk:NovartisMember |
| 2086 |
Tesaro [member] |
Member |
|
|
gsk:TesaroMember |
| 2087 |
Disclosure of debt [line items] |
LineItems |
|
|
gsk:DisclosureOfDebtLineItems |
| 2088 |
Effective Interest rate on liquid investment |
Concept (Percent) |
As Of |
|
gsk:EffectiveInterestRateOnAvailableForSaleFinancialInvestments |
| 2089 |
Liquid investment |
Concept (Monetary) |
As Of |
Debit |
gsk:LiquidInvestments |
| 2090 |
Effective Interest rate on cash and cash equivalents |
Concept (Percent) |
For Period |
|
gsk:EffectiveInterestRateOnCashAndCashEquivalents |
| 2091 |
Interest income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueFromInterest |
| 2092 |
Non-interest bearing holdings |
Concept (Monetary) |
As Of |
Debit |
gsk:NonInterestBearingDemandDepositsAmount |
| 2093 |
Commercial paper authorized |
Concept (Monetary) |
As Of |
Credit |
gsk:CommercialPaperAuthorized |
| 2094 |
Commercial paper issued |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CommercialPapersIssued |
| 2095 |
Credit Facility available amount |
Concept (Monetary) |
As Of |
Credit |
gsk:CreditFacilityAvailableAmount |
| 2096 |
Number of transactions active |
Concept (Integer) |
For Period |
|
gsk:NumberOfTransactionsActive |
| 2097 |
Drawn bank facility |
Concept (Monetary) |
As Of |
Credit |
gsk:DrawnBankFacility |
| 2098 |
Undrawn bank facility |
Concept (Monetary) |
As Of |
Credit |
gsk:UndrawnBankFacility |
| 2099 |
Weighted average interest rate of borrowings |
Concept (Percent) |
For Period |
|
gsk:WeightedAverageInterestRateOnBorrowings |
| 2100 |
Weighted average interest rate on current bank loans and overdrafts |
Concept (Percent) |
As Of |
|
gsk:WeightedAverageInterestRateOnCurrentBankLoansAndOverdrafts |
| 2101 |
Weighted average interest rate on short-term loan |
Concept (Percent) |
As Of |
|
gsk:WeightedAverageInterestRateOnShorttermLoan |
| 2102 |
Average effective pre-swap interest rate notes as short |
Concept (Percent) |
As Of |
|
gsk:AverageEffectivePreSwapInterestRateShortTerm |
| 2103 |
Coupon note interest rate |
Concept (Percent) |
As Of |
|
gsk:CouponNoteInterestRate |
| 2104 |
Long-term borrowings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LongtermBorrowings |
| 2105 |
Average effective pre-swap interest rate notes |
Concept (Percent) |
For Period |
|
gsk:AverageEffectivePreSwapInterestRateNotesIssued |
| 2106 |
Interest at effective rates |
Concept (Percent) |
For Period |
|
gsk:CarryInterestAtEffectiveRates |
| 2107 |
Repayment dates |
Concept (Year) |
For Period |
|
gsk:RepaymentYear |
| 2108 |
Pledged investments value |
Concept (Monetary) |
For Period |
Debit |
gsk:PledgedInvestments |
| 2109 |
Other non current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherNoncurrentAssets |
| 2110 |
1189 - Disclosure - Net Debt - Schedule of Finance Lease Obligations (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureNetDebtScheduleOfFinanceLeaseObligations |
| 2111 |
Disclosure of maturity analysis for non-derivative financial liabilities [table] |
Table |
* |
* |
ifrs-full:DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable |
| 2112 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 2113 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 2114 |
Not later than 1 year [member] |
Member |
|
|
ifrs-full:NotLaterThanOneYearMember |
| 2115 |
Between 1 and 2 years [member] |
Member |
|
|
ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember |
| 2116 |
Between 2 and 3 years [member] |
Member |
|
|
ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember |
| 2117 |
Between 3 and 4 Years [Member] |
Member |
|
|
ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember |
| 2118 |
Between 4 and 5 years [member] |
Member |
|
|
ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember |
| 2119 |
Later than 5 years [member] |
Member |
|
|
ifrs-full:LaterThanFiveYearsMember |
| 2120 |
Disclosure of maturity analysis for non-derivative financial liabilities [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems |
| 2121 |
Total future rental payments |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:GrossFinanceLeaseObligations |
| 2122 |
Future finance charges |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:FutureFinanceChargeOnFinanceLease |
| 2123 |
Total finance lease obligations |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:FinanceLeaseLiabilities |
| 2124 |
1190 - Disclosure - Contingent Liabilities - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureContingentLiabilitiesAdditionalInformation |
| 2125 |
Implied Table |
Table |
* |
* |
implied:Table |
| 2126 |
Disclosure of contingent liabilities [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfContingentLiabilitiesAbstract |
| 2127 |
Contingent liabilities, comprising guarantees, discounted bills and other items |
Concept (Monetary) |
As Of |
|
ifrs-full:EstimatedFinancialEffectOfContingentLiabilities |
| 2128 |
Financial assets were pledged as collateral for contingent liabilities |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities |
| 2129 |
1191 - Disclosure - Share Capital and Share Premium Account - Summary of Share Capital and Share Premium (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremium |
| 2130 |
Disclosure Of Classes Share Capital And Share Premium [table] |
Table |
* |
* |
gsk:DisclosureOfClassesShareCapitalAndSharePremiumTable |
| 2131 |
Components of equity [axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 2132 |
Equity [member] |
Member |
|
|
ifrs-full:EquityMember |
| 2133 |
Share premium [member] |
Member |
|
|
ifrs-full:SharePremiumMember |
| 2134 |
Share capital [member] |
Member |
|
|
ifrs-full:IssuedCapitalMember |
| 2135 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 2136 |
Share capital [member] |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 2137 |
Ordinary shares [member] |
Member |
|
|
ifrs-full:OrdinarySharesMember |
| 2138 |
Disclosure Of Classes Of Share Capital And Share Premium [line items] |
LineItems |
|
|
gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems |
| 2139 |
Share capital issued and fully paid beginning balance |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssuedAndFullyPaid |
| 2140 |
Shares Authorised |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesAuthorised |
| 2141 |
Shares Authorised, value |
Concept (Monetary) |
As Of |
Credit |
gsk:AmountOfSharesAuthorised |
| 2142 |
Issued under employee share schemes |
Concept (Shares) |
As Of |
|
gsk:NumberOfSharesIssuedAndFullyPaidUnderEmployeeShareSchemes |
| 2143 |
Ordinary shares acquired by ESOP Trusts |
Concept (Shares) |
As Of |
|
gsk:NumberOfTreasurySharesTransferredToEmployeeShareTrusts |
| 2144 |
Share capital issued and fully paid ending balance |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssuedAndFullyPaid |
| 2145 |
Equity at beginning of period |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 2146 |
Issued under employee share schemes |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IssueOfEquity |
| 2147 |
Ordinary shares acquired by ESOP Trusts |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions |
| 2148 |
Issued under employee share schemes |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IssueOfEquity |
| 2149 |
Ordinary shares acquired by ESOP Trusts |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions |
| 2150 |
Equity at end of period |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 2151 |
Issued under employee share schemes |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IssueOfEquity |
| 2152 |
Ordinary shares acquired by ESOP Trusts |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions |
| 2153 |
1192 - Disclosure - Share Capital and Share Premium Account - Summary of Share Capital and Share Premium (Parenthetical) (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureShareCapitalAndSharePremiumAccountSummaryOfShareCapitalAndSharePremiumParenthetical |
| 2154 |
Implied Table |
Table |
* |
* |
implied:Table |
| 2155 |
Disclosure Of Classes Of Share Capital And Share Premium [abstract] |
Abstract |
|
|
gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract |
| 2156 |
Ordinary price per share |
Concept (Share) |
As Of |
|
ifrs-full:ParValuePerShare |
| 2157 |
1193 - Disclosure - Share Capital and Share Premium Account - Summary of Share Capital (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureShareCapitalAndSharePremiumAccountSummaryOfShareCapital |
| 2158 |
Implied Table |
Table |
* |
* |
implied:Table |
| 2159 |
Disclosure Of Classes Of Share Capital And Share Premium [abstract] |
Abstract |
|
|
gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumAbstract |
| 2160 |
Number of shares issuable under employee share schemes |
Concept (Decimal) |
As Of |
|
gsk:SharesReservedForIssueUnderEmployeeShareSchemes |
| 2161 |
Number of unissued shares not under option |
Concept (Shares) |
For Period |
|
gsk:NumberOfUnIssuedSharesNotUnderOption |
| 2162 |
1194 - Disclosure - Share Capital and Share Premium Account - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureShareCapitalAndSharePremiumAccountAdditionalInformation |
| 2163 |
Disclosure Of Classes Share Capital And Share Premium [table] |
Table |
* |
* |
gsk:DisclosureOfClassesShareCapitalAndSharePremiumTable |
| 2164 |
Components of equity [axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 2165 |
Equity [member] |
Member |
|
|
ifrs-full:EquityMember |
| 2166 |
Employee share ownership plan [member] |
Member |
|
|
gsk:EmployeeShareOwnershipPlanMember |
| 2167 |
Treasury shares [member] |
Member |
|
|
ifrs-full:TreasurySharesMember |
| 2168 |
Free issue [member] |
Member |
|
|
gsk:FreeIssueMember |
| 2169 |
Disclosure Of Classes Of Share Capital And Share Premium [line items] |
LineItems |
|
|
gsk:DisclosureOfClassesOfShareCapitalAndSharePremiumLineItems |
| 2170 |
Share capital issued |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssued |
| 2171 |
1195 - Disclosure - Movements in Equity - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureMovementsInEquityAdditionalInformation |
| 2172 |
Statement of changes in equity [table] |
Table |
* |
* |
ifrs-full:StatementOfChangesInEquityTable |
| 2173 |
Miscellaneous Components Of Equity [axis] |
Axis |
|
|
gsk:MiscellaneousComponentsOfEquityAxis |
| 2174 |
Miscellaneous Components Of Equity [domain] |
Member |
|
|
gsk:MiscellaneousComponentsOfEquityDomain |
| 2175 |
Merger and premerger reserves [member] |
Member |
|
|
gsk:MergerAndPremergerReservesMember |
| 2176 |
Capital redemption reserve [member] |
Member |
|
|
ifrs-full:CapitalRedemptionReserveMember |
| 2177 |
Components of equity [axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 2178 |
Equity [member] |
Member |
|
|
ifrs-full:EquityMember |
| 2179 |
Associates and joint ventures [member] |
Member |
|
|
gsk:AssociatesAndJointVenturesMember |
| 2180 |
Statement of changes in equity [line items] |
LineItems |
|
|
ifrs-full:StatementOfChangesInEquityLineItems |
| 2181 |
Retained losses and other reserves |
Concept (Monetary) |
As Of |
Credit |
gsk:RetainedEarningsAndOtherReserves |
| 2182 |
Other reserve |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherReserves |
| 2183 |
1196 - Disclosure - Movements in Equity - Summary of Cumulative Translation Exchange in Equity (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureMovementsInEquitySummaryOfCumulativeTranslationExchangeInEquity |
| 2184 |
Statement of changes in equity [table] |
Table |
* |
* |
ifrs-full:StatementOfChangesInEquityTable |
| 2185 |
Components of equity [axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 2186 |
Equity [member] |
Member |
|
|
ifrs-full:EquityMember |
| 2187 |
Retained earnings [member] |
Member |
|
|
ifrs-full:RetainedEarningsMember |
| 2188 |
Fair value reserve [member] |
Member |
|
|
gsk:FairValueReserveMember |
| 2189 |
Non- controlling interests [member] |
Member |
|
|
ifrs-full:NoncontrollingInterestsMember |
| 2190 |
Statement of changes in equity [line items] |
LineItems |
|
|
ifrs-full:StatementOfChangesInEquityLineItems |
| 2191 |
Beginning balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ReserveOfExchangeDifferencesOnTranslation |
| 2192 |
Exchange movements on overseas net assets |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation |
| 2193 |
Reclassification of exchange on liquidation or disposal of overseas subsidiaries |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax |
| 2194 |
Ending balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ReserveOfExchangeDifferencesOnTranslation |
| 2195 |
1197 - Disclosure - Movements in Equity - Analysis of Other Comprehensive Income by Equity Category (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureMovementsInEquityAnalysisOfOtherComprehensiveIncomeByEquityCategory |
| 2196 |
Statement of changes in equity [table] |
Table |
* |
* |
ifrs-full:StatementOfChangesInEquityTable |
| 2197 |
Components of equity [axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 2198 |
Equity [member] |
Member |
|
|
ifrs-full:EquityMember |
| 2199 |
Retained earnings [member] |
Member |
|
|
ifrs-full:RetainedEarningsMember |
| 2200 |
Other reserves [member] |
Member |
|
|
ifrs-full:OtherReservesMember |
| 2201 |
Non- controlling interests [member] |
Member |
|
|
ifrs-full:NoncontrollingInterestsMember |
| 2202 |
Statement of changes in equity [line items] |
LineItems |
|
|
ifrs-full:StatementOfChangesInEquityLineItems |
| 2203 |
Items that may be subsequently reclassified to income statement: |
Abstract |
|
|
ifrs-full:ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract |
| 2204 |
Exchange movements on overseas net assets and net investment hedges |
Concept (Monetary) |
For Period |
Credit |
gsk:ExchangeMovementsOnOverseasNetAssetsAndNetInvestmentHedges |
| 2205 |
Reclassification of exchange on liquidation or disposal of overseas subsidiaries |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax |
| 2206 |
Fair value movements on available-for-sale investments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsBeforeTax |
| 2207 |
Reclassification of fair value movements on available-for-sale investments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReclassificationAdjustmentsOnAvailableforsaleFinancialAssetsBeforeTax |
| 2208 |
Deferred tax on fair value movements on available-for-sale investments |
Concept (Monetary) |
For Period |
Debit |
gsk:DeferredTaxOnFairValueMovementsOnAvailableForSaleInvestments |
| 2209 |
Deferred tax reversed on reclassification of available-for-sale investments |
Concept (Monetary) |
For Period |
Debit |
gsk:DeferredTaxReversedOnReclassificationOfAvailableForSaleInvestments |
| 2210 |
Reclassification of cash flow hedges to income statement |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax |
| 2211 |
Fair value movements on cash flow hedges |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax |
| 2212 |
Reclassification of cash flow hedges on income and expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax |
| 2213 |
Deferred tax on fair value movements on cash flow hedges |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome |
| 2214 |
Deferred tax reversed on reclassification of cash flow hedges |
Concept (Monetary) |
For Period |
Credit |
gsk:DeferredTaxReversedOnReclassificationOfCashFlowHedges |
| 2215 |
Items that will not be reclassified to income statement: |
Abstract |
|
|
ifrs-full:ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract |
| 2216 |
Exchange movements on overseas net assets of non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
gsk:ExchangeMovementsOnOverseasNetAssetsOfNonControllingInterests |
| 2217 |
Fair value movements on equity investments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments |
| 2218 |
Deferred tax on fair value movements on equity investments |
Concept (Monetary) |
For Period |
Credit |
gsk:OtherComprehensiveIncomeDeferredTaxOnFairValueMovementsOnEquityInvestments |
| 2219 |
Remeasurement gains (losses) on defined benefit plans |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans |
| 2220 |
Tax on remeasurement gains (losses) in defined benefit plans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome |
| 2221 |
Other comprehensive income for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncome |
| 2222 |
1198 - Disclosure - Movements in Equity - Analysis of Other Reserves (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureMovementsInEquityAnalysisOfOtherReserves |
| 2223 |
Statement of changes in equity [table] |
Table |
* |
* |
ifrs-full:StatementOfChangesInEquityTable |
| 2224 |
Components of equity [axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 2225 |
Equity [member] |
Member |
|
|
ifrs-full:EquityMember |
| 2226 |
ESOP trust shares [member] |
Member |
|
|
gsk:EsopTrustMember |
| 2227 |
Fair value reserve [member] |
Member |
|
|
gsk:FairValueReserveMember |
| 2228 |
Cash Flow Hedges Reserve [Member] |
Member |
|
|
ifrs-full:ReserveOfCashFlowHedgesMember |
| 2229 |
Other reserves [member] |
Member |
|
|
ifrs-full:OtherReservesMember |
| 2230 |
Statement of changes in equity [line items] |
LineItems |
|
|
ifrs-full:StatementOfChangesInEquityLineItems |
| 2231 |
Other reserves, beginning balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherReserves |
| 2232 |
Implementation of IFRS 9 |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseDueToTheAdoptionOfIFRS9 |
| 2233 |
At 31 December, as adjusted |
Concept (Monetary) |
As Of |
Credit |
gsk:OtherReservesEndingBalanceAsAdjusted |
| 2234 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Debit |
gsk:ExchangeAdjustments |
| 2235 |
Transferred to income and expense in the year on disposals |
Concept (Monetary) |
For Period |
Debit |
gsk:TransferredIncomeExpenseOnDisposals |
| 2236 |
Transferred to Retained earnings in the year on disposal of equity investments |
Concept (Monetary) |
For Period |
Credit |
gsk:TransferredToRetainedEarningsOnDisposalOfEquityInvestments |
| 2237 |
Transferred to income and expense in the year on impairments |
Concept (Monetary) |
For Period |
Debit |
gsk:TransferredIncomeExpenseOnImpairments |
| 2238 |
Net fair value movement in the year |
Concept (Monetary) |
For Period |
Debit |
gsk:NetFairValueMovements |
| 2239 |
Ordinary shares acquired by ESOP Trusts |
Concept (Monetary) |
For Period |
Debit |
gsk:OrdinarySharesAcquiredByEsopTrustsIncludedInOtherReserves |
| 2240 |
Write-down of shares held by ESOP Trusts |
Concept (Monetary) |
For Period |
Credit |
gsk:WritedownOfSharesHeldByEsopTrusts |
| 2241 |
Other reserves, ending balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherReserves |
| 2242 |
1199 - Disclosure - Related Party Transactions - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation |
| 2243 |
Disclosure of transactions between related parties [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable |
| 2244 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 2245 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 2246 |
Innoviva incorporation [member] |
Member |
|
|
gsk:InnovivaIncorporationMember |
| 2247 |
Joint ventures where entity is venturer [member] |
Member |
|
|
ifrs-full:JointVenturesWhereEntityIsVenturerMember |
| 2248 |
Medicxi Ventures I Limited Partner [member] |
Member |
|
|
gsk:MedicxiVenturesILimitedPartnerMember |
| 2249 |
Index ventures life VI [member] |
Member |
|
|
gsk:IndexVenturesLifeVIMember |
| 2250 |
Kurma Biofund II, FCPR [member] |
Member |
|
|
gsk:KurmaBiofundIifcprMember |
| 2251 |
Apollo Therapeutics LLP [member] |
Member |
|
|
gsk:ApolloTherapeuticsLLPMember |
| 2252 |
Longwood Founders Fund LP [member] |
Member |
|
|
gsk:LongwoodFoundersFundLPMember |
| 2253 |
Qura Therapeutics LLC [member] |
Member |
|
|
gsk:QuraTherapeuticsLLCMember |
| 2254 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 2255 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 2256 |
Japan Vaccine Company Limited [member] |
Member |
|
|
gsk:JapanVaccineCompanyLimitedMember |
| 2257 |
Disclosure of transactions between related parties [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems |
| 2258 |
Number of shares owned |
Concept (Shares) |
As Of |
|
ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates |
| 2259 |
Percentage of shares owned |
Concept (Percent) |
For Period |
|
ifrs-full:ProportionOfOwnershipInterestInAssociate |
| 2260 |
Royalty charge |
Concept (Monetary) |
For Period |
Debit |
gsk:RoyaltiesChargedInIncomeStatement |
| 2261 |
Royalty payable |
Concept (Monetary) |
For Period |
Debit |
gsk:RoyaltiesPayableToAssociates |
| 2262 |
Ownership interest |
Concept (Percent) |
For Period |
|
ifrs-full:ProportionOfOwnershipInterestInJointVenture |
| 2263 |
Sale of vaccine product |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions |
| 2264 |
Trading balance receivable |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:AmountsReceivableRelatedPartyTransactions |
| 2265 |
Trading balance payable |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:AmountsPayableRelatedPartyTransactions |
| 2266 |
Loans outstanding |
Concept (Monetary) |
For Period |
Credit |
gsk:LoansReceivableMadeByEntityRelatedPartyTransactions |
| 2267 |
Increase in equity investment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod |
| 2268 |
Decrease in liability |
Concept (Monetary) |
For Period |
Credit |
gsk:AdjustmentsForIncreaseDecreaseInLiabilities |
| 2269 |
Liability |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Liabilities |
| 2270 |
1200 - Disclosure - Adjustments Reconciling Profit After Tax to Operating Cash Flows - Summary of Cash Generated from Operations (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAdjustmentsReconcilingProfitAfterTaxToOperatingCashFlowsSummaryOfCashGeneratedFromOperations |
| 2271 |
Implied Table |
Table |
* |
* |
implied:Table |
| 2272 |
Adjustments to reconcile profit (loss) [abstract] |
Abstract |
|
|
ifrs-full:AdjustmentsForReconcileProfitLossAbstract |
| 2273 |
Profit after tax |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 2274 |
Tax on profits |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncomeTaxExpense |
| 2275 |
Share of after tax profits of associates and joint ventures |
Concept (Monetary) |
For Period |
Debit |
gsk:AdjustmentsForShareOfAfterTaxProfitsOfAssociatesAndJointVentures |
| 2276 |
Finance expense net of finance income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:AdjustmentsForFinanceIncomeCost |
| 2277 |
Depreciation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDepreciationExpense |
| 2278 |
Amortisation of intangible assets |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForAmortisationExpense |
| 2279 |
Impairment and assets written off |
Concept (Monetary) |
For Period |
Debit |
gsk:AdjustmentsForImpairmentAndAssetsWrittenOff |
| 2280 |
Profit on sale of businesses |
Concept (Monetary) |
For Period |
Credit |
gsk:AdjustmentsForProfitOnSaleOfBusinesses |
| 2281 |
Profit on sale of intangible assets |
Concept (Monetary) |
For Period |
Debit |
gsk:AdjustmentsForProfitOnSaleOfIntangibleAssets |
| 2282 |
Profit on sale of investments in associates |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates |
| 2283 |
Profit on sale of equity investments |
Concept (Monetary) |
For Period |
Credit |
gsk:AdjustmentsForProfitOnSaleOfEquityInvestments |
| 2284 |
Gain on Consumer Healthcare Joint Venture put hedging |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax |
| 2285 |
Business acquisition costs |
Concept (Monetary) |
For Period |
Debit |
gsk:AdjustmentsForAcquisitionCosts |
| 2286 |
Changes in working capital: |
Abstract |
|
|
gsk:ChangesInWorkingCapitalAbstract |
| 2287 |
Decrease/(increase) in inventories |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDecreaseIncreaseInInventories |
| 2288 |
Increase in trade receivables |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable |
| 2289 |
Increase in trade payables |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable |
| 2290 |
Decrease in other receivables |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables |
| 2291 |
Contingent consideration paid (see Note •) |
Concept (Monetary) |
For Period |
Debit |
gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid |
| 2292 |
Other non-cash increase in contingent consideration liabilities |
Concept (Monetary) |
For Period |
Debit |
gsk:AdjustmentsForDecreaseIncreaseInOtherNonCashContingentConsiderationLiabilities |
| 2293 |
Increase in other payables |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables |
| 2294 |
Increase/(decrease) in pension and other provisions |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities |
| 2295 |
Share-based incentive plans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForSharebasedPayments |
| 2296 |
Fair value adjustments |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForFairValueGainsLosses |
| 2297 |
Other |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OtherAdjustmentsToReconcileProfitLoss |
| 2298 |
Adjustments reconciling profit after tax to operating cash flows |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForReconcileProfitLoss |
| 2299 |
Cash generated from operations |
Concept (Monetary) |
For Period |
|
ifrs-full:CashFlowsFromUsedInOperations |
| 2300 |
1201 - Disclosure - Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Net Debt (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfNetDebt |
| 2301 |
Implied Table |
Table |
* |
* |
implied:Table |
| 2302 |
Disclosure of net debt [abstract] |
Abstract |
|
|
gsk:DisclosureOfNetDebtAbstract |
| 2303 |
Net debt at beginning of year |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Borrowings |
| 2304 |
Increase/(decrease) in cash and bank overdrafts |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges |
| 2305 |
Decrease in liquid investments |
Concept (Monetary) |
For Period |
Debit |
gsk:DecreaseIncreaseInLiquidInvestment |
| 2306 |
Net increase in long-term loans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromNoncurrentBorrowings |
| 2307 |
Repayment of short-term Notes |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RepaymentsOfCurrentBorrowings |
| 2308 |
(Increase in)/repayment of other short-term loans |
Concept (Monetary) |
For Period |
Debit |
gsk:ProceedsFromRepaymentsOfOtherCurrentBorrowings |
| 2309 |
Net repayment of obligations under finance leases |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities |
| 2310 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Debit |
gsk:ExchangeOnNetDebt |
| 2311 |
Other non-cash movements |
Concept (Monetary) |
For Period |
Debit |
gsk:OtherAdjustmentsForNoncashItemsToNetDebt |
| 2312 |
Movement in net debt |
Concept (Monetary) |
For Period |
Debit |
gsk:ChangesInNetDebt |
| 2313 |
Net debt at end of year |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Borrowings |
| 2314 |
1202 - Disclosure - Reconciliation of Net Cash Flow to Movement in Net Debt - Summary of Analysis of Changes in Net Debt (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureReconciliationOfNetCashFlowToMovementInNetDebtSummaryOfAnalysisOfChangesInNetDebt |
| 2315 |
Disclosure of reconciliation of liabilities arising from financing activities [table] |
Table |
* |
* |
ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable |
| 2316 |
Classes of financial assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialAssetsAxis |
| 2317 |
Financial assets, class [member] |
Member |
|
|
ifrs-full:FinancialAssetsMember |
| 2318 |
Liquid Investments [member] |
Member |
|
|
gsk:LiquidInvestmentsMember |
| 2319 |
Cash and cash equivalents [member] |
Member |
|
|
gsk:CashAndCashEquivalentMember |
| 2320 |
Cash and cash equivalents - AHFS [member] |
Member |
|
|
gsk:CashAndCashEquivalentsAHFSMember |
| 2321 |
Overdrafts [member] |
Member |
|
|
gsk:BankOverdrafts1Member |
| 2322 |
Cash and cash equivalents and overdrafts [member] |
Member |
|
|
gsk:CashAndBankOverdraftsMember |
| 2323 |
Derivative financial instruments [member] |
Member |
|
|
gsk:DerivativeFinancialInstrumentsMember |
| 2324 |
Other financing items [member] |
Member |
|
|
gsk:OtherFinancingItemsMember |
| 2325 |
Borrowings by name [axis] |
Axis |
|
|
ifrs-full:BorrowingsByNameAxis |
| 2326 |
Borrowings by name [member] |
Member |
|
|
ifrs-full:BorrowingsByNameMember |
| 2327 |
Commercial paper [member] |
Member |
|
|
gsk:CommercialPaper1Member |
| 2328 |
European/US Medium Term Notes and Bank Facilities [member] |
Member |
|
|
gsk:EuropeanUsMediumTermNotesAndBankFacilitiesMember |
| 2329 |
Other [member] |
Member |
|
|
gsk:OtherCurrentDebtMember |
| 2330 |
European/US Medium Term Notes and Bank Facilities Non-current [member] |
Member |
|
|
gsk:EuropeanUsMediumTermNotesAndBankFacilitiesNoncurrentMember |
| 2331 |
Other non-current debt [member] |
Member |
|
|
gsk:OtherNoncurrentDebtMember |
| 2332 |
Liabilities arising from financing activities [axis] |
Axis |
|
|
ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis |
| 2333 |
Liabilities arising from financing activities [member] |
Member |
|
|
ifrs-full:LiabilitiesArisingFromFinancingActivitiesMember |
| 2334 |
Short-term borrowings [member] |
Member |
|
|
ifrs-full:ShorttermBorrowingsMember |
| 2335 |
Long Term Borrowings [Member] |
Member |
|
|
ifrs-full:LongtermBorrowingsMember |
| 2336 |
Total Debt [member] |
Member |
|
|
gsk:TotalDebtMember |
| 2337 |
Assets held to hedge liabilities arising from financing activities [member] |
Member |
|
|
ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember |
| 2338 |
Accrued interest [member] |
Member |
|
|
gsk:AccruedInterestMember |
| 2339 |
Disclosure of reconciliation of liabilities arising from financing activities [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems |
| 2340 |
Beginning balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LiabilitiesArisingFromFinancingActivities |
| 2341 |
Exchange |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities |
| 2342 |
Other |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities |
| 2343 |
Profit and loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss |
| 2344 |
Reclassification |
Concept (Monetary) |
For Period |
Credit |
gsk:ReclassificationOfNetDebt |
| 2345 |
Cash flow |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities |
| 2346 |
Ending balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LiabilitiesArisingFromFinancingActivities |
| 2347 |
1203 - Disclosure - Acquisitions and Disposals - 2016 Acquisitions - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAcquisitionsAndDisposals2016AcquisitionsAdditionalInformation |
| 2348 |
Disclosure of detailed information about business combination [table] |
Table |
* |
* |
ifrs-full:DisclosureOfBusinessCombinationsTable |
| 2349 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 2350 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 2351 |
2018 Acquisition [member] |
Member |
|
|
gsk:TwoThousandEighteenAcquisitionMember |
| 2352 |
2017 acquisition [member] |
Member |
|
|
gsk:TwoThousandSeventeenAcquisitionMember |
| 2353 |
2016 acquisitions [member] |
Member |
|
|
gsk:TwoThousandSixteenAcquisitionMember |
| 2354 |
HIV R&D preclinical and discovery stage portfolio [member] |
Member |
|
|
gsk:HIVRAndDPreclinicalAndDiscoveryStagePortfolioMember |
| 2355 |
Galvani Bioelectronics Limited [member] |
Member |
|
|
gsk:GalvaniBioelectronicsLimitedMember |
| 2356 |
GSK Consumer Healthcare Limited With Hindustan Unilever Limited [member] |
Member |
|
|
gsk:GskConsumerHealthcarelimitedwithhindustanunileverlimitedMember |
| 2357 |
Tesaro, Inc.[member] |
Member |
|
|
gsk:TesaroIncMember |
| 2358 |
Associates [axis] |
Axis |
|
|
ifrs-full:SignificantInvestmentsInAssociatesAxis |
| 2359 |
Entity's total for associates [member] |
Member |
|
|
ifrs-full:EntitysTotalForAssociatesMember |
| 2360 |
Associates [member] |
Member |
|
|
ifrs-full:AssociatesMember |
| 2361 |
Assets and liabilities classified as held for sale [axis] |
Axis |
|
|
ifrs-full:AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis |
| 2362 |
Assets and liabilities not classified as held for sale [member] |
Member |
|
|
ifrs-full:AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember |
| 2363 |
Disposal groups classified as held for sale [member] |
Member |
|
|
ifrs-full:DisposalGroupsClassifiedAsHeldForSaleMember |
| 2364 |
Continuing and discontinued operations [axis] |
Axis |
|
|
ifrs-full:ContinuingAndDiscontinuedOperationsAxis |
| 2365 |
Continuing operations [member] |
Member |
|
|
ifrs-full:ContinuingOperationsMember |
| 2366 |
2017 disposals [member] |
Member |
|
|
gsk:TwoThousandSeventeenBusinessDisposalsMember |
| 2367 |
2016 business disposals [member] |
Member |
|
|
gsk:TwoThousandSixteenBusinessDisposalsMember |
| 2368 |
2018 disposals [member] |
Member |
|
|
gsk:TwoThousandEighteenBusinessDisposalsMember |
| 2369 |
Non-adjusting events after reporting period [axis] |
Axis |
|
|
ifrs-full:NonadjustingEventsAfterReportingPeriodAxis |
| 2370 |
Non-adjusting events after reporting period [member] |
Member |
|
|
ifrs-full:NonadjustingEventsMember |
| 2371 |
Other disposals of assets [member] |
Member |
|
|
ifrs-full:OtherDisposalsOfAssetsMember |
| 2372 |
Major business combination [member] |
Member |
|
|
ifrs-full:MajorBusinessCombinationMember |
| 2373 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 2374 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 2375 |
Pfizer [member] |
Member |
|
|
gsk:PfizerMember |
| 2376 |
Joint ventures [axis] |
Axis |
|
|
ifrs-full:JointVenturesAxis |
| 2377 |
Entity's total for joint ventures [member] |
Member |
|
|
ifrs-full:EntitysTotalForJointVenturesMember |
| 2378 |
Pfizer's Consumer Health Business [member] |
Member |
|
|
gsk:PfizerConsumerHealthBusinessMember |
| 2379 |
Ownership [Axis] |
Axis |
|
|
srt:OwnershipAxis |
| 2380 |
Ownership [Domain] |
Member |
|
|
srt:OwnershipDomain |
| 2381 |
GSK Consumer Healthcare Limited [member] |
Member |
|
|
gsk:GskConsumerHealthcareLimitedMember |
| 2382 |
Hedging instruments [axis] |
Axis |
|
|
ifrs-full:HedgingInstrumentsAxis |
| 2383 |
Hedging instruments [member] |
Member |
|
|
ifrs-full:HedgingInstrumentsMember |
| 2384 |
Embedded Derivative [member] |
Member |
|
|
gsk:EmbeddedDerivativeMember |
| 2385 |
Disclosure of detailed information about business combination [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfBusinessCombinationsLineItems |
| 2386 |
Number of acquisitions |
Concept (Integer) |
As Of |
|
gsk:NumberOfAcquisitions |
| 2387 |
Cash consideration |
Concept (Monetary) |
For Period |
Debit |
gsk:NetCashConsiderationOnDisposals |
| 2388 |
Total consideration value |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations |
| 2389 |
Percentage of ownership |
Concept (Percent) |
For Period |
|
gsk:PercentageOfOwnership |
| 2390 |
Fair value assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsAtFairValue |
| 2391 |
Cash consideration |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CashTransferred |
| 2392 |
Percentage acquired |
Concept (Percent) |
As Of |
|
ifrs-full:PercentageOfVotingEquityInterestsAcquired |
| 2393 |
Percentage of holding in joint venture |
Concept (Percent) |
For Period |
|
ifrs-full:ProportionOfOwnershipInterestInJointVenture |
| 2394 |
Deferred consideration receivable |
Concept (Monetary) |
For Period |
Credit |
gsk:DeferredConsiderationReceivableOnDisposals |
| 2395 |
Cash investment in associates and joint ventures |
Concept (Monetary) |
For Period |
Debit |
gsk:CashInvestmentsInJointVenturesAndAssociates |
| 2396 |
Cash consideration paid |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents |
| 2397 |
Number of investment holdings sold |
Concept (Integer) |
For Period |
|
gsk:NumberOfInvestmentsSold |
| 2398 |
Cash consideration |
Concept (Monetary) |
For Period |
Debit |
gsk:PaymentOfCashConsideration |
| 2399 |
Initial estimate of recognised for contingent consideration |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:ContingentConsiderationArrangementsAndIndemnificationAssetsRecognisedAsOfAcquisitionDate |
| 2400 |
Intangible assets |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill |
| 2401 |
Goodwill |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Goodwill |
| 2402 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate |
| 2403 |
Proportion of non-controlling interest |
Concept (Percent) |
For Period |
|
gsk:ProportionOfNonControllingInterest |
| 2404 |
Fair value of shareholdings |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FairValueOfAcquiredReceivables |
| 2405 |
Non controlling interest |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate |
| 2406 |
1204 - Disclosure - Acquisitions and Disposals - Summary of Investment in Associates and Joint Ventures (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAcquisitionsAndDisposalsSummaryOfInvestmentInAssociatesAndJointVentures |
| 2407 |
Disclosure of detailed information about business combination [table] |
Table |
* |
* |
ifrs-full:DisclosureOfBusinessCombinationsTable |
| 2408 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 2409 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 2410 |
Business combinations [member] |
Member |
|
|
ifrs-full:BusinessCombinationsMember |
| 2411 |
Associates and JV investments [member] |
Member |
|
|
gsk:AssociatesAndJointVenturesInvestmentsMember |
| 2412 |
Continuing and discontinued operations [axis] |
Axis |
|
|
ifrs-full:ContinuingAndDiscontinuedOperationsAxis |
| 2413 |
Continuing operations [member] |
Member |
|
|
ifrs-full:ContinuingOperationsMember |
| 2414 |
2018 disposals [member] |
Member |
|
|
gsk:TwoThousandEighteenBusinessDisposalsMember |
| 2415 |
2018 investments [member] |
Member |
|
|
gsk:TwoThousandEighteenInvestmentsMember |
| 2416 |
Associates and joint ventures 2018 disposals [member] |
Member |
|
|
gsk:AssociatesAndJointVenturesTwoThousandEighteenDisposalsMember |
| 2417 |
2017 disposals [member] |
Member |
|
|
gsk:TwoThousandSeventeenBusinessDisposalsMember |
| 2418 |
2017 investments [member] |
Member |
|
|
gsk:TwoThousandSeventeenInvestmentsMember |
| 2419 |
Associates and joint ventures 2017 disposals [member] |
Member |
|
|
gsk:AssociatesAndJointVenturesTwoThousandSeventeenDisposalsMember |
| 2420 |
Disclosure of detailed information about business combination [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfBusinessCombinationsLineItems |
| 2421 |
Cash consideration |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents |
| 2422 |
Net deferred consideration received |
Concept (Monetary) |
For Period |
Debit |
gsk:DeferredConsiderationReceived |
| 2423 |
Cash and cash equivalents divested |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013 |
| 2424 |
Transaction costs paid |
Concept (Monetary) |
For Period |
Credit |
gsk:PaymentsMadeForTransactionCostsAndOther |
| 2425 |
Cash inflow |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInInvestingActivities |
| 2426 |
1205 - Disclosure - Acquisitions and Disposals - Summary of Profit on Disposal of Businesses (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAcquisitionsAndDisposalsSummaryOfProfitOnDisposalOfBusinesses |
| 2427 |
Disclosure of detailed information about business combination [table] |
Table |
* |
* |
ifrs-full:DisclosureOfBusinessCombinationsTable |
| 2428 |
Continuing and discontinued operations [axis] |
Axis |
|
|
ifrs-full:ContinuingAndDiscontinuedOperationsAxis |
| 2429 |
Continuing operations [member] |
Member |
|
|
ifrs-full:ContinuingOperationsMember |
| 2430 |
2017 disposals [member] |
Member |
|
|
gsk:TwoThousandSeventeenBusinessDisposalsMember |
| 2431 |
Disclosure of detailed information about business combination [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfBusinessCombinationsLineItems |
| 2432 |
Consideration including currency forwards and purchase adjustments |
Concept (Monetary) |
For Period |
Debit |
gsk:NetCashConsiderationOnDisposals |
| 2433 |
Net assets sold: |
Abstract |
|
|
ifrs-full:AssetsAbstract |
| 2434 |
Goodwill |
Concept (Monetary) |
For Period |
Credit |
gsk:DisposalsGoodwill |
| 2435 |
Intangible assets |
Concept (Monetary) |
For Period |
Credit |
gsk:DisposalsIntangibleAssets |
| 2436 |
Property, plant and equipment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DisposalsPropertyPlantAndEquipment |
| 2437 |
Inventory |
Concept (Monetary) |
For Period |
Credit |
gsk:DisposalsInventory |
| 2438 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CashTransferred |
| 2439 |
Other net assets |
Concept (Monetary) |
For Period |
Credit |
gsk:DisposalsOtherNetAssets |
| 2440 |
Net assets sold |
Concept (Monetary) |
As Of |
Debit |
gsk:DisposalGroupAssetsNet |
| 2441 |
Transaction costs |
Concept (Monetary) |
For Period |
Credit |
gsk:TransactionCostsOnAcquisition |
| 2442 |
Reclassification of exchange from other comprehensive income |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax |
| 2443 |
Profit on disposal |
Concept (Monetary) |
For Period |
Credit |
gsk:GainLossOnDisposalsOfBusiness |
| 2444 |
1206 - Disclosure - Acquisitions and Disposals - Summary of Disposal of Associates (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAcquisitionsAndDisposalsSummaryOfDisposalOfAssociates |
| 2445 |
Disclosure of detailed information about business combination [table] |
Table |
* |
* |
ifrs-full:DisclosureOfBusinessCombinationsTable |
| 2446 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 2447 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 2448 |
Investment associates and joint ventures [member] |
Member |
|
|
gsk:InvestmentAssociatesAndJointVenturesMember |
| 2449 |
Continuing and discontinued operations [axis] |
Axis |
|
|
ifrs-full:ContinuingAndDiscontinuedOperationsAxis |
| 2450 |
Continuing operations [member] |
Member |
|
|
ifrs-full:ContinuingOperationsMember |
| 2451 |
2017 disposals [member] |
Member |
|
|
gsk:TwoThousandSeventeenBusinessDisposalsMember |
| 2452 |
Disclosure of detailed information about business combination [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfBusinessCombinationsLineItems |
| 2453 |
Cash consideration |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents |
| 2454 |
Net book value of shares |
Concept (Monetary) |
For Period |
Debit |
gsk:NetBookValueOfSharesFromInvestmentsInAssociatesAndJointVentures |
| 2455 |
Reclassification of exchange from other comprehensive income |
Concept (Monetary) |
For Period |
Debit |
gsk:ReclassificationOfExchangeFromOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod |
| 2456 |
Transaction costs |
Concept (Monetary) |
For Period |
Debit |
gsk:TransactionFees |
| 2457 |
Profit on disposal |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments |
| 2458 |
1207 - Disclosure - Acquisitions and Disposals - Summary of Cash Flows from Business Combinations (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureAcquisitionsAndDisposalsSummaryOfCashFlowsFromBusinessCombinations |
| 2459 |
Disclosure of detailed information about business combination [table] |
Table |
* |
* |
ifrs-full:DisclosureOfBusinessCombinationsTable |
| 2460 |
Continuing and discontinued operations [axis] |
Axis |
|
|
ifrs-full:ContinuingAndDiscontinuedOperationsAxis |
| 2461 |
Continuing operations [member] |
Member |
|
|
ifrs-full:ContinuingOperationsMember |
| 2462 |
Business acquisitions [member] |
Member |
|
|
gsk:AcquisitionsMember |
| 2463 |
Business disposals [member] |
Member |
|
|
gsk:BusinessDisposalMember |
| 2464 |
Disclosure of detailed information about business combination [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfBusinessCombinationsLineItems |
| 2465 |
Cash consideration (paid)/received after purchase adjustments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ConsiderationPaidReceived |
| 2466 |
Cash and cash equivalents acquired |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CashTransferred |
| 2467 |
Cash inflow |
Concept (Monetary) |
For Period |
Debit |
gsk:ProceedsFromSmallBusiness |
| 2468 |
1208 - Disclosure - Contingent consideration liabilities - Summary of Fair Value Contingent Consideration (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureContingentConsiderationLiabilitiesSummaryOfFairValueContingentConsideration |
| 2469 |
Disclosure of contingent liabilities in business combination [table] |
Table |
* |
* |
ifrs-full:DisclosureOfContingentLiabilitiesInBusinessCombinationTable |
| 2470 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 2471 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 2472 |
Shionogi ViiV healthcare joint venture [member] |
Member |
|
|
gsk:ShionogiViiVHealthcareJointVentureMember |
| 2473 |
Novartis [member] |
Member |
|
|
gsk:NovartisMember |
| 2474 |
Other [member] |
Member |
|
|
gsk:OtherBusinessMember |
| 2475 |
Disclosure of contingent liabilities in business combination [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems |
| 2476 |
Beginning balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination |
| 2477 |
Additions through business combinations |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination |
| 2478 |
Remeasurement through income statement |
Concept (Monetary) |
For Period |
Credit |
gsk:RemeasurementThroughIncomeStatementIncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination |
| 2479 |
Cash payments: operating cash flows |
Concept (Monetary) |
For Period |
Debit |
gsk:AdjustmentsForDecreaseIncreaseInContingentConsiderationPaid |
| 2480 |
Cash payments: investing activities |
Concept (Monetary) |
For Period |
Credit |
gsk:ContingentConsiderationPaid |
| 2481 |
Other movements |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseThroughOtherMovementsFinancialLiability |
| 2482 |
Ending balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination |
| 2483 |
1209 - Disclosure - Contingent Consideration Liabilities - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureContingentConsiderationLiabilitiesAdditionalInformation |
| 2484 |
Disclosure Of Fair Value Of Contingent Consideration [table] |
Table |
* |
* |
gsk:DisclosureOfFairValueOfContingentConsiderationTable |
| 2485 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 2486 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 2487 |
Novartis [member] |
Member |
|
|
gsk:NovartisMember |
| 2488 |
Shionogi ViiV healthcare joint venture [member] |
Member |
|
|
gsk:ShionogiViiVHealthcareJointVentureMember |
| 2489 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 2490 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 2491 |
Bottom of range [member] |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 2492 |
Top of range [member] |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 2493 |
Disclosure of fair value of contingent consideration [line items] |
LineItems |
|
|
gsk:DisclosureOfFairValueOfContingentConsiderationLineItems |
| 2494 |
Contingent consideration payable |
Concept (Monetary) |
As Of |
Credit |
gsk:ContingentConsiderationLiabilitiesCurrent |
| 2495 |
Contingent consideration settled |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination |
| 2496 |
Contingent consideration liability discount percentage |
Concept (Percent) |
As Of |
|
gsk:ContingentConsiderationPayableDiscountedPercentage |
| 2497 |
1210 - Disclosure - Contingent consideration liabilities - Summary of Possible Changes in key Inputs to Valuation of Contingent Consideration Liabilities (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureContingentConsiderationLiabilitiesSummaryOfPossibleChangesInKeyInputsToValuationOfContingentConsiderationLiabilities |
| 2498 |
Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [table] |
Table |
* |
* |
gsk:DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable |
| 2499 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 2500 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 2501 |
Shionogi ViiV healthcare joint venture [member] |
Member |
|
|
gsk:ShionogiViiVHealthcareJointVentureMember |
| 2502 |
Novartis vaccines [member] |
Member |
|
|
gsk:NovartisVaccinesMember |
| 2503 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 2504 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 2505 |
10 cent appreciation of the US Dollar [member] |
Member |
|
|
gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember |
| 2506 |
10 cent depreciation of US Dollar [member] |
Member |
|
|
gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember |
| 2507 |
10 cent appreciation of the Euro [member] |
Member |
|
|
gsk:CurrencyRiskTenCentAppreciationOfEuroMember |
| 2508 |
10 cent depreciation of Euro [member] |
Member |
|
|
gsk:CurrencyRiskTenCentDepreciationOfEuroMember |
| 2509 |
Disclosure of valuation techniques and key model inputs used to measure contingent consideration [line items] |
LineItems |
|
|
gsk:DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationLineItems |
| 2510 |
10% increase in sales forecasts |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseInSalesForecastAmount |
| 2511 |
10% decrease in sales forecasts |
Concept (Monetary) |
For Period |
Debit |
gsk:DecreaseInSalesForecastAmount |
| 2512 |
1% increase in discount rate |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseInDiscountRateAmount |
| 2513 |
1% decrease in discount rate |
Concept (Monetary) |
For Period |
Debit |
gsk:DecreaseInDiscountRateAmount |
| 2514 |
5% increase in probability of milestone success |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseInProbabilityOfMilestoneSuccessAmount |
| 2515 |
5% decrease in probability of milestone success |
Concept (Monetary) |
For Period |
Debit |
gsk:DecreaseInProbabilityOfMilestoneSuccessAmount |
| 2516 |
10 cent appreciation of US Dollar |
Concept (Monetary) |
For Period |
Credit |
gsk:AppreciationOfUSDollar |
| 2517 |
10 cent depreciation of US Dollar |
Concept (Monetary) |
For Period |
Debit |
gsk:DepreciationOfUSDollar |
| 2518 |
10 cent appreciation of Euro |
Concept (Monetary) |
For Period |
Credit |
gsk:AppreciationOfEuro |
| 2519 |
10 cent depreciation of Euro |
Concept (Monetary) |
For Period |
Debit |
gsk:DepreciationOfEuro |
| 2520 |
1211 - Disclosure - Contingent consideration liabilities - Summary of Possible Changes in key Inputs to Valuation of Contingent Consideration Liabilities (Parenthetical) (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureContingentConsiderationLiabilitiesSummaryOfPossibleChangesInKeyInputsToValuationOfContingentConsiderationLiabilitiesParenthetical |
| 2521 |
Disclosure Of Valuation Techniques And Key Model Inputs Used To Measure Contingent Consideration [table] |
Table |
* |
* |
gsk:DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationTable |
| 2522 |
Categories of related parties [axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 2523 |
Entity's total for related parties [member] |
Member |
|
|
ifrs-full:EntitysTotalForRelatedPartiesMember |
| 2524 |
Shionogi ViiV healthcare joint venture [member] |
Member |
|
|
gsk:ShionogiViiVHealthcareJointVentureMember |
| 2525 |
Novartis vaccines [member] |
Member |
|
|
gsk:NovartisVaccinesMember |
| 2526 |
Disclosure of valuation techniques and key model inputs used to measure contingent consideration [line items] |
LineItems |
|
|
gsk:DisclosureOfValuationTechniquesAndKeyModelInputsUsedToMeasureContingentConsiderationLineItems |
| 2527 |
Increase in sales forecasts |
Concept (Percent) |
For Period |
|
gsk:IncreaseInSalesForecastPercentage |
| 2528 |
Decrease in sales forecasts |
Concept (Percent) |
For Period |
|
gsk:DecreaseInSalesForecastPercentage |
| 2529 |
increase in discount rate |
Concept (Percent) |
For Period |
|
gsk:IncreaseInDiscountRatePercentage |
| 2530 |
Decrease in discount rate |
Concept (Percent) |
For Period |
|
gsk:DecreaseInDiscountRatePercentage |
| 2531 |
Increase in probability of milestone success |
Concept (Percent) |
For Period |
|
gsk:IncreaseInProbabilityOfMilestoneSuccessPercentage |
| 2532 |
Decrease in probability of milestone success |
Concept (Percent) |
For Period |
|
gsk:DecreaseInProbabilityOfMilestoneSuccessPercentage |
| 2533 |
1212 - Disclosure - Non-controlling interests - Summarised Financial Information of ViiV Healthcare Group and GSK Consumer Healthcare Joint Venture (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureNoncontrollingInterestsSummarisedFinancialInformationOfViiVHealthcareGroupAndGSKConsumerHealthcareJointVenture |
| 2534 |
Disclosure of Non-controlling Interests [table] |
Table |
* |
* |
gsk:DisclosureOfNoncontrollingInterestsTable |
| 2535 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 2536 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 2537 |
ViiV healthcare [member] |
Member |
|
|
gsk:ViiVHealthCareMember |
| 2538 |
Consumer health care joint venture [member] |
Member |
|
|
gsk:ConsumerHealthCareJointVentureMember |
| 2539 |
Disclosure of noncontrolling interests [line items] |
LineItems |
|
|
gsk:DisclosureOfNoncontrollingInterestsLineItems |
| 2540 |
Total comprehensive income/(expense) for the year attributable to non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 2541 |
Dividends paid to non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DividendsPaidToNoncontrollingInterests |
| 2542 |
Non-controlling interests in the Consolidated balance sheet |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncontrollingInterests |
| 2543 |
Turnover |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:Revenue |
| 2544 |
Profit/(loss) after taxation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossAttributableToNoncontrollingInterests |
| 2545 |
Other comprehensive (expense)/income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:OtherComprehensiveIncome |
| 2546 |
Total comprehensive (expense)/income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests |
| 2547 |
Non-current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentAssets |
| 2548 |
Current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentAssets |
| 2549 |
Total assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Assets |
| 2550 |
Current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentLiabilities |
| 2551 |
Non-current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentLiabilities |
| 2552 |
Total liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Liabilities |
| 2553 |
Net assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NetAssetsLiabilities |
| 2554 |
Net cash inflow from operating activities |
Concept (Monetary) |
For Period |
|
ifrs-full:CashFlowsFromUsedInOperatingActivities |
| 2555 |
Net cash inflow/(outflow) from investing activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInInvestingActivities |
| 2556 |
Net cash outflow from financing activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInFinancingActivities |
| 2557 |
(Decrease)/increase in cash and bank overdrafts in the year |
Concept (Monetary) |
For Period |
Debit |
gsk:IncreaseDecreaseInCashAndBankOverdrafts |
| 2558 |
1213 - Disclosure - Non-controlling interests - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureNoncontrollingInterestsAdditionalInformation |
| 2559 |
Disclosure of Non-controlling Interests [table] |
Table |
* |
* |
gsk:DisclosureOfNoncontrollingInterestsTable |
| 2560 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 2561 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 2562 |
ViiV healthcare [member] |
Member |
|
|
gsk:ViiVHealthCareMember |
| 2563 |
Shionogi ViiV healthcare joint venture [member] |
Member |
|
|
gsk:ShionogiViiVHealthcareJointVentureMember |
| 2564 |
Consumer health care joint venture [member] |
Member |
|
|
gsk:ConsumerHealthCareJointVentureMember |
| 2565 |
Disclosure of noncontrolling interests [line items] |
LineItems |
|
|
gsk:DisclosureOfNoncontrollingInterestsLineItems |
| 2566 |
Profit after taxation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLossAttributableToNoncontrollingInterests |
| 2567 |
Remeasurement of contingent consideration payable for acquisition |
Concept (Monetary) |
For Period |
Credit |
gsk:RemeasurementsOfContingentConsiderationPayableForAcquisition |
| 2568 |
Joint venture ownership percentage |
Concept (Percent) |
For Period |
|
ifrs-full:ProportionOfOwnershipInterestInAssociate |
| 2569 |
1214 - Disclosure - Non-controlling interests - Schedule of Amount Attributable to VIIV Healthcare Group Included in GSK's Consolidated Statement of Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Balance Sheet (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureNoncontrollingInterestsScheduleOfAmountAttributableToVIIVHealthcareGroupIncludedInGSKsConsolidatedStatementOfComprehensiveIncomeConsolidatedStatementOfChangesInEquityAndConsolida_Xb |
| 2570 |
Disclosure of Non-controlling Interests [table] |
Table |
* |
* |
gsk:DisclosureOfNoncontrollingInterestsTable |
| 2571 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 2572 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 2573 |
Consumer health care joint venture [member] |
Member |
|
|
gsk:ConsumerHealthCareJointVentureMember |
| 2574 |
Disclosure of noncontrolling interests [line items] |
LineItems |
|
|
gsk:DisclosureOfNoncontrollingInterestsLineItems |
| 2575 |
Total comprehensive income/(expense) for the year attributable to non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 2576 |
Dividends paid to non-controlling interests |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DividendsPaidToNoncontrollingInterests |
| 2577 |
Non-controlling interests in the Consolidated balance sheet |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncontrollingInterests |
| 2578 |
1215 - Disclosure - Commitments - Schedule of Contractual Obligations and Commitments (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureCommitmentsScheduleOfContractualObligationsAndCommitments |
| 2579 |
Implied Table |
Table |
* |
* |
implied:Table |
| 2580 |
Disclosure Of Contractual Obligations And Commitments [abstract] |
Abstract |
|
|
gsk:DisclosureOfContractualObligationsAndCommitmentsAbstract |
| 2581 |
Intangible assets |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets |
| 2582 |
Property, plant and equipment |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment |
| 2583 |
Investments |
Concept (Monetary) |
As Of |
Credit |
gsk:ContractualObligationsAndCommitmentsOfInvestments |
| 2584 |
Purchase commitments |
Concept (Monetary) |
As Of |
Credit |
gsk:ContractualObligationsAndCommitmentsOfPurchaseCommitments |
| 2585 |
Pensions |
Concept (Monetary) |
As Of |
Credit |
gsk:ContractualObligationsAndCommitmentsOfPensions |
| 2586 |
Other commitments |
Concept (Monetary) |
As Of |
Credit |
gsk:ContractualObligationsAndCommitmentsOfOtherCommitments |
| 2587 |
Interest on loans |
Concept (Monetary) |
As Of |
Credit |
gsk:ContractualObligationsAndCommitmentsOfInterestOnLoans |
| 2588 |
Finance lease charges |
Concept (Monetary) |
As Of |
Credit |
gsk:ContractualObligationsAndCommitmentsOfFinanceLeaseCharges |
| 2589 |
Total contractual obligations and commitments |
Concept (Monetary) |
As Of |
Credit |
gsk:ContractualObligationsAndCommitments |
| 2590 |
1216 - Disclosure - Commitments - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureCommitmentsAdditionalInformation |
| 2591 |
Implied Table |
Table |
* |
* |
implied:Table |
| 2592 |
Disclosure of Commitments [abstract] |
Abstract |
|
|
gsk:DisclosureOfCommitmentsAbstract |
| 2593 |
Payment due, 2019 |
Concept (Monetary) |
For Period |
Credit |
gsk:ContributionsToEliminateThePensionDeficitPaymentsDueInOneYears |
| 2594 |
Payment due, 2020 |
Concept (Monetary) |
For Period |
Credit |
gsk:ContributionsToEliminateThePensionDeficitPaymentsDueInTwoYears |
| 2595 |
Payment due, 2021 |
Concept (Monetary) |
For Period |
Credit |
gsk:ContributionsToEliminateThePensionDeficitPaymentsDueInThreeYears |
| 2596 |
Payment due, 2022 |
Concept (Monetary) |
For Period |
Credit |
gsk:ContributionsToEliminateThePensionDeficitPaymentsDueInFourYears |
| 2597 |
Ongoing annual funding requirement |
Concept (Monetary) |
For Period |
Credit |
gsk:OngoingAnnualUKPensionFundingRequirement |
| 2598 |
Commitments under non-cancellable operating leases |
Concept (Monetary) |
For Period |
Credit |
gsk:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseRecognised |
| 2599 |
1217 - Disclosure - Commitments - Summary of Commitments Under Non-Cancellable Operating Leases (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureCommitmentsSummaryOfCommitmentsUnderNonCancellableOperatingLeases |
| 2600 |
Disclosure of finance lease and operating lease by lessee [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable |
| 2601 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 2602 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 2603 |
Not later than 1 year [member] |
Member |
|
|
ifrs-full:NotLaterThanOneYearMember |
| 2604 |
Between 1 and 2 years [member] |
Member |
|
|
ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember |
| 2605 |
Between 2 and 3 years [member] |
Member |
|
|
ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember |
| 2606 |
Between 3 and 4 Years [Member] |
Member |
|
|
ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember |
| 2607 |
Between 4 and 5 years [member] |
Member |
|
|
ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember |
| 2608 |
Later than 5 years [member] |
Member |
|
|
ifrs-full:LaterThanFiveYearsMember |
| 2609 |
Disclosure of operating lease by lessee [line items] |
LineItems |
|
|
gsk:DisclosureOfOperatingLeaseByLesseeLineItems |
| 2610 |
Total commitments under non-cancellable operating leases |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease |
| 2611 |
1218 - Disclosure - Financial instruments and related disclosures - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresAdditionalInformation |
| 2612 |
Disclosure of detailed information about financial instruments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinancialInstrumentsTable |
| 2613 |
Subsidiaries [axis] |
Axis |
|
|
ifrs-full:SignificantInvestmentsInSubsidiariesAxis |
| 2614 |
Entity's total for subsidiaries [member] |
Member |
|
|
ifrs-full:EntitysTotalForSubsidiariesMember |
| 2615 |
ViiV healthcare [member] |
Member |
|
|
gsk:ViiVHealthCareMember |
| 2616 |
Segments [axis] |
Axis |
|
|
ifrs-full:SegmentsAxis |
| 2617 |
Segments [member] |
Member |
|
|
ifrs-full:SegmentsMember |
| 2618 |
Pharmaceuticals and Vaccines [member] |
Member |
|
|
gsk:PharmaceuticalsAndVaccinesMember |
| 2619 |
Classes of assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfAssetsAxis |
| 2620 |
Assets [member] |
Member |
|
|
ifrs-full:ClassesOfAssetsMember |
| 2621 |
US commercial paper program [member] |
Member |
|
|
gsk:UsCommercialPaperProgramMember |
| 2622 |
Types of insurance contracts [axis] |
Axis |
|
|
ifrs-full:TypesOfInsuranceContractsAxis |
| 2623 |
Types of insurance contracts [member] |
Member |
|
|
ifrs-full:InsuranceContractsMember |
| 2624 |
Global insurance programme [member] |
Member |
|
|
gsk:GlobalInsuranceProgrammeMember |
| 2625 |
Counterparties [axis] |
Axis |
|
|
ifrs-full:CounterpartiesAxis |
| 2626 |
Counterparties [member] |
Member |
|
|
ifrs-full:CounterpartiesMember |
| 2627 |
HDFC bank [member] |
Member |
|
|
gsk:HDFCBankMember |
| 2628 |
State Bank of India [member] |
Member |
|
|
gsk:StateBankOfIndiaMember |
| 2629 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 2630 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 2631 |
Top of range [member] |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 2632 |
Types of interest rates [axis] |
Axis |
|
|
ifrs-full:TypesOfInterestRatesAxis |
| 2633 |
Interest rate types [member] |
Member |
|
|
ifrs-full:InterestRateTypesMember |
| 2634 |
Floating interest rate [member] |
Member |
|
|
ifrs-full:FloatingInterestRateMember |
| 2635 |
External credit grades [axis] |
Axis |
|
|
ifrs-full:ExternalCreditGradesAxis |
| 2636 |
Entity's total for external credit grades [member] |
Member |
|
|
ifrs-full:EntitysTotalForExternalCreditGradesMember |
| 2637 |
External credit grades [member] |
Member |
|
|
ifrs-full:ExternalCreditGradesMember |
| 2638 |
BBB/Baa [member] |
Member |
|
|
gsk:BbbOrBaaMember |
| 2639 |
BBB -/ Baa3 Rated [member] |
Member |
|
|
gsk:BBB-OrBaaThreeRatedMember |
| 2640 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 2641 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 2642 |
Liquidity risk [member] |
Member |
|
|
ifrs-full:LiquidityRiskMember |
| 2643 |
Credit risk [member] |
Member |
|
|
ifrs-full:CreditRiskMember |
| 2644 |
1% (100 basis points) increase in sterling interest rates [member] |
Member |
|
|
gsk:InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember |
| 2645 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 2646 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 2647 |
Not later than three months [member] |
Member |
|
|
ifrs-full:NotLaterThanThreeMonthsMember |
| 2648 |
Not later than 1 year [member] |
Member |
|
|
ifrs-full:NotLaterThanOneYearMember |
| 2649 |
Later than one year and not later than five years [member] |
Member |
|
|
ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember |
| 2650 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 2651 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 2652 |
Non USA [member] |
Member |
|
|
gsk:NonUsaMember |
| 2653 |
US [member] |
Member |
|
|
country:US |
| 2654 |
Nigeria [member] |
Member |
|
|
country:NG |
| 2655 |
Austria [member] |
Member |
|
|
country:AT |
| 2656 |
Argentina [member] |
Member |
|
|
country:AR |
| 2657 |
Uruquay [member] |
Member |
|
|
country:UY |
| 2658 |
Levels of fair value hierarchy [axis] |
Axis |
|
|
ifrs-full:LevelsOfFairValueHierarchyAxis |
| 2659 |
All levels of fair value hierarchy [member] |
Member |
|
|
ifrs-full:AllLevelsOfFairValueHierarchyMember |
| 2660 |
Level 3 [member] |
Member |
|
|
ifrs-full:Level3OfFairValueHierarchyMember |
| 2661 |
Joint ventures [axis] |
Axis |
|
|
ifrs-full:JointVenturesAxis |
| 2662 |
Entity's total for joint ventures [member] |
Member |
|
|
ifrs-full:EntitysTotalForJointVenturesMember |
| 2663 |
Shionogi ViiV healthcare joint venture [member] |
Member |
|
|
gsk:ShionogiViiVHealthcareJointVentureMember |
| 2664 |
Novartis [member] |
Member |
|
|
gsk:NovartisMember |
| 2665 |
Classes of financial assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialAssetsAxis |
| 2666 |
Financial assets, class [member] |
Member |
|
|
ifrs-full:FinancialAssetsMember |
| 2667 |
Equity investments [member] |
Member |
|
|
ifrs-full:EquityInvestmentsMember |
| 2668 |
Borrowings by name [axis] |
Axis |
|
|
ifrs-full:BorrowingsByNameAxis |
| 2669 |
Borrowings by name [member] |
Member |
|
|
ifrs-full:BorrowingsByNameMember |
| 2670 |
Bonds In A Designated Hedging Relationship [member] |
Member |
|
|
gsk:BondsInDesignatedHedgingRelationshipMember |
| 2671 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 2672 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 2673 |
Novartis [member] |
Member |
|
|
gsk:NovartisMember |
| 2674 |
Tesaro [member] |
Member |
|
|
gsk:TesaroMember |
| 2675 |
Consumer health care joint venture [member] |
Member |
|
|
gsk:ConsumerHealthCareJointVentureMember |
| 2676 |
Disclosure of detailed information about financial instruments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsLineItems |
| 2677 |
Borrowings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Borrowings |
| 2678 |
Non-controlling interests |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncontrollingInterests |
| 2679 |
Total capital |
Concept (Monetary) |
As Of |
Credit |
gsk:EquityAndDebtNet |
| 2680 |
Cash and cash equivalents and liquid investments |
Concept (Monetary) |
As Of |
Debit |
gsk:CashAndCashEquivalentsAndLiquidInvestments |
| 2681 |
Cash and cash equivalents and liquid investments held centrally |
Concept (Monetary) |
As Of |
Debit |
gsk:CashAndCashEquivalentsAndLiquidInvestmentsHeld |
| 2682 |
Drawn amount |
Concept (Monetary) |
As Of |
|
ifrs-full:NotionalAmount |
| 2683 |
Short-term finance through issuance of commercial paper |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CommercialPapersIssued |
| 2684 |
Committed facilities during the period |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:UndrawnBorrowingFacilities |
| 2685 |
Description of contractual committed facilities |
Concept (Text/String) |
For Period |
|
gsk:DescriptionOfContractualCommittedFacilities |
| 2686 |
Description of maturity date of borrowings |
Concept (Text/String) |
For Period |
|
ifrs-full:BorrowingsMaturity |
| 2687 |
Borrowings maturity extension period |
Concept (Text/String) |
For Period |
|
gsk:BorrowingsMaturityExtensionOptionPeriod |
| 2688 |
Amount held at European medium term note programme |
Concept (Monetary) |
As Of |
Credit |
gsk:AmountHeldAtEuropeanMediumTermNoteProgramme |
| 2689 |
Notes issued at European medium term note programme |
Concept (Monetary) |
As Of |
Credit |
gsk:NotesIssuedAtEuropeanMediumTermNoteProgramme |
| 2690 |
Notes issued under us shelf registration |
Concept (Monetary) |
As Of |
Credit |
gsk:NotesIssuedUnderUsShelfRegistration |
| 2691 |
Maximum exposure to credit risk |
Concept (Monetary) |
As Of |
|
ifrs-full:MaximumExposureToCreditRisk |
| 2692 |
Concentration of credit risk |
Concept (Monetary) |
As Of |
|
ifrs-full:CreditExposure |
| 2693 |
Amount of cash held at unrated counter parties |
Concept (Monetary) |
As Of |
Debit |
gsk:CashHeldAtUnratedCounterparties |
| 2694 |
Cash in transit |
Concept (Monetary) |
As Of |
Debit |
gsk:CashHeldAtUnratedCounterpartiesCashInTransitElement |
| 2695 |
Bank balances and deposits held with counter parties |
Concept (Monetary) |
As Of |
Debit |
gsk:BankBalancesAndDepositHeldWithCounterparties |
| 2696 |
Balances or deposits with banks |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:BalancesWithBanks |
| 2697 |
Cash reserves |
Concept (Monetary) |
As Of |
Credit |
gsk:CashReserves |
| 2698 |
Cash held by subsidiary |
Concept (Monetary) |
As Of |
Debit |
gsk:CashHeldWithSubsidiaryCompany |
| 2699 |
Percentage of ownership interest in subsidiary |
Concept (Percent) |
For Period |
|
ifrs-full:ProportionOfOwnershipInterestInSubsidiary |
| 2700 |
Maximum percentage of trade receivables balance held by major customer account |
Concept (Percent) |
For Period |
|
gsk:PercentageOfAccountsReceivableByMajorCustomer |
| 2701 |
Number of major customers accounting for more than 5% of trade receivables |
Concept (Integer) |
For Period |
|
gsk:NumberOfMajorCustomers |
| 2702 |
Percentage of sales to three largest wholesalers |
Concept (Percent) |
For Period |
|
gsk:ConcentrationsOfRiskRevenuePercentage |
| 2703 |
Group trade receivables due from three largest US wholesalers |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:TradeReceivables |
| 2704 |
Cash and cash equivalents reported in assets held for sale |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalentsClassifiedAsPartOfDisposalGroupHeldForSale |
| 2705 |
Carrying value of shares held by trust under employee share ownership plan |
Concept (Monetary) |
As Of |
Debit |
gsk:CarryingValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan |
| 2706 |
Market value of shares held by trust under employee share ownership plan |
Concept (Monetary) |
As Of |
Debit |
gsk:FairValueOfSharesHeldByTrustUnderEmployeeShareOwnershipPlan |
| 2707 |
Treasury shares at cost |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:TreasuryShares |
| 2708 |
Net losses recognised in the income statement |
Concept (Monetary) |
For Period |
|
ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets |
| 2709 |
Remeasurement through income statement |
Concept (Monetary) |
For Period |
Debit |
gsk:RemeasurementThroughIncomeStatement |
| 2710 |
Net gains recognised in other comprehensive income |
Concept (Monetary) |
For Period |
|
ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementAssets |
| 2711 |
Net gains (losses) on financial investments held |
Concept (Monetary) |
For Period |
Credit |
gsk:GainsLossesTransfersOutOfLevelOfFairValueHierarchyAssets |
| 2712 |
Net gains (losses) on equity investments held |
Concept (Monetary) |
For Period |
Credit |
gsk:GainsLossesOnAvailableForSaleInvestmentsInOtherComprehensiveIncomeStillHeld |
| 2713 |
Contingent consideration liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination |
| 2714 |
Borrowings excluding obligations under finance leases |
Concept (Monetary) |
As Of |
Credit |
gsk:BorrowingsExcludingObligationsUnderFinanceLease |
| 2715 |
Impact on income through interest rate movements |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements |
| 2716 |
Percentage of increase in interest rate |
Concept (Percent) |
For Period |
|
gsk:PercentageOfIncreaseInInterestRate |
| 2717 |
Increase in anticipated ontractual cashflows for repayment of debt and debt interest |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseInAnticipatedContractualCashFlowsForRepaymentOfDebtAndDebtInterest |
| 2718 |
PercentageOfDivestmentStake |
Concept (Percent) |
For Period |
|
gsk:PercentageOfDivestmentStake |
| 2719 |
1219 - Disclosure - Financial Instruments and Related Disclosures - Summary of External Credit Exposure (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresSummaryOfExternalCreditExposure |
| 2720 |
Disclosure of external credit grades [table] |
Table |
* |
* |
ifrs-full:DisclosureOfExternalCreditExposuresTable |
| 2721 |
External credit grades [axis] |
Axis |
|
|
ifrs-full:ExternalCreditGradesAxis |
| 2722 |
Entity's total for external credit grades [member] |
Member |
|
|
ifrs-full:EntitysTotalForExternalCreditGradesMember |
| 2723 |
AAA/Aaa [member] |
Member |
|
|
gsk:AAAOrAaaMember |
| 2724 |
AA/Aa [member] |
Member |
|
|
gsk:AaOrAaMember |
| 2725 |
A/A [member] |
Member |
|
|
gsk:AorAMember |
| 2726 |
BBB/Baa [member] |
Member |
|
|
gsk:BbbOrBaaMember |
| 2727 |
BB+/Ba1 and Below/Unrated [member] |
Member |
|
|
gsk:BBPlusOrBaOneMember |
| 2728 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 2729 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 2730 |
Credit risk [member] |
Member |
|
|
ifrs-full:CreditRiskMember |
| 2731 |
Disclosure of external credit grades [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfExternalCreditExposuresLineItems |
| 2732 |
Bank balances and deposits |
Concept (Monetary) |
As Of |
Debit |
gsk:BankBalancesAndDepositHeldWithCounterparties |
| 2733 |
US Treasury and Treasury repo only money market funds |
Concept (Monetary) |
As Of |
Debit |
gsk:UsTreasuryAndTreasuryRepoOnlyMoneyMarketFunds |
| 2734 |
Liquidity funds |
Concept (Monetary) |
As Of |
Credit |
gsk:LiquidityFunds |
| 2735 |
Government securities |
Concept (Monetary) |
As Of |
Debit |
gsk:GovernmentSecurities |
| 2736 |
3rd party financial derivatives |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:DerivativeFinancialAssets |
| 2737 |
Total |
Concept (Monetary) |
As Of |
|
ifrs-full:RatedCreditExposures |
| 2738 |
1220 - Disclosure - Financial Instruments and Related Disclosures - Summary of Financial Assets and Liabilities (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndLiabilities |
| 2739 |
Disclosure of detailed information about financial instruments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinancialInstrumentsTable |
| 2740 |
Borrowings by name [axis] |
Axis |
|
|
ifrs-full:BorrowingsByNameAxis |
| 2741 |
Borrowings by name [member] |
Member |
|
|
ifrs-full:BorrowingsByNameMember |
| 2742 |
Bonds In A Designated Hedging Relationship [member] |
Member |
|
|
gsk:BondsInDesignatedHedgingRelationshipMember |
| 2743 |
Other Bonds [member] |
Member |
|
|
gsk:OtherBondsMember |
| 2744 |
Bank Loans and Overdrafts [member] |
Member |
|
|
gsk:BankLoansAndOverdraftsMember |
| 2745 |
Commercial paper [member] |
Member |
|
|
gsk:CommercialPaper1Member |
| 2746 |
Other Borrowing [member] |
Member |
|
|
gsk:OtherBorrowingMember |
| 2747 |
Classes of financial liabilities [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialLiabilitiesAxis |
| 2748 |
Financial liabilities, class [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesMember |
| 2749 |
Financial Liabilities at Amortised Cost, Category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember |
| 2750 |
Contingent Consideration Liabilities [member] |
Member |
|
|
gsk:ContingentConsiderationLiabilitiesMember |
| 2751 |
Trade and other payable [member] |
Member |
|
|
gsk:TradeAndOtherPayableMember |
| 2752 |
Other provisions [member] |
Member |
|
|
ifrs-full:OtherProvisionsMember |
| 2753 |
Other non current liabilities [member] |
Member |
|
|
gsk:OtherNonCurrentLiabilitiesMember |
| 2754 |
Other assets classified as held for sale [member] |
Member |
|
|
gsk:OtherAssetsClassifiedAsHeldForSaleMember |
| 2755 |
Derivatives Financial Liabilities Designated At Fair Value Through Profit Or Loss [member] |
Member |
|
|
gsk:DerivativesFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLossMember |
| 2756 |
Derivatives financial liabilities classified as held for trading under IAS39 [member] |
Member |
|
|
gsk:DerivativesFinancialLiabilitiesClassifiedAsHeldForTradingUnderIAS39Member |
| 2757 |
Classes of financial assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialAssetsAxis |
| 2758 |
Financial assets, class [member] |
Member |
|
|
ifrs-full:FinancialAssetsMember |
| 2759 |
Other investments [member] |
Member |
|
|
gsk:OtherInvestmentsMember |
| 2760 |
Trade and other receivable [member] |
Member |
|
|
gsk:TradeAndOtherReceivableMember |
| 2761 |
Liquid Investments [member] |
Member |
|
|
gsk:LiquidInvestmentsMember |
| 2762 |
Cash and cash equivalents [member] |
Member |
|
|
gsk:CashAndCashEquivalents1Member |
| 2763 |
Other items in Assets held for sale [member] |
Member |
|
|
gsk:OtherItemsInAssetsHeldForSaleMember |
| 2764 |
Derivatives designated and effective as hedging instruments [member] |
Member |
|
|
gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember |
| 2765 |
Held for trading derivatives that are not in a designated and effective hedging relationship [member] |
Member |
|
|
gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember |
| 2766 |
Other Noncurrent Assets [member] |
Member |
|
|
gsk:OtherNoncurrentAssetsMember |
| 2767 |
Government bonds [member] |
Member |
|
|
gsk:GovernmentBondsMember |
| 2768 |
Trade and Other Receivables and Certain Other Non-current Assets in Scope of IAS 39 [member] |
Member |
|
|
gsk:TradeAndOtherReceivablesAndCertainOtherNoncurrentAssetsInScopeOfIAS39Member |
| 2769 |
Derivatives Financial Assets Designated At Fair Value Through Profit Or Loss [member] |
Member |
|
|
gsk:DerivativesFinancialAssetsDesignatedAtFairValueThroughProfitOrLossMember |
| 2770 |
Derivatives Financial Assets Classified As Held For Trading Under IAS39 [member] |
Member |
|
|
gsk:DerivativesFinancialAssetsClassifiedAsHeldForTradingUnderIAS39Member |
| 2771 |
Categories of financial liabilities [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialLiabilitiesAxis |
| 2772 |
Financial liabilities, category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesCategoryMember |
| 2773 |
Financial Liabilities at Amortised Cost, Category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember |
| 2774 |
Trade and other payable [member] |
Member |
|
|
gsk:TradeAndOtherPayableMember |
| 2775 |
Other provisions [member] |
Member |
|
|
ifrs-full:OtherProvisionsMember |
| 2776 |
Other non current liabilities [member] |
Member |
|
|
gsk:OtherNonCurrentLiabilitiesMember |
| 2777 |
Other assets classified as held for sale [member] |
Member |
|
|
gsk:OtherAssetsClassifiedAsHeldForSaleMember |
| 2778 |
Financial Liabilities at Fair Value Through Profit or Loss, Category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember |
| 2779 |
Categories of financial assets [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialAssetsAxis |
| 2780 |
Financial assets, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsCategoryMember |
| 2781 |
Financial assets at fair value through other comprehensive income, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember |
| 2782 |
Financial assets at amortised cost, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember |
| 2783 |
Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember |
| 2784 |
Financial liabilities at fair value through profit or loss, mandatorily measured at fair value, category [member] |
Member |
|
|
gsk:FinancialLiabilitiesAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember |
| 2785 |
Financial Assets Available-for-sale, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAvailableforsaleCategoryMember |
| 2786 |
Loans and Receivables, Category [member] |
Member |
|
|
ifrs-full:LoansAndReceivablesCategoryMember |
| 2787 |
Financial Assets at Fair Value Through Profit or Loss, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember |
| 2788 |
Disclosure of detailed information about financial instruments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsLineItems |
| 2789 |
Borrowings excluding obligations under finance leases |
Concept (Monetary) |
As Of |
Credit |
gsk:BorrowingsExcludingObligationsUnderFinanceLeaseAtFairValue |
| 2790 |
Total financial assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssets |
| 2791 |
Obligations under finance leases |
Concept (Monetary) |
As Of |
Credit |
gsk:ObligationsUnderFinanceLeasesAtFairvalue |
| 2792 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 2793 |
Total borrowings |
Concept (Monetary) |
As Of |
Credit |
gsk:BorrowingsAtFairValue |
| 2794 |
Trade and other payables, Other provisions and certain Other non-current liabilities in scope of IAS 39 |
Concept (Monetary) |
As Of |
Credit |
gsk:TradeAndOtherPayablesOtherProvisionsAndCertainOtherNoncurrentLiabilitiesInScopeOfIaS39AtFairValue |
| 2795 |
Borrowings excluding obligations under finance leases: |
Concept (Monetary) |
As Of |
Credit |
gsk:BorrowingsExcludingObligationsUnderFinanceLease |
| 2796 |
Obligations under finance leases |
Concept (Monetary) |
As Of |
Credit |
gsk:ObligationsUnderFinanceLeases |
| 2797 |
Total borrowings |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Borrowings |
| 2798 |
Trade and other payables, Other provisions and certain Other non-current liabilities in scope of IAS 39 |
Concept (Monetary) |
As Of |
Credit |
gsk:TradeAndOtherPayablesOtherProvisionsAndCertainOtherNoncurrentLiabilitiesInScopeOfIas39 |
| 2799 |
Total financial liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:FinancialLiabilities |
| 2800 |
Net financial assets and financial liabilities |
Concept (Monetary) |
As Of |
Debit |
gsk:NetFinancialAssetsLiabilities |
| 2801 |
Total financial assets fair value |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsAtFairValue |
| 2802 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 2803 |
Total financial liabilities fair value |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:FinancialLiabilitiesAtFairValue |
| 2804 |
Net financial assets and financial liabilities |
Concept (Monetary) |
As Of |
Debit |
gsk:NetFinancialAssetsFinancialLiabilitiesAtFairValue |
| 2805 |
1221 - Disclosure - Financial Instruments and Related Disclosures - Summary of Fair Value of Financial Instruments (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresSummaryOfFairValueOfFinancialInstruments |
| 2806 |
Disclosure of financial assets [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinancialAssetsTable |
| 2807 |
Measurement [axis] |
Axis |
|
|
ifrs-full:MeasurementAxis |
| 2808 |
Aggregated measurement [member] |
Member |
|
|
ifrs-full:AggregatedMeasurementMember |
| 2809 |
At Fair Value [Member] |
Member |
|
|
ifrs-full:AtFairValueMember |
| 2810 |
Levels of fair value hierarchy [axis] |
Axis |
|
|
ifrs-full:LevelsOfFairValueHierarchyAxis |
| 2811 |
All levels of fair value hierarchy [member] |
Member |
|
|
ifrs-full:AllLevelsOfFairValueHierarchyMember |
| 2812 |
Level 1 of fair value hierarchy [member] |
Member |
|
|
ifrs-full:Level1OfFairValueHierarchyMember |
| 2813 |
Level 2 of fair value hierarchy [member] |
Member |
|
|
ifrs-full:Level2OfFairValueHierarchyMember |
| 2814 |
Level 3 [member] |
Member |
|
|
ifrs-full:Level3OfFairValueHierarchyMember |
| 2815 |
Categories of financial liabilities [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialLiabilitiesAxis |
| 2816 |
Financial liabilities, category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesCategoryMember |
| 2817 |
Financial Liabilities at Fair Value Through Profit or Loss, Category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember |
| 2818 |
Financial Liabilities at Fair Value Through Profit or Loss, Designated Upon Initial Recognition or Subsequently, Category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember |
| 2819 |
Financial Liabilities at Fair Value Through Profit or Loss That Meet Definition of Held for Trading, Category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember |
| 2820 |
Categories of financial assets [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialAssetsAxis |
| 2821 |
Financial assets, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsCategoryMember |
| 2822 |
Financial assets at fair value through other comprehensive income, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember |
| 2823 |
Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember |
| 2824 |
Financial Assets Available-for-sale, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAvailableforsaleCategoryMember |
| 2825 |
Financial Assets at Fair Value Through Profit or Loss, Designated Upon Initial Recognition or Subsequently, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember |
| 2826 |
Financial Assets at Fair Value Through Profit or Loss, Classified as Held for Trading, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember |
| 2827 |
Classes of financial liabilities [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialLiabilitiesAxis |
| 2828 |
Financial liabilities, class [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesMember |
| 2829 |
Contingent Consideration Liabilities [member] |
Member |
|
|
gsk:ContingentConsiderationLiabilitiesMember |
| 2830 |
Derivatives designated and effective as hedging instruments [member] |
Member |
|
|
gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember |
| 2831 |
Held for trading derivatives that are not in a designated and effective hedging relationship [member] |
Member |
|
|
gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember |
| 2832 |
Classes of financial assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialAssetsAxis |
| 2833 |
Financial assets, class [member] |
Member |
|
|
ifrs-full:FinancialAssetsMember |
| 2834 |
Other investments [member] |
Member |
|
|
gsk:OtherInvestmentsMember |
| 2835 |
Trade and other receivable [member] |
Member |
|
|
gsk:TradeAndOtherReceivableMember |
| 2836 |
Other Noncurrent Assets [member] |
Member |
|
|
gsk:OtherNoncurrentAssetsMember |
| 2837 |
Derivatives designated and effective as hedging instruments [member] |
Member |
|
|
gsk:DerivativesDesignatedAndEffectiveAsHedgingInstrumentsMember |
| 2838 |
Held for trading derivatives that are not in a designated and effective hedging relationship [member] |
Member |
|
|
gsk:HeldForTradingDerivativesThatAreNotInDesignatedAndEffectiveHedgingRelationshipMember |
| 2839 |
Cash and cash equivalents [member] |
Member |
|
|
gsk:CashAndCashEquivalents1Member |
| 2840 |
Liquid Investments [member] |
Member |
|
|
gsk:LiquidInvestmentsMember |
| 2841 |
Derivatives Financial Assets Designated At Fair Value Through Profit Or Loss [member] |
Member |
|
|
gsk:DerivativesFinancialAssetsDesignatedAtFairValueThroughProfitOrLossMember |
| 2842 |
Derivatives assets held for trading [member] |
Member |
|
|
gsk:DerivativesAssetsHeldForTradingMember |
| 2843 |
Disclosure Of Financial Assets And Liabilities [line items] |
LineItems |
|
|
gsk:DisclosureOfFinancialAssetsAndLiabilitiesLineItems |
| 2844 |
Financial assets at fair value |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssetsAtFairValue |
| 2845 |
Financial liabilities at fair value |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:FinancialLiabilitiesAtFairValue |
| 2846 |
1222 - Disclosure - Financial Instruments and Related Disclosures - Summary of Movement in Financial Instruments Measured Using Level 3 Valuation Method (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresSummaryOfMovementInFinancialInstrumentsMeasuredUsingLevel3ValuationMethod |
| 2847 |
Disclosure Of Fair Value Measurements Of Assets And Liabilities [table] |
Table |
* |
* |
gsk:DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesTable |
| 2848 |
Levels of fair value hierarchy [axis] |
Axis |
|
|
ifrs-full:LevelsOfFairValueHierarchyAxis |
| 2849 |
All levels of fair value hierarchy [member] |
Member |
|
|
ifrs-full:AllLevelsOfFairValueHierarchyMember |
| 2850 |
Level 3 [member] |
Member |
|
|
ifrs-full:Level3OfFairValueHierarchyMember |
| 2851 |
Disclosure of fair value measurements of assets and liabilities [line items] |
LineItems |
|
|
gsk:DisclosureOfFairValueMeasurementsOfAssetsAndLiabilitiesLineItems |
| 2852 |
Beginning balance |
Concept (Monetary) |
As Of |
Debit |
gsk:FinancialAssetsAndLiabilities |
| 2853 |
Net losses recognised in the income statement |
Concept (Monetary) |
For Period |
Credit |
gsk:GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssetsAndLiabilities |
| 2854 |
Net gains recognised in other comprehensive income |
Concept (Monetary) |
For Period |
Credit |
gsk:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasuremenTassetsAndLiabilities |
| 2855 |
Contingent consideration for businesses divested/acquired during the year |
Concept (Monetary) |
For Period |
Credit |
gsk:ContingentConsiderationLiabilitiesForBusinessesAcquiredDuringPeriod |
| 2856 |
Payment of contingent consideration liabilities |
Concept (Monetary) |
For Period |
Credit |
gsk:PaymentOfContingentConsiderationLiabilities |
| 2857 |
Additions |
Concept (Monetary) |
For Period |
Credit |
gsk:AdditionsFairValueMeasurementAssetsAndLiabilities |
| 2858 |
Disposals and settlements |
Concept (Monetary) |
For Period |
Credit |
gsk:DisposalsAndSettlementsFairValueMeasurementAssetsAndLiabilities |
| 2859 |
Transfers from Level 3 |
Concept (Monetary) |
For Period |
Credit |
gsk:TransfersOutOfLevelThreeOfFairValueHierarchyAssetsAndLiabilities |
| 2860 |
Exchange adjustments |
Concept (Monetary) |
For Period |
Credit |
gsk:ExchangeFairValueMeasurementAssetsAndLiabilities |
| 2861 |
Ending balance |
Concept (Monetary) |
As Of |
Debit |
gsk:FinancialAssetsAndLiabilities |
| 2862 |
1223 - Disclosure - Financial instruments and related disclosures - Summary of Financial Assets and Non Financial Assets (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresSummaryOfFinancialAssetsAndNonFinancialAssets |
| 2863 |
Disclosure of financial assets and non financial assets [table] |
Table |
* |
* |
gsk:DisclosureOfFinancialAssetsAndNonFinancialAssetsTable |
| 2864 |
Categories of financial assets [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialAssetsAxis |
| 2865 |
Financial assets, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsCategoryMember |
| 2866 |
Financial Assets at Fair Value Through Profit or Loss, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember |
| 2867 |
Financial assets at fair value through other comprehensive income, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember |
| 2868 |
Amortised cost [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesAtAmortisedCostMember |
| 2869 |
Financial Instruments [member] |
Member |
|
|
gsk:FinancialInstrumentsMember |
| 2870 |
Non Financial Instruments [member] |
Member |
|
|
gsk:NonFinancialInstrumentsMember |
| 2871 |
Loans and Receivables, Category [member] |
Member |
|
|
ifrs-full:LoansAndReceivablesCategoryMember |
| 2872 |
Classes of financial assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialAssetsAxis |
| 2873 |
Financial assets, class [member] |
Member |
|
|
ifrs-full:FinancialAssetsMember |
| 2874 |
Trade and Other Receivables and Certain Other Non-current Assets in Scope of IAS 39 [member] |
Member |
|
|
gsk:TradeAndOtherReceivablesAndCertainOtherNoncurrentAssetsInScopeOfIAS39Member |
| 2875 |
Disclosure of financial assets and non financial assets [line items] |
LineItems |
|
|
gsk:DisclosureOfFinancialAssetsAndNonFinancialAssetsLineItems |
| 2876 |
Trade and other receivables (Note 24) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:TradeAndOtherReceivables |
| 2877 |
Other non-current assets (Note 22) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherNoncurrentAssets |
| 2878 |
Other items in Assets held for sale (Note 26) |
Concept (Monetary) |
As Of |
Debit |
gsk:OtherItemsInAssetsLiabilitiesHeldForSale |
| 2879 |
Financial assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssets |
| 2880 |
1224 - Disclosure - Financial instruments and related disclosures - Schedule Of Ageing Financial Assets (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresScheduleOfAgeingFinancialAssets |
| 2881 |
Disclosure of financial assets that are either past due or impaired [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable |
| 2882 |
Impairment of financial assets [axis] |
Axis |
|
|
ifrs-full:ImpairmentOfFinancialAssetsAxis |
| 2883 |
Entity's total for impairment of financial assets [member] |
Member |
|
|
ifrs-full:EntitysTotalForImpairmentOfFinancialAssetsMember |
| 2884 |
Financial Assets Past Due and No Provision for Bad and Doubtful Debt [member] |
Member |
|
|
ifrs-full:FinancialAssetsPastDueButNotImpairedMember |
| 2885 |
Past due status [axis] |
Axis |
|
|
ifrs-full:PastDueStatusAxis |
| 2886 |
Past due status [member] |
Member |
|
|
ifrs-full:PastDueStatusMember |
| 2887 |
1 - 30 days [member] |
Member |
|
|
ifrs-full:NotLaterThanOneMonthMember |
| 2888 |
31 - 90 days [member] |
Member |
|
|
ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember |
| 2889 |
91 - 180 days [member] |
Member |
|
|
ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember |
| 2890 |
181 - 365 days [member] |
Member |
|
|
ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember |
| 2891 |
Later Than One Year [Member] |
Member |
|
|
ifrs-full:LaterThanOneYearMember |
| 2892 |
Disclosure of financial assets that are either past due or impaired [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems |
| 2893 |
Financial assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialAssets |
| 2894 |
1225 - Disclosure - Financial instruments and related disclosures - Reconciliation of financial instruments within Trade and other payables, Other provisions, Other non-current liabilities and Contingent consideration liabilities (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresReconciliationOfFinancialInstrumentsWithinTradeAndOtherPayablesOtherProvisionsOtherNoncurrentLiabilitiesAndContingentConsiderationLiabili_Xa |
| 2895 |
Disclosure of financial liabilities [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinancialLiabilitiesTable |
| 2896 |
Categories of financial liabilities [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialLiabilitiesAxis |
| 2897 |
Financial liabilities, category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesCategoryMember |
| 2898 |
Financial Liabilities at Fair Value Through Profit or Loss, Category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember |
| 2899 |
Other Liabilities [member] |
Member |
|
|
gsk:OtherLiabilitiesMember |
| 2900 |
Financial Instruments [member] |
Member |
|
|
gsk:FinancialInstrumentsMember |
| 2901 |
Non Financial Instruments [member] |
Member |
|
|
gsk:NonFinancialInstrumentsMember |
| 2902 |
Amortised cost [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesAtAmortisedCostMember |
| 2903 |
Classes of financial liabilities [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialLiabilitiesAxis |
| 2904 |
Financial liabilities, class [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesMember |
| 2905 |
Trade and Other Payables, Other Provisions and Certain Other Non-Current Liabilities in Scope of IFRS9 (2017 - IAS39) [member] |
Member |
|
|
gsk:TradeAndOtherPayablesOtherProvisionsAndCertainOtherNoncurrentLiabilitiesInScopeOfIAS39Member |
| 2906 |
Disclosure of financial liabilities [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinancialLiabilitiesLineItems |
| 2907 |
Trade and other payables (Note 27) |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherPayables |
| 2908 |
Other provisions (Note 29) |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherProvisions |
| 2909 |
Other non-currentliabilities (Note 30) |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherNoncurrentLiabilities |
| 2910 |
Contingent consideration liabilities (Note 39) |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate |
| 2911 |
Other items in Assets held for sale (Note 26) |
Concept (Monetary) |
As Of |
Debit |
gsk:OtherItemsInAssetsLiabilitiesHeldForSale |
| 2912 |
Financial liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:FinancialLiabilities |
| 2913 |
1226 - Disclosure - Financial instruments and related disclosures - Fair Values of Derivatives Held (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeld |
| 2914 |
Disclosure of detailed information about hedging instruments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsTable |
| 2915 |
Categories of financial liabilities [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialLiabilitiesAxis |
| 2916 |
Financial liabilities, category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesCategoryMember |
| 2917 |
Financial Liabilities at Fair Value Through Profit or Loss, Designated Upon Initial Recognition or Subsequently, Category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember |
| 2918 |
Financial Liabilities at Fair Value Through Profit or Loss That Meet Definition of Held for Trading, Category [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossThatMeetDefinitionOfHeldForTradingCategoryMember |
| 2919 |
Categories of financial assets [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialAssetsAxis |
| 2920 |
Financial assets, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsCategoryMember |
| 2921 |
Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember |
| 2922 |
Financial Assets at Fair Value Through Profit or Loss, Classified as Held for Trading, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember |
| 2923 |
Types of hedges [axis] |
Axis |
|
|
ifrs-full:TypesOfHedgesAxis |
| 2924 |
Hedges [member] |
Member |
|
|
ifrs-full:TypesOfHedgesMember |
| 2925 |
Cash Flow Hedges [member] |
Member |
|
|
ifrs-full:CashFlowHedgesMember |
| 2926 |
Net Investment Hedges [member] |
Member |
|
|
gsk:NetInvestmentHedgesMember |
| 2927 |
Hedging instruments [axis] |
Axis |
|
|
ifrs-full:HedgingInstrumentsAxis |
| 2928 |
Hedging instruments [member] |
Member |
|
|
ifrs-full:HedgingInstrumentsMember |
| 2929 |
Interest rate swap contract [member] |
Member |
|
|
ifrs-full:InterestRateSwapContractMember |
| 2930 |
Foreign Exchange Contracts [member] |
Member |
|
|
gsk:ForeignExchangeContractsMember |
| 2931 |
Embedded and Other Derivatives [member] |
Member |
|
|
gsk:EmbeddedAndOtherDerivativesMember |
| 2932 |
Cross currency swap [member] |
Member |
|
|
gsk:CrossCurrencySwapMember |
| 2933 |
Disclosure of detailed information about hedging instruments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems |
| 2934 |
Financial assets, Non current |
Concept (Monetary) |
As Of |
Debit |
gsk:HedgingInstrumentAssetsNoncurrent |
| 2935 |
Financial assets, current |
Concept (Monetary) |
As Of |
Debit |
gsk:HedgingInstrumentAssetsCurrent |
| 2936 |
Financial assets, current |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:HedgingInstrumentAssets |
| 2937 |
Financial liabilities non current |
Concept (Monetary) |
As Of |
Credit |
gsk:HedgingInstrumentLiabilitiesNoncurrent |
| 2938 |
Financial Liabilities, current |
Concept (Monetary) |
As Of |
Credit |
gsk:HedgingInstrumentLiabilitiesCurrent |
| 2939 |
Total derivative instruments |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:HedgingInstrumentLiabilities |
| 2940 |
1227 - Disclosure - Financial instruments and related disclosures - Fair Values of Derivatives Held (Parenthetical) (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresFairValuesOfDerivativesHeldParenthetical |
| 2941 |
Disclosure of detailed information about hedging instruments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsTable |
| 2942 |
Categories of financial assets [axis] |
Axis |
|
|
ifrs-full:CategoriesOfFinancialAssetsAxis |
| 2943 |
Financial assets, category [member] |
Member |
|
|
ifrs-full:FinancialAssetsCategoryMember |
| 2944 |
Financial Assets at Fair Value Through Profit or Loss, Mandatory Measured at Fair Value, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValueCategoryMember |
| 2945 |
Financial Assets at Fair Value Through Profit or Loss, Classified as Held for Trading, Category [member] |
Member |
|
|
ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTradingCategoryMember |
| 2946 |
Hedging instruments [axis] |
Axis |
|
|
ifrs-full:HedgingInstrumentsAxis |
| 2947 |
Hedging instruments [member] |
Member |
|
|
ifrs-full:HedgingInstrumentsMember |
| 2948 |
Interest rate swap contract [member] |
Member |
|
|
ifrs-full:InterestRateSwapContractMember |
| 2949 |
Foreign Exchange Contracts [member] |
Member |
|
|
gsk:ForeignExchangeContractsMember |
| 2950 |
Cross currency swap [member] |
Member |
|
|
gsk:CrossCurrencySwapMember |
| 2951 |
Types of hedges [axis] |
Axis |
|
|
ifrs-full:TypesOfHedgesAxis |
| 2952 |
Hedges [member] |
Member |
|
|
ifrs-full:TypesOfHedgesMember |
| 2953 |
Cash Flow Hedges [member] |
Member |
|
|
ifrs-full:CashFlowHedgesMember |
| 2954 |
Net Investment Hedges [member] |
Member |
|
|
gsk:NetInvestmentHedgesMember |
| 2955 |
Disclosure of detailed information about hedging instruments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsLineItems |
| 2956 |
Principal amount |
Concept (Decimal) |
As Of |
|
ifrs-full:NominalAmountOfHedgingInstrument |
| 2957 |
1228 - Disclosure - Financial Instruments and Related Disclosures - Summary of Detailed Information of Foreign Exchange Forward Contracts, Swaps Outstanding and Related Hedged Items (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfForeignExchangeForwardContractsSwapsOutstandingAndRelatedHedgedItems |
| 2958 |
Disclosure of detailed information about hedged items [table] |
Table |
* |
* |
ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsTable |
| 2959 |
Hedging instruments [axis] |
Axis |
|
|
ifrs-full:HedgingInstrumentsAxis |
| 2960 |
Hedging instruments [member] |
Member |
|
|
ifrs-full:HedgingInstrumentsMember |
| 2961 |
Foreign Exchange Contracts [member] |
Member |
|
|
gsk:ForeignExchangeContractsMember |
| 2962 |
Types of hedges [axis] |
Axis |
|
|
ifrs-full:TypesOfHedgesAxis |
| 2963 |
Hedges [member] |
Member |
|
|
ifrs-full:TypesOfHedgesMember |
| 2964 |
Cash Flow Hedges [member] |
Member |
|
|
ifrs-full:CashFlowHedgesMember |
| 2965 |
Net Investment Hedges [member] |
Member |
|
|
gsk:NetInvestmentHedgesMember |
| 2966 |
Hedges of net investment in foreign operations [member] |
Member |
|
|
ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember |
| 2967 |
Hedged items [axis] |
Axis |
|
|
ifrs-full:HedgedItemsAxis |
| 2968 |
Hedged items [member] |
Member |
|
|
ifrs-full:HedgedItemsMember |
| 2969 |
Buy Foreign Currency Less than 3 months [member] |
Member |
|
|
gsk:BuyForeignCurrencyLessThanThreeMonthsMember |
| 2970 |
Buy Foreign Currency 3 to 6 months [member] |
Member |
|
|
gsk:BuyForeignCurrencyThreeToSixMonthsMember |
| 2971 |
Buy Foreign Currency over 6 months [member] |
Member |
|
|
gsk:BuyForeignCurrencyOverSixMonthsMember |
| 2972 |
Sell Foreign Currency Less than 3 months [member] |
Member |
|
|
gsk:SellForeignCurrencyLessThanThreeMonthsMember |
| 2973 |
Sell Foreign Currency 3 to 6 months [member] |
Member |
|
|
gsk:SellForeignCurrencyThreeToSixMonthsMember |
| 2974 |
Sell Foreign Currency over 6 months [member] |
Member |
|
|
gsk:SellForeignCurrencyOverSixMonthsMember |
| 2975 |
Variability in cash flows from a highly probable forecast transaction [member] |
Member |
|
|
gsk:VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember |
| 2976 |
Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued [member] |
Member |
|
|
gsk:VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember |
| 2977 |
Disclosure of detailed information about hedged items [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsLineItems |
| 2978 |
Average exchange rate |
Concept (Decimal) |
For Period |
|
ifrs-full:AverageForeignExchangeRate |
| 2979 |
Foreign currency |
Concept (Text/String) |
For Period |
|
gsk:DescriptionOfForeignCurrency |
| 2980 |
Notional value |
Concept (Decimal) |
As Of |
|
ifrs-full:NominalAmountOfHedgingInstrument |
| 2981 |
Fair value |
Concept (Monetary) |
As Of |
|
ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue |
| 2982 |
Change in value for calculating hedge ineffectiveness |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness |
| 2983 |
Balance in cash flow hedge reserve/foreign currency translation reserve for continuing hedges |
Concept (Monetary) |
For Period |
Credit |
gsk:ReserveOfCashFlowHedgesOrExchangeDifferencesOnTranslationContinuingHedges |
| 2984 |
1229 - Disclosure - Financial Instruments and Related Disclosures - Summary of Effectiveness of Hedging Relationships and Amounts Reclassified from Hedging Reserve to Profit or Loss (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresSummaryOfEffectivenessOfHedgingRelationshipsAndAmountsReclassifiedFromHedgingReserveToProfitOrLoss |
| 2985 |
Disclosure of detailed information about hedging instruments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsTable |
| 2986 |
Types of hedges [axis] |
Axis |
|
|
ifrs-full:TypesOfHedgesAxis |
| 2987 |
Hedges [member] |
Member |
|
|
ifrs-full:TypesOfHedgesMember |
| 2988 |
Cash Flow Hedges [member] |
Member |
|
|
ifrs-full:CashFlowHedgesMember |
| 2989 |
Hedges of net investment in foreign operations [member] |
Member |
|
|
ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember |
| 2990 |
Hedging instruments [axis] |
Axis |
|
|
ifrs-full:HedgingInstrumentsAxis |
| 2991 |
Hedging instruments [member] |
Member |
|
|
ifrs-full:HedgingInstrumentsMember |
| 2992 |
Foreign Exchange Contracts [member] |
Member |
|
|
gsk:ForeignExchangeContractsMember |
| 2993 |
Hedged items [axis] |
Axis |
|
|
ifrs-full:HedgedItemsAxis |
| 2994 |
Hedged items [member] |
Member |
|
|
ifrs-full:HedgedItemsMember |
| 2995 |
Variability in cash flows from a highly probable forecast transaction [member] |
Member |
|
|
gsk:VariabilityInCashFlowsFromHighlyProbableForecastTransactionMember |
| 2996 |
Variability in cash flows from foreign exchange exposure arising on Euro denominated coupon payments relating to debt issued [member] |
Member |
|
|
gsk:VariabilityInCashFlowsFromForeignExchangeExposureArisingOnEuroDenominatedCouponPaymentsRelatingToDebtIssuedMember |
| 2997 |
Variability in cash flows [member] |
Member |
|
|
gsk:VariabilityInCashFlowsMember |
| 2998 |
Pre-hedging of long-term interest rates [member] |
Member |
|
|
gsk:PrehedgingOfLongtermInterestRatesMember |
| 2999 |
Disclosure of detailed information about hedged items [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsLineItems |
| 3000 |
Hedging gains/(losses) recognised in reserves |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ReserveOfGainsAndLossesOnHedgingInstrumentsThatHedgeInvestmentsInEquityInstruments |
| 3001 |
Amount of hedge ineffectiveness recognised in profit or loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss |
| 3002 |
Line item in profit or loss in which hedge ineffectiveness is included |
Concept (Text/String) |
For Period |
|
ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesRecognisedHedgeIneffectiveness |
| 3003 |
Amount reclassified to profit or loss as hedged future cash flows no longer expected to occur |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedFutureCashFlowsAreNoLongerExpectedToOccurNetOfTax |
| 3004 |
Amount reclassified to profit or loss as hedged item affects profit or loss |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesForWhichHedgedItemAffectedProfitOrLossNetOfTax |
| 3005 |
Amount reclassified to profit or loss line item in which reclassification adjustment is included |
Concept (Text/String) |
For Period |
|
ifrs-full:DescriptionOfLineItemInStatementOfComprehensiveIncomeThatIncludesReclassificationAdjustments |
| 3006 |
1230 - Disclosure - Financial Instruments and Related Disclosures - Summary of Detailed Information of Interest Rate Swap Contracts Outstanding and Related Hedged Items (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresSummaryOfDetailedInformationOfInterestRateSwapContractsOutstandingAndRelatedHedgedItems |
| 3007 |
Disclosure of detailed information about hedged items [table] |
Table |
* |
* |
ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsTable |
| 3008 |
Hedging instruments [axis] |
Axis |
|
|
ifrs-full:HedgingInstrumentsAxis |
| 3009 |
Hedging instruments [member] |
Member |
|
|
ifrs-full:HedgingInstrumentsMember |
| 3010 |
Interest rate swap contract [member] |
Member |
|
|
ifrs-full:InterestRateSwapContractMember |
| 3011 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 3012 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 3013 |
Not later than 1 year [member] |
Member |
|
|
ifrs-full:NotLaterThanOneYearMember |
| 3014 |
Between 1 and 2 years [member] |
Member |
|
|
ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember |
| 3015 |
Later than 2 years and not later than 5 years [member] |
Member |
|
|
ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember |
| 3016 |
Later than 5 years [member] |
Member |
|
|
ifrs-full:LaterThanFiveYearsMember |
| 3017 |
Hedged items [axis] |
Axis |
|
|
ifrs-full:HedgedItemsAxis |
| 3018 |
Hedged items [member] |
Member |
|
|
ifrs-full:HedgedItemsMember |
| 3019 |
Variable rate borrowings [member] |
Member |
|
|
gsk:VariableRateBorrowingsMember |
| 3020 |
Disclosure of detailed information about hedged items [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfDetailedInformationAboutHedgedItemsLineItems |
| 3021 |
Average contracted fixed rate % |
Concept (Percent) |
As Of |
|
gsk:AverageFixedInterestRateOfHedgingInstrument |
| 3022 |
Notional principal value £m |
Concept (Decimal) |
As Of |
|
ifrs-full:NominalAmountOfHedgingInstrument |
| 3023 |
Change in fair value for recognising hedge ineffectiveness £m |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness |
| 3024 |
Fair value assets/ (liabilities) £m |
Concept (Monetary) |
As Of |
Debit |
gsk:DerivativeFinancialAssetsLiabilities |
| 3025 |
Change in value used for calculating hedge ineffectiveness |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness |
| 3026 |
Balance in cash flow hedge reserve for continuing hedges |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ReserveOfCashFlowHedgesContinuingHedges |
| 3027 |
1231 - Disclosure - Financial instruments and related disclosures - Schedule of Offsetting of Financial Assets and Liabilities (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresScheduleOfOffsettingOfFinancialAssetsAndLiabilities |
| 3028 |
Disclosure Of Offsetting Of Financial Assets And Financial Liabilities [table] |
Table |
* |
* |
gsk:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesTable |
| 3029 |
Types of financial liabilities [axis] |
Axis |
|
|
ifrs-full:TypesOfFinancialLiabilitiesAxis |
| 3030 |
Financial liabilities, type [member] |
Member |
|
|
ifrs-full:FinancialLiabilitiesTypeMember |
| 3031 |
Trades and other payables [member] |
Member |
|
|
gsk:TradesAndOtherPayablesMember |
| 3032 |
Derivative financial liabilities [member] |
Member |
|
|
gsk:DerivativeFinancialLiabilitiesMember |
| 3033 |
Types of financial assets [axis] |
Axis |
|
|
ifrs-full:TypesOfFinancialAssetsAxis |
| 3034 |
Financial assets, type [member] |
Member |
|
|
ifrs-full:FinancialAssetsTypeMember |
| 3035 |
Trade and other receivable [member] |
Member |
|
|
gsk:TradeAndOtherReceivableMember |
| 3036 |
Derivative financial assets [member] |
Member |
|
|
gsk:DerivativeFinancialAssetsMember |
| 3037 |
Disclosure of offsetting of financial assets and financial liabilities [line items] |
LineItems |
|
|
gsk:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesLineItems |
| 3038 |
Gross financial assets/(liabilities) |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements |
| 3039 |
Gross financial (Liabilities)/assets set off |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:GrossFinancialLiabilitiesSetOffAgainstFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements |
| 3040 |
Gross financial assets/(liabilities) |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements |
| 3041 |
Net financial assets/(liabilities)per balance sheet |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition |
| 3042 |
Gross financial (Liabilities)/assets set off |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:GrossFinancialAssetsSetOffAgainstFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements |
| 3043 |
Related amounts not set off in the balance sheet |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets |
| 3044 |
Net financial assets/(liabilities)per balance sheet |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreementsInStatementOfFinancialPosition |
| 3045 |
Net amount |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements |
| 3046 |
Related amounts not set off in the balance sheet |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities |
| 3047 |
Net amount |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements |
| 3048 |
1232 - Disclosure - Financial instruments and related disclosures - Schedule of Debt Interest Rate Repricing (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresScheduleOfDebtInterestRateRepricing |
| 3049 |
Disclosure of debt interest rate repricing [table] |
Table |
* |
* |
gsk:DisclosureOfDebtInterestRateRepricingTable |
| 3050 |
Types of interest rates [axis] |
Axis |
|
|
ifrs-full:TypesOfInterestRatesAxis |
| 3051 |
Interest rate types [member] |
Member |
|
|
ifrs-full:InterestRateTypesMember |
| 3052 |
Floating and Fixed Rate Debt [member] |
Member |
|
|
gsk:FloatingAndFixedRateDebtMember |
| 3053 |
Fixed interest rate [member] |
Member |
|
|
ifrs-full:FixedInterestRateMember |
| 3054 |
Floating interest rate [member] |
Member |
|
|
ifrs-full:FloatingInterestRateMember |
| 3055 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 3056 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 3057 |
Later Than One Year [Member] |
Member |
|
|
ifrs-full:LaterThanOneYearMember |
| 3058 |
Between 1 and 2 years [member] |
Member |
|
|
ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember |
| 3059 |
Between 2 and 3 years [member] |
Member |
|
|
ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember |
| 3060 |
Between 3 and 4 Years [Member] |
Member |
|
|
ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember |
| 3061 |
Between 4 and 5 years [member] |
Member |
|
|
ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember |
| 3062 |
Between Five and Ten Years [Member] |
Member |
|
|
ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember |
| 3063 |
Greater Than Ten Years [Member] |
Member |
|
|
ifrs-full:LaterThanTenYearsMember |
| 3064 |
Disclosure of debt interest rate repricing [line items] |
LineItems |
|
|
gsk:DisclosureOfDebtInterestRateRepricingLineItems |
| 3065 |
Total debt |
Concept (Monetary) |
As Of |
Credit |
gsk:Debt |
| 3066 |
Total interest bearing |
Concept (Monetary) |
As Of |
Credit |
gsk:InterestBearingDebt |
| 3067 |
Non-interest bearing |
Concept (Monetary) |
As Of |
Credit |
gsk:NoninterestBearingDebt |
| 3068 |
1233 - Disclosure - Financial instruments and related disclosures - Impact of Non-functional Currency Foreign Exchange Exposures (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresImpactOfNonfunctionalCurrencyForeignExchangeExposures |
| 3069 |
Disclosure of nature and extent of risks arising from financial instruments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable |
| 3070 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 3071 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 3072 |
10 cent appreciation of the US Dollar [member] |
Member |
|
|
gsk:CurrencyRiskTenCentAppreciationOfUSDollarMember |
| 3073 |
10 cent appreciation of the Euro [member] |
Member |
|
|
gsk:CurrencyRiskTenCentAppreciationOfEuroMember |
| 3074 |
10 Yen appreciation of the Yen [Member] |
Member |
|
|
gsk:CurrencyRiskTenYenAppreciationOfYenMember |
| 3075 |
10 cent depreciation of US Dollar [member] |
Member |
|
|
gsk:CurrencyRiskTenCentDepreciationOfUSDollarMember |
| 3076 |
10 cent depreciation of Euro [member] |
Member |
|
|
gsk:CurrencyRiskTenCentDepreciationOfEuroMember |
| 3077 |
Yen Exchange Rates [Member] |
Member |
|
|
gsk:CurrencyRiskTenCentDepreciationOfYenMember |
| 3078 |
10 cent depreciation of Yen [member] |
Member |
|
|
gsk:CurrencyRiskTenYenDepreciationOfYenMember |
| 3079 |
Disclosure of nature and extent of risks arising from financial instruments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems |
| 3080 |
Increase/(decrease) in income |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseInIncomeThroughForeignCurrencyExchangeExposures |
| 3081 |
(Increase)/decrease in net debt |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseInNetDebtThroughForeignCurrencyExchangeExposures |
| 3082 |
1234 - Disclosure - Financial instruments and related disclosures - Impact of Interest Rate Currency Movements (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresImpactOfInterestRateCurrencyMovements |
| 3083 |
Disclosure of nature and extent of risks arising from financial instruments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable |
| 3084 |
Types of risks [axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 3085 |
Risks [member] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 3086 |
1% (100 basis points) increase in sterling interest rates [member] |
Member |
|
|
gsk:InterestRateRiskOnePercentIncreaseInSterlingInterestRatesMember |
| 3087 |
1% (100 Basis Points) Increase in US Dollar Interest Rates [Member] |
Member |
|
|
gsk:InterestRateRiskOnePercentIncreaseInUsDollarInterestRatesMember |
| 3088 |
1% (100 Basis Points) Increase in Euro Interest Rates [Member] |
Member |
|
|
gsk:InterestRateRiskOnePercentIncreaseInEuroInterestRatesMember |
| 3089 |
Disclosure of nature and extent of risks arising from financial instruments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems |
| 3090 |
Increase/(decrease) in income |
Concept (Monetary) |
For Period |
Credit |
gsk:IncreaseDecreaseInIncomeThroughInterestRateMovements |
| 3091 |
1235 - Disclosure - Financial instruments and related disclosures - Summary of Maturity Analysis for Non-derivative Financial Liabilities (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresSummaryOfMaturityAnalysisForNonderivativeFinancialLiabilities |
| 3092 |
Disclosure of maturity analysis for non-derivative financial liabilities [table] |
Table |
* |
* |
ifrs-full:DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable |
| 3093 |
Hedging instruments [axis] |
Axis |
|
|
ifrs-full:HedgingInstrumentsAxis |
| 3094 |
Hedging instruments [member] |
Member |
|
|
ifrs-full:HedgingInstrumentsMember |
| 3095 |
Non Derivatives Financial Liabilities [member] |
Member |
|
|
gsk:NonDerivativesFinancialLiabilitiesMember |
| 3096 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 3097 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 3098 |
Not later than 1 year [member] |
Member |
|
|
ifrs-full:NotLaterThanOneYearMember |
| 3099 |
Between 1 and 2 years [member] |
Member |
|
|
ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember |
| 3100 |
Between 2 and 3 years [member] |
Member |
|
|
ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember |
| 3101 |
Between 3 and 4 Years [Member] |
Member |
|
|
ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember |
| 3102 |
Between 4 and 5 years [member] |
Member |
|
|
ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember |
| 3103 |
Between Five and Ten Years [Member] |
Member |
|
|
ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember |
| 3104 |
Greater Than Ten Years [Member] |
Member |
|
|
ifrs-full:LaterThanTenYearsMember |
| 3105 |
Disclosure of maturity analysis for non-derivative financial liabilities [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems |
| 3106 |
Debt |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:BankBorrowingsUndiscountedCashFlows |
| 3107 |
Interest on debt |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:InterestExpenseOnBorrowings |
| 3108 |
Obligations under finance leases |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:FinanceLeaseLiabilities |
| 3109 |
Finance charge on obligations under finance leases |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:FutureFinanceChargeOnFinanceLease |
| 3110 |
Trade payables and other liabilities not in net debt |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows |
| 3111 |
Total |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows |
| 3112 |
1236 - Disclosure - Financial instruments and related disclosures - Summary Anticipated Contractual Cash Flows for Derivative Instruments, Excluding Embedded Derivatives and Equity Options, Using Undiscounted Cash Flows (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureFinancialInstrumentsAndRelatedDisclosuresSummaryAnticipatedContractualCashFlowsForDerivativeInstrumentsExcludingEmbeddedDerivativesAndEquityOptionsUsingUndiscountedCashFlows |
| 3113 |
Disclosure of detailed information about financial instruments [table] |
Table |
* |
* |
ifrs-full:DisclosureOfFinancialInstrumentsTable |
| 3114 |
Classes of financial assets [axis] |
Axis |
|
|
ifrs-full:ClassesOfFinancialAssetsAxis |
| 3115 |
Financial assets, class [member] |
Member |
|
|
ifrs-full:FinancialAssetsMember |
| 3116 |
Derivative Instruments [Member] |
Member |
|
|
ifrs-full:DerivativesMember |
| 3117 |
Maturity [axis] |
Axis |
|
|
ifrs-full:MaturityAxis |
| 3118 |
Aggregated time bands [member] |
Member |
|
|
ifrs-full:AggregatedTimeBandsMember |
| 3119 |
Not later than 1 year [member] |
Member |
|
|
ifrs-full:NotLaterThanOneYearMember |
| 3120 |
Between 1 and 2 years [member] |
Member |
|
|
ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember |
| 3121 |
Between 2 and 3 years [member] |
Member |
|
|
ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember |
| 3122 |
Debt Instrument 1 [axis] |
Axis |
|
|
gsk:DebtInstrument1Axis |
| 3123 |
Debt Instrument [domain] |
Member |
|
|
gsk:DebtInstrumentDomain |
| 3124 |
Interest rate swap contract [member] |
Member |
|
|
ifrs-full:InterestRateSwapContractMember |
| 3125 |
Foreign Exchange Forward Contracts and Swaps [member] |
Member |
|
|
gsk:ForeignExchangeForwardContractsAndSwapsMember |
| 3126 |
Disclosure of detailed information about financial instruments [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfFinancialInstrumentsLineItems |
| 3127 |
Receivable, Foreign exchange forward contracts and swaps |
Concept (Monetary) |
As Of |
Debit |
gsk:ReceivablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows |
| 3128 |
Payables, Interest rate swaps |
Concept (Monetary) |
As Of |
Credit |
gsk:PayablesOnDerivativeFinancialInstrumentsUndiscountedCashFlows |
| 3129 |
1237 - Disclosure - Employee Share Schemes - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEmployeeShareSchemesAdditionalInformation |
| 3130 |
Disclosure Of Employee Share Schemes [table] |
Table |
* |
* |
gsk:DisclosureOfEmployeeShareSchemesTable |
| 3131 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 3132 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 3133 |
Savings-Related Share Option Schemes [member] |
Member |
|
|
gsk:SavingsRelatedShareOptionSchemesMember |
| 3134 |
Share Value Plan [member] |
Member |
|
|
gsk:ShareValuePlanMember |
| 3135 |
Performance Share Plan [member] |
Member |
|
|
gsk:PerformanceSharePlansMember |
| 3136 |
Award type. |
Axis |
|
|
gsk:AwardType1Axis |
| 3137 |
Equity Award [domain] |
Member |
|
|
gsk:EquityAwardDomain |
| 3138 |
American Depositary Shares [member] |
Member |
|
|
gsk:AmericanDepositarySharesMember |
| 3139 |
Disclosure of employee share schemes [line items] |
LineItems |
|
|
gsk:DisclosureOfEmployeeShareSchemesLineItems |
| 3140 |
Share options granted at percentage below market price |
Concept (Percent) |
For Period |
|
gsk:AtPercentageBelowMarketPrice |
| 3141 |
Cost of share-based incentive plans |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees |
| 3142 |
Expected future dividend yield percentage share granted |
Concept (Percent) |
For Period |
|
gsk:ExpectedFutureDividendYieldPercentageShareGranted |
| 3143 |
Number of awards granted |
Concept (Decimal) |
For Period |
|
gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement |
| 3144 |
Weighted average fair value of awards |
Concept (Share) |
For Period |
|
gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare |
| 3145 |
Number of outstanding awards |
Concept (Decimal) |
As Of |
|
gsk:NumberOfOutstandingAwards |
| 3146 |
Number of options granted |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 3147 |
Weighted average fair value of options granted |
Concept (Share) |
As Of |
|
gsk:WeightedAverageFairValueOfShareOptionGrantedInShareBasedPaymentArrangement |
| 3148 |
Number share options were not exercisable |
Concept (Decimal) |
As Of |
|
gsk:NumberOfShareOptionsNotExercisableInShareBasedPaymentArrangement |
| 3149 |
1238 - Disclosure - Employee Share Schemes - Schedule of Number of Shares and ADS Issuable (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEmployeeShareSchemesScheduleOfNumberOfSharesAndADSIssuable |
| 3150 |
Disclosure of terms and conditions of share-based payment arrangement [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 3151 |
Award type. |
Axis |
|
|
gsk:AwardType1Axis |
| 3152 |
Equity Award [domain] |
Member |
|
|
gsk:EquityAwardDomain |
| 3153 |
American Depositary Shares [member] |
Member |
|
|
gsk:AmericanDepositarySharesMember |
| 3154 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 3155 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 3156 |
Share Value Plan [member] |
Member |
|
|
gsk:ShareValuePlanMember |
| 3157 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 3158 |
Number of shares, Beginning balance |
Concept (Decimal) |
As Of |
|
gsk:NumberOfOutstandingShareAwards |
| 3159 |
Number of shares, Awards granted |
Concept (Decimal) |
For Period |
|
gsk:NumberOfShareAwardsGrantedInSharebasedPaymentArrangement |
| 3160 |
Number of shares, Awards exercised |
Concept (Decimal) |
For Period |
|
gsk:NumberOfShareAwardsExercisedInSharebasedPaymentArrangement |
| 3161 |
Number of shares, Awards cancelled |
Concept (Decimal) |
For Period |
|
gsk:NumberOfShareAwardsForfeitedInSharebasedPaymentArrangement |
| 3162 |
Number of shares, Ending balance |
Concept (Decimal) |
As Of |
|
gsk:NumberOfOutstandingShareAwards |
| 3163 |
Weighted fair value, Awards granted |
Concept (Share) |
For Period |
|
gsk:WeightedAverageFairValueAtMeasurementDateShareAwardsGrantedPerShare |
| 3164 |
1239 - Disclosure - Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentCharge |
| 3165 |
Disclosure Of Share Options And Savings Related Options [table] |
Table |
* |
* |
gsk:DisclosureOfShareOptionsAndSavingsRelatedOptionsTable |
| 3166 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 3167 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 3168 |
Share Options and Savings-Related Options [member] |
Member |
|
|
gsk:ShareOptionsAndSavingsRelatedOptionsMember |
| 3169 |
Disclosure of share options and savings related options [line items] |
LineItems |
|
|
gsk:DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems |
| 3170 |
Risk-free interest rate |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted |
| 3171 |
Dividend yield |
Concept (Percent) |
For Period |
|
gsk:DividendYieldShareOptionsGranted |
| 3172 |
Volatility |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted |
| 3173 |
Expected life |
Concept (xbrli:durationItemType) |
For Period |
|
gsk:ExpectedLifeOfShareOptionsGranted |
| 3174 |
Savings-related options grant price (including 20% discount) |
Concept (Share) |
For Period |
|
gsk:SavingsRelatedOptionsGrantPrice |
| 3175 |
1240 - Disclosure - Employee Share Schemes - Summary of Valuation Model Used to Valuing Saving - Related Option to Arrive at the Share Based Payment Charge (Parenthetical) (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEmployeeShareSchemesSummaryOfValuationModelUsedToValuingSavingRelatedOptionToArriveAtTheShareBasedPaymentChargeParenthetical |
| 3176 |
Disclosure Of Share Options And Savings Related Options [table] |
Table |
* |
* |
gsk:DisclosureOfShareOptionsAndSavingsRelatedOptionsTable |
| 3177 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 3178 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 3179 |
Share Options and Savings-Related Options [member] |
Member |
|
|
gsk:ShareOptionsAndSavingsRelatedOptionsMember |
| 3180 |
Disclosure of share options and savings related options [line items] |
LineItems |
|
|
gsk:DisclosureOfShareOptionsAndSavingsRelatedOptionsLineItems |
| 3181 |
Savings-related options grant price discount |
Concept (Percent) |
For Period |
|
gsk:SavingsRelatedOptionsGrantPriceDiscount |
| 3182 |
1241 - Disclosure - Employee Share Schemes - Summary of Option Outstanding (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEmployeeShareSchemesSummaryOfOptionOutstanding |
| 3183 |
Disclosure of terms and conditions of share-based payment arrangement [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 3184 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 3185 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 3186 |
Share Option Schemes [member] |
Member |
|
|
gsk:ShareOptionSchemesMember |
| 3187 |
Share Option Schemes American Depositary Shares [member] |
Member |
|
|
gsk:ShareOptionSchemesAmericanDepositarySharesMember |
| 3188 |
Savings-Related Share Option Schemes [member] |
Member |
|
|
gsk:SavingsRelatedShareOptionSchemesMember |
| 3189 |
Range [axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 3190 |
Ranges [member] |
Member |
|
|
ifrs-full:RangesMember |
| 3191 |
Top of range [member] |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 3192 |
Bottom of range [member] |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 3193 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 3194 |
Number of Shares |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 3195 |
Share option schemes - shares Weighted exercise price |
Concept (Share) |
As Of |
|
gsk:WeightedAverageExercisePriceOfShareOptionOutstandingInShareBasedPaymentArrangement |
| 3196 |
Range of exercise prices on options outstanding at year end |
Concept (Share) |
As Of |
|
gsk:WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement |
| 3197 |
Weighted average market price on exercise during year |
Concept (Share) |
As Of |
|
gsk:WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement |
| 3198 |
Weighted average remaining contractual life |
Concept (Decimal) |
As Of |
|
ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions |
| 3199 |
1242 - Disclosure - Employee Share Schemes - Summary of Shares Held for Share Award Schemes (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureEmployeeShareSchemesSummaryOfSharesHeldForShareAwardSchemes |
| 3200 |
Disclosure of terms and conditions of share-based payment arrangement [table] |
Table |
* |
* |
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable |
| 3201 |
Types of share-based payment arrangements [axis] |
Axis |
|
|
ifrs-full:TypesOfSharebasedPaymentArrangementsAxis |
| 3202 |
Share-based payment arrangements [member] |
Member |
|
|
ifrs-full:SharebasedPaymentArrangementsMember |
| 3203 |
Employee share ownership plan [member] |
Member |
|
|
gsk:EmployeeShareOwnershipPlanMember |
| 3204 |
Disclosure of terms and conditions of share-based payment arrangement [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems |
| 3205 |
Shares held for share award schemes, Number of shares |
Concept (Decimal) |
As Of |
|
gsk:NumberOfSharesHeldForShareAwardSchemes |
| 3206 |
Shares held for share award schemes, Nominal value |
Concept (Monetary) |
As Of |
Credit |
gsk:NominalValueOfSharesHeldForShareAwardSchemes |
| 3207 |
Shares held for share award schemes, Carrying value |
Concept (Monetary) |
As Of |
Credit |
gsk:CarryingValueOfSharesHeldForShareAwardSchemes |
| 3208 |
Shares held for share award schemes, Market value |
Concept (Monetary) |
As Of |
Credit |
gsk:MarketValueOfSharesHeldForShareAwardSchemes |
| 3209 |
Shares held for share option schemes, Number of shares |
Concept (Decimal) |
As Of |
|
gsk:NumberOfSharesHeldForShareOptionSchemes |
| 3210 |
Shares held for share option schemes, Nominal value |
Concept (Monetary) |
As Of |
Credit |
gsk:NominalValueOfSharesHeldForShareOptionSchemes |
| 3211 |
Shares held for share option schemes, Carrying value |
Concept (Monetary) |
As Of |
Credit |
gsk:CarryingValueOfSharesHeldForShareOptionSchemes |
| 3212 |
Shares held for share option schemes, Market value |
Concept (Monetary) |
As Of |
Credit |
gsk:MarketValueOfSharesHeldForShareOptionSchemes |
| 3213 |
1243 - Disclosure - Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroup |
| 3214 |
Disclosure of subsidiaries [table] |
Table |
* |
* |
ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesTable |
| 3215 |
Subsidiaries [axis] |
Axis |
|
|
ifrs-full:SignificantInvestmentsInSubsidiariesAxis |
| 3216 |
Entity's total for subsidiaries [member] |
Member |
|
|
ifrs-full:EntitysTotalForSubsidiariesMember |
| 3217 |
Glaxo Group Limited [member] |
Member |
|
|
gsk:GlaxoGroupLimitedMember |
| 3218 |
Glaxo Operations UK Limited [member] |
Member |
|
|
gsk:GlaxoOperationsUkLimitedMember |
| 3219 |
GlaxoSmithKline Capital PLC [member] |
Member |
|
|
gsk:GlaxoSmithKlineCapitalPLCMember |
| 3220 |
GlaxoSmithKline Consumer Healthcare Holdings Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember |
| 3221 |
GlaxoSmithKline Consumer Healthcare (UK) Trading Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareTradingLimitedMember |
| 3222 |
GlaxoSmithKline Consumer Trading Services Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerTradingServicesLimitedMember |
| 3223 |
GlaxoSmithKline Export Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineExportLimitedMember |
| 3224 |
GlaxoSmithKline Finance PLC [member] |
Member |
|
|
gsk:GlaxoSmithKlineFinancePLCMember |
| 3225 |
GlaxoSmithKline Holdings Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineHoldingsLimitedMember |
| 3226 |
GlaxoSmithKline Research and Development Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineResearchAndDevelopmentLimitedMember |
| 3227 |
GlaxoSmithKline Services Unlimited [member] |
Member |
|
|
gsk:GlaxoSmithKlineServicesUnlimitedMember |
| 3228 |
GlaxoSmithKline UK Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineUnitedKingdomLimitedMember |
| 3229 |
Setfirst Limited [member] |
Member |
|
|
gsk:SetFirstLimitedMember |
| 3230 |
SmithKline Beecham Limited [member] |
Member |
|
|
gsk:SmithKlineBeechamLimitedMember |
| 3231 |
ViiV Health Care Limited [member] |
Member |
|
|
gsk:ViiVHealthCareLimitedMember |
| 3232 |
ViiV Healthcare UK Limited [member] |
Member |
|
|
gsk:ViiVHealthCareUnitedKingdomLimitedMember |
| 3233 |
Block Drug Company Inc. [member] |
Member |
|
|
gsk:BlockDrugCompanyIncMember |
| 3234 |
Corixa Corporation [member] |
Member |
|
|
gsk:CorixaCorporationMember |
| 3235 |
GlaxoSmithKline Capital Inc. [member] |
Member |
|
|
gsk:GlaxoSmithKlineCapitalIncMember |
| 3236 |
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC [member] |
Member |
|
|
gsk:GlaxosmithklineConsumerHealthcareHoldingsUSLLCMember |
| 3237 |
GlaxoSmithKline Consumer Health Care L P [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareLPMember |
| 3238 |
GlaxoSmithKline Holdings (Americas) Inc. [member] |
Member |
|
|
gsk:GlaxoSmithKlineHoldingsIncMember |
| 3239 |
GlaxoSmithKline LLC [member] |
Member |
|
|
gsk:GlaxoSmithKlineLLCMember |
| 3240 |
Human Genome Sciences, Inc. [member] |
Member |
|
|
gsk:HumanGenomeSciencesIncMember |
| 3241 |
GSK Consumer Health, Inc [member] |
Member |
|
|
gsk:GskConsumerHealthIncMember |
| 3242 |
S.R One, Limited [member] |
Member |
|
|
gsk:SROneLimitedMember |
| 3243 |
Stiefel Laboratories, Inc. [member] |
Member |
|
|
gsk:StiefelLaboratoriesIncMember |
| 3244 |
Vii V Health Care Company [member] |
Member |
|
|
gsk:ViiVHealthCareCompanyMember |
| 3245 |
GlaxoSmithKline Argentina S.A. [member] |
Member |
|
|
gsk:GlaxoSmithKlineArgentinaSAMember |
| 3246 |
GlaxoSmithKline Australia Pty Ltd [Member] |
Member |
|
|
gsk:GlaxoSmithKlineAustraliaPtyLtdMember |
| 3247 |
GlaxoSmithKline Consumer Healthcare Australia Pty Ltd [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareAustraliaPtyLtdMember |
| 3248 |
GlaxoSmithKline Brasil Limitada [Member] |
Member |
|
|
gsk:GlaxoSmithKlineBrasilLimitadaMember |
| 3249 |
GlaxoSmithKline Consumer Healthcare Inc. [Member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareIncMember |
| 3250 |
GlaxoSmithKline Inc. [Member] |
Member |
|
|
gsk:GlaxoSmithKlineIncMember |
| 3251 |
ID Biomedical Corporation of Quebec [Member] |
Member |
|
|
gsk:IDBiomedicalCorporationOfQuebecMember |
| 3252 |
GlaxoSmithKline Limited [Member] |
Member |
|
|
gsk:GlaxoSmithKlineLimitedMember |
| 3253 |
GlaxoSmithKline (Tianjin) Co. Ltd [member] |
Member |
|
|
gsk:GlaxoSmithKlineTianjinCoLtdMember |
| 3254 |
Sino-American Tianjin Smith Kline and French Laboratories Ltd [Member] |
Member |
|
|
gsk:SinoAmericanTianjinSmithKlineAndFrenchLaboratoriesLtdMember |
| 3255 |
GlaxoSmithKline Consumer Healthcare Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareLimitedMember |
| 3256 |
GlaxoSmithKline Pharmaceuticals Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlinePharmaceuticalsLimitedMember |
| 3257 |
GlaxoSmithKline Consumer Healthcare Japan K.K. [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareJapanKKMember |
| 3258 |
GlaxoSmithKline K.K. [member] |
Member |
|
|
gsk:GlaxoSmithKlineKKMember |
| 3259 |
ViiV Healthcare Kabushiki Kaisha [member] |
Member |
|
|
gsk:ViiVHealthCareKabushikiKaishaMember |
| 3260 |
GlaxoSmithKline Pakistan Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlinePakistanLimitedMember |
| 3261 |
Glaxo Wellcome Manufacturing Pte Ltd. [member] |
Member |
|
|
gsk:GlaxoWellcomeManufacturingPteLtdMember |
| 3262 |
GlaxoSmithKline Korea Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineKoreaLimitedMember |
| 3263 |
GlaxoSmithKline llaclari Sanayi ve Ticaret A.S. [member] |
Member |
|
|
gsk:GlaxoSmithKlineLlaclariSanayiVeTicaretAsMember |
| 3264 |
GlaxoSmithKline Biologicals SA [member] |
Member |
|
|
gsk:GlaxoSmithKlineBiologicalsSAMember |
| 3265 |
GlaxoSmithKline Pharmaceuticals S.A. [member] |
Member |
|
|
gsk:GlaxoSmithKlinePharmaceuticalsSAMember |
| 3266 |
GlaxoSmithKline Biologicals S.A.S. [member] |
Member |
|
|
gsk:GlaxoSmithKlineBiologicalsSASMember |
| 3267 |
GlaxoSmithKline Sante Grand Public SAS [member] |
Member |
|
|
gsk:GlaxoSmithKlineSanteGrandPublicSASMember |
| 3268 |
Laboratoire GlaxoSmithKline [member] |
Member |
|
|
gsk:LaboratoireGlaxoSmithKlineMember |
| 3269 |
ViiV Healthcare SAS [member] |
Member |
|
|
gsk:ViiVHealthcareSASMember |
| 3270 |
GlaxoSmithKline Consumer Healthcare GmbH and Co. KG [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareGmbHAndCoKGMember |
| 3271 |
GlaxoSmithKline GmbH and Co. KG [member] |
Member |
|
|
gsk:GlaxoSmithKlineGmbHAndCoKGMember |
| 3272 |
GSK Vaccines GmbH [member] |
Member |
|
|
gsk:GSKVaccinesGmbHMember |
| 3273 |
GlaxoSmithKline Consumer Healthcare S.p.A. [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareSPAMember |
| 3274 |
GlaxoSmithKline S.p.A. [member] |
Member |
|
|
gsk:GlaxoSmithKlineSPAMember |
| 3275 |
GSK Vaccines S.r.l. [member] |
Member |
|
|
gsk:GSKVaccinesSRLMember |
| 3276 |
GlaxoSmithKline B.V. [member] |
Member |
|
|
gsk:GlaxoSmithKlineBVMember |
| 3277 |
GlaxoSmithKline Consumer Healthcare S p z o o [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthcareSPZOOMember |
| 3278 |
GSK Services Sp z o.o. [member] |
Member |
|
|
gsk:GSKServicesSPZOOMember |
| 3279 |
GlaxoSmithKline Trading Services Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineTradingServicesLimitedMember |
| 3280 |
GlaxoSmithKline Healthcare AO [member] |
Member |
|
|
gsk:GlaxoSmithKlineHealthcareAoMember |
| 3281 |
GlaxoSmithKline S.A. [member] |
Member |
|
|
gsk:GlaxoSmithKlineSAMember |
| 3282 |
Laboratorios ViiV Healthcare, S.L. [member] |
Member |
|
|
gsk:LaboratoriosViiVHealthCareSLMember |
| 3283 |
GSK Consumer Healthcare S.A [member] |
Member |
|
|
gsk:GSKConsumerHealthcareSAMember |
| 3284 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 3285 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 3286 |
UK [member] |
Member |
|
|
ifrs-full:CountryOfDomicileMember |
| 3287 |
US [member] |
Member |
|
|
country:US |
| 3288 |
Argentina [member] |
Member |
|
|
country:AR |
| 3289 |
Australia [member] |
Member |
|
|
country:AU |
| 3290 |
Brazil [member] |
Member |
|
|
country:BR |
| 3291 |
Canada [member] |
Member |
|
|
country:CA |
| 3292 |
China [member] |
Member |
|
|
country:HK |
| 3293 |
China [member] |
Member |
|
|
country:CN |
| 3294 |
India [member] |
Member |
|
|
country:IN |
| 3295 |
Japan [member] |
Member |
|
|
country:JP |
| 3296 |
Pakistan [member] |
Member |
|
|
country:PK |
| 3297 |
Singapore [member] |
Member |
|
|
country:SG |
| 3298 |
Republic of Korea [member] |
Member |
|
|
country:KR |
| 3299 |
Turkey [member] |
Member |
|
|
country:TR |
| 3300 |
Belgium [member] |
Member |
|
|
country:BE |
| 3301 |
France [member] |
Member |
|
|
country:FR |
| 3302 |
Germany [member] |
Member |
|
|
country:DE |
| 3303 |
Italy [member] |
Member |
|
|
country:IT |
| 3304 |
Netherlands [member] |
Member |
|
|
country:NL |
| 3305 |
Poland [member] |
Member |
|
|
country:PL |
| 3306 |
Ireland [member] |
Member |
|
|
country:IE |
| 3307 |
Russia [member] |
Member |
|
|
country:RU |
| 3308 |
Spain [member] |
Member |
|
|
country:ES |
| 3309 |
Switzerland [member] |
Member |
|
|
country:CH |
| 3310 |
Disclosure of subsidiaries [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesLineItems |
| 3311 |
Name of subsidiary |
Concept (Text/String) |
For Period |
|
ifrs-full:NameOfSubsidiary |
| 3312 |
1244 - Disclosure - Principal Group companies - Schedule of the Subsidiaries and Their Counties of Incorporation and the Equity Share Capital of These Entities wholly owned by the Group (Parenthetical) (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePrincipalGroupCompaniesScheduleOfTheSubsidiariesAndTheirCountiesOfIncorporationAndTheEquityShareCapitalOfTheseEntitiesWhollyOwnedByTheGroupParenthetical |
| 3313 |
Disclosure of subsidiaries [table] |
Table |
* |
* |
ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesTable |
| 3314 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 3315 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 3316 |
UK [member] |
Member |
|
|
ifrs-full:CountryOfDomicileMember |
| 3317 |
US [member] |
Member |
|
|
country:US |
| 3318 |
Argentina [member] |
Member |
|
|
country:AR |
| 3319 |
Australia [member] |
Member |
|
|
country:AU |
| 3320 |
Brazil [member] |
Member |
|
|
country:BR |
| 3321 |
Canada [member] |
Member |
|
|
country:CA |
| 3322 |
China [member] |
Member |
|
|
country:HK |
| 3323 |
China [member] |
Member |
|
|
country:CN |
| 3324 |
India [member] |
Member |
|
|
country:IN |
| 3325 |
Japan [member] |
Member |
|
|
country:JP |
| 3326 |
Pakistan [member] |
Member |
|
|
country:PK |
| 3327 |
Singapore [member] |
Member |
|
|
country:SG |
| 3328 |
Republic of Korea [member] |
Member |
|
|
country:KR |
| 3329 |
Turkey [member] |
Member |
|
|
country:TR |
| 3330 |
Belgium [member] |
Member |
|
|
country:BE |
| 3331 |
France [member] |
Member |
|
|
country:FR |
| 3332 |
Germany [member] |
Member |
|
|
country:DE |
| 3333 |
Italy [member] |
Member |
|
|
country:IT |
| 3334 |
Netherlands [member] |
Member |
|
|
country:NL |
| 3335 |
Poland [member] |
Member |
|
|
country:PL |
| 3336 |
Ireland [member] |
Member |
|
|
country:IE |
| 3337 |
Russia [member] |
Member |
|
|
country:RU |
| 3338 |
Spain [member] |
Member |
|
|
country:ES |
| 3339 |
Switzerland [member] |
Member |
|
|
country:CH |
| 3340 |
Subsidiaries [axis] |
Axis |
|
|
ifrs-full:SignificantInvestmentsInSubsidiariesAxis |
| 3341 |
Entity's total for subsidiaries [member] |
Member |
|
|
ifrs-full:EntitysTotalForSubsidiariesMember |
| 3342 |
Glaxo Group Limited [member] |
Member |
|
|
gsk:GlaxoGroupLimitedMember |
| 3343 |
Glaxo Operations UK Limited [member] |
Member |
|
|
gsk:GlaxoOperationsUkLimitedMember |
| 3344 |
GlaxoSmithKline Capital PLC [member] |
Member |
|
|
gsk:GlaxoSmithKlineCapitalPLCMember |
| 3345 |
GlaxoSmithKline Consumer Healthcare Holdings Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthcareHoldingsLimitedMember |
| 3346 |
GlaxoSmithKline Consumer Healthcare (UK) Trading Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareTradingLimitedMember |
| 3347 |
GlaxoSmithKline Consumer Trading Services Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerTradingServicesLimitedMember |
| 3348 |
GlaxoSmithKline Export Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineExportLimitedMember |
| 3349 |
GlaxoSmithKline Finance PLC [member] |
Member |
|
|
gsk:GlaxoSmithKlineFinancePLCMember |
| 3350 |
GlaxoSmithKline Holdings Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineHoldingsLimitedMember |
| 3351 |
GlaxoSmithKline Research and Development Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineResearchAndDevelopmentLimitedMember |
| 3352 |
GlaxoSmithKline Services Unlimited [member] |
Member |
|
|
gsk:GlaxoSmithKlineServicesUnlimitedMember |
| 3353 |
GlaxoSmithKline UK Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineUnitedKingdomLimitedMember |
| 3354 |
Setfirst Limited [member] |
Member |
|
|
gsk:SetFirstLimitedMember |
| 3355 |
SmithKline Beecham Limited [member] |
Member |
|
|
gsk:SmithKlineBeechamLimitedMember |
| 3356 |
ViiV Health Care Limited [member] |
Member |
|
|
gsk:ViiVHealthCareLimitedMember |
| 3357 |
ViiV Healthcare UK Limited [member] |
Member |
|
|
gsk:ViiVHealthCareUnitedKingdomLimitedMember |
| 3358 |
Block Drug Company Inc. [member] |
Member |
|
|
gsk:BlockDrugCompanyIncMember |
| 3359 |
Corixa Corporation [member] |
Member |
|
|
gsk:CorixaCorporationMember |
| 3360 |
GlaxoSmithKline Capital Inc. [member] |
Member |
|
|
gsk:GlaxoSmithKlineCapitalIncMember |
| 3361 |
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC [member] |
Member |
|
|
gsk:GlaxosmithklineConsumerHealthcareHoldingsUSLLCMember |
| 3362 |
GlaxoSmithKline Consumer Health Care L P [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareLPMember |
| 3363 |
GlaxoSmithKline Holdings (Americas) Inc. [member] |
Member |
|
|
gsk:GlaxoSmithKlineHoldingsIncMember |
| 3364 |
GlaxoSmithKline LLC [member] |
Member |
|
|
gsk:GlaxoSmithKlineLLCMember |
| 3365 |
Human Genome Sciences, Inc. [member] |
Member |
|
|
gsk:HumanGenomeSciencesIncMember |
| 3366 |
GSK Consumer Health, Inc [member] |
Member |
|
|
gsk:GskConsumerHealthIncMember |
| 3367 |
S.R One, Limited [member] |
Member |
|
|
gsk:SROneLimitedMember |
| 3368 |
Stiefel Laboratories, Inc. [member] |
Member |
|
|
gsk:StiefelLaboratoriesIncMember |
| 3369 |
Vii V Health Care Company [member] |
Member |
|
|
gsk:ViiVHealthCareCompanyMember |
| 3370 |
GlaxoSmithKline Argentina S.A. [member] |
Member |
|
|
gsk:GlaxoSmithKlineArgentinaSAMember |
| 3371 |
GlaxoSmithKline Australia Pty Ltd [Member] |
Member |
|
|
gsk:GlaxoSmithKlineAustraliaPtyLtdMember |
| 3372 |
GlaxoSmithKline Consumer Healthcare Australia Pty Ltd [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareAustraliaPtyLtdMember |
| 3373 |
GlaxoSmithKline Brasil Limitada [Member] |
Member |
|
|
gsk:GlaxoSmithKlineBrasilLimitadaMember |
| 3374 |
GlaxoSmithKline Consumer Healthcare Inc. [Member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareIncMember |
| 3375 |
GlaxoSmithKline Inc. [Member] |
Member |
|
|
gsk:GlaxoSmithKlineIncMember |
| 3376 |
ID Biomedical Corporation of Quebec [Member] |
Member |
|
|
gsk:IDBiomedicalCorporationOfQuebecMember |
| 3377 |
GlaxoSmithKline Limited [Member] |
Member |
|
|
gsk:GlaxoSmithKlineLimitedMember |
| 3378 |
GlaxoSmithKline (Tianjin) Co. Ltd [member] |
Member |
|
|
gsk:GlaxoSmithKlineTianjinCoLtdMember |
| 3379 |
Sino-American Tianjin Smith Kline and French Laboratories Ltd [Member] |
Member |
|
|
gsk:SinoAmericanTianjinSmithKlineAndFrenchLaboratoriesLtdMember |
| 3380 |
GlaxoSmithKline Consumer Healthcare Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareLimitedMember |
| 3381 |
GlaxoSmithKline Pharmaceuticals Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlinePharmaceuticalsLimitedMember |
| 3382 |
GlaxoSmithKline Consumer Healthcare Japan K.K. [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareJapanKKMember |
| 3383 |
GlaxoSmithKline K.K. [member] |
Member |
|
|
gsk:GlaxoSmithKlineKKMember |
| 3384 |
ViiV Healthcare Kabushiki Kaisha [member] |
Member |
|
|
gsk:ViiVHealthCareKabushikiKaishaMember |
| 3385 |
GlaxoSmithKline Pakistan Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlinePakistanLimitedMember |
| 3386 |
Glaxo Wellcome Manufacturing Pte Ltd. [member] |
Member |
|
|
gsk:GlaxoWellcomeManufacturingPteLtdMember |
| 3387 |
GlaxoSmithKline Korea Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineKoreaLimitedMember |
| 3388 |
GlaxoSmithKline llaclari Sanayi ve Ticaret A.S. [member] |
Member |
|
|
gsk:GlaxoSmithKlineLlaclariSanayiVeTicaretAsMember |
| 3389 |
GlaxoSmithKline Biologicals SA [member] |
Member |
|
|
gsk:GlaxoSmithKlineBiologicalsSAMember |
| 3390 |
GlaxoSmithKline Pharmaceuticals S.A. [member] |
Member |
|
|
gsk:GlaxoSmithKlinePharmaceuticalsSAMember |
| 3391 |
GlaxoSmithKline Biologicals S.A.S. [member] |
Member |
|
|
gsk:GlaxoSmithKlineBiologicalsSASMember |
| 3392 |
GlaxoSmithKline Sante Grand Public SAS [member] |
Member |
|
|
gsk:GlaxoSmithKlineSanteGrandPublicSASMember |
| 3393 |
Laboratoire GlaxoSmithKline [member] |
Member |
|
|
gsk:LaboratoireGlaxoSmithKlineMember |
| 3394 |
ViiV Healthcare SAS [member] |
Member |
|
|
gsk:ViiVHealthcareSASMember |
| 3395 |
GlaxoSmithKline Consumer Healthcare GmbH and Co. KG [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareGmbHAndCoKGMember |
| 3396 |
GlaxoSmithKline GmbH and Co. KG [member] |
Member |
|
|
gsk:GlaxoSmithKlineGmbHAndCoKGMember |
| 3397 |
GSK Vaccines GmbH [member] |
Member |
|
|
gsk:GSKVaccinesGmbHMember |
| 3398 |
GlaxoSmithKline Consumer Healthcare S.p.A. [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthCareSPAMember |
| 3399 |
GlaxoSmithKline S.p.A. [member] |
Member |
|
|
gsk:GlaxoSmithKlineSPAMember |
| 3400 |
GSK Vaccines S.r.l. [member] |
Member |
|
|
gsk:GSKVaccinesSRLMember |
| 3401 |
GlaxoSmithKline B.V. [member] |
Member |
|
|
gsk:GlaxoSmithKlineBVMember |
| 3402 |
GlaxoSmithKline Consumer Healthcare S p z o o [member] |
Member |
|
|
gsk:GlaxoSmithKlineConsumerHealthcareSPZOOMember |
| 3403 |
GSK Services Sp z o.o. [member] |
Member |
|
|
gsk:GSKServicesSPZOOMember |
| 3404 |
GlaxoSmithKline Trading Services Limited [member] |
Member |
|
|
gsk:GlaxoSmithKlineTradingServicesLimitedMember |
| 3405 |
GlaxoSmithKline Healthcare AO [member] |
Member |
|
|
gsk:GlaxoSmithKlineHealthcareAoMember |
| 3406 |
GlaxoSmithKline S.A. [member] |
Member |
|
|
gsk:GlaxoSmithKlineSAMember |
| 3407 |
Laboratorios ViiV Healthcare, S.L. [member] |
Member |
|
|
gsk:LaboratoriosViiVHealthCareSLMember |
| 3408 |
GSK Consumer Healthcare S.A [member] |
Member |
|
|
gsk:GSKConsumerHealthcareSAMember |
| 3409 |
Disclosure of subsidiaries [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesLineItems |
| 3410 |
Country of incorporation |
Concept (Text/String) |
For Period |
|
ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary |
| 3411 |
Proportion of ownership interest in subsidiary |
Concept (Percent) |
For Period |
|
ifrs-full:ProportionOfOwnershipInterestInSubsidiary |
| 3412 |
1245 - Disclosure - Legal Proceedings - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosureLegalProceedingsAdditionalInformation |
| 3413 |
Disclosure Of Legal Proceedings [table] |
Table |
* |
* |
gsk:DisclosureOfLegalProceedingsTable |
| 3414 |
Classes of contingent liabilities [axis] |
Axis |
|
|
ifrs-full:ClassesOfContingentLiabilitiesAxis |
| 3415 |
Contingent liabilities [member] |
Member |
|
|
ifrs-full:ContingentLiabilitiesMember |
| 3416 |
Dolin case [member] |
Member |
|
|
gsk:DolinCaseMember |
| 3417 |
UK Competition and Markets Authority [member] |
Member |
|
|
gsk:UKCompetitionAndMarketsAuthorityMember |
| 3418 |
Geographical areas [axis] |
Axis |
|
|
ifrs-full:GeographicalAreasAxis |
| 3419 |
Geographical areas [member] |
Member |
|
|
ifrs-full:GeographicalAreasMember |
| 3420 |
US [member] |
Member |
|
|
country:US |
| 3421 |
Disclosure of Legal Proceedings [line items] |
LineItems |
|
|
gsk:DisclosureOfLegalProceedingsLineItems |
| 3422 |
Provisions for legal and other disputes |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LegalProceedingsProvision |
| 3423 |
Legal and other disputes receivable |
Concept (Monetary) |
As Of |
Debit |
gsk:LegalProceedingsRecoverableProvision |
| 3424 |
Net exposure on legal proceedings |
Concept (Monetary) |
As Of |
Credit |
gsk:NetExposureOnLegalProceedings |
| 3425 |
Amount of compensation awarded to plaintiff |
Concept (Monetary) |
For Period |
Debit |
gsk:AmountOfCompensationAwardedToPlaintiff |
| 3426 |
Civil penalty |
Concept (Monetary) |
For Period |
Debit |
gsk:LitigationClaimsForCivilPenalty |
| 3427 |
Fine paid by group |
Concept (Monetary) |
As Of |
Debit |
gsk:FinesAndPenaltiesPayableByGroup |
| 3428 |
Fine paid by other companies |
Concept (Monetary) |
As Of |
Debit |
gsk:FinesAndPenaltiesPayableByOther |
| 3429 |
1246 - Disclosure - Post Balance Sheet Events - Additional Information (Detail) |
Network |
* |
* |
http://www.gsk.com/taxonomy/role/DisclosurePostBalanceSheetEventsAdditionalInformation |
| 3430 |
Disclosure of non-adjusting events after reporting period [table] |
Table |
* |
* |
ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodTable |
| 3431 |
Non-adjusting events after reporting period [axis] |
Axis |
|
|
ifrs-full:NonadjustingEventsAfterReportingPeriodAxis |
| 3432 |
Non-adjusting events after reporting period [member] |
Member |
|
|
ifrs-full:NonadjustingEventsMember |
| 3433 |
Major business combination [member] |
Member |
|
|
ifrs-full:MajorBusinessCombinationMember |
| 3434 |
Business combinations [axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 3435 |
Entity's total for business combinations [member] |
Member |
|
|
ifrs-full:EntitysTotalForBusinessCombinationsMember |
| 3436 |
Tesaro, Inc.[member] |
Member |
|
|
gsk:TesaroIncMember |
| 3437 |
Disclosure of non-adjusting events after reporting period [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems |
| 3438 |
Cash consideration |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CashTransferred |